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NOMENCLATURE AND DESCRIPTION FOR RATING GUIDELINE
RECOMMENDATIONS
Within each recommendation, the strength of recommendation is indicated as Level 1, Level 2, or not graded, and the quality of the
supporting evidence is shown as A, B, C, or D.
ImplicationsGradea96Patients CliniciansKidnePolicyLevel 1
“We recommend”Most people in your situation would
want the recommended course of
action, and only a small proportion
would not.Most patients should receive the
recommended course of action.The recommendation can be
evaluated as a candidate for
developing a policy or a performance
measure.Level 2
“We suggest”The majority of people in your
situation would want the
recommended course of action, but
many would not.Different choices will be appropriate
for different patients. Each patient
needs help to arrive at a management
decision consistent with her or his
values and preferences.The recommendation is likely to
require substantial debate and
involvement of stakeholders before
policy can be determined.aThe additional category “not graded” is used, typically, to provide guidance based on common sense or where the topic does not allow adequate application of evidence.
The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations
are generally written as simple declarative statements. They should not be interpreted as being weaker recommendations than Level 1 or 2 recommendations.
Grade Quality of evidence MeaningA High We are conﬁdent that the true effect lies close to the estimate of the effect.
B Moderate The true effect is likely to be close to the estimate of the effect, but there is a possibility
that it is substantially different.
C Low The true effect may be substantially different from the estimate of the effect.
D Very low The estimate of effect is very uncertain, and often will be far from the truth.y International Supplements (2018) 8, 91–165
www.kisupplements.org CKD nomenc l a tu reCURRENT CHRONIC KIDNEY DISEASE (CKD) NOMENCLATURE USED BY KDIGO
CKD is deﬁned as abnormalities of kidney structure or function, present for >3 months, with implications for health. CKD is classiﬁed
based on cause, GFR category (G1–G5), and albuminuria category (A1–A3), abbreviated as CGA.
Prognosis of CKD by GFR and albuminuria category
Prognosis of CKD by GFR













































G1 Normal or high ≥90
G2 Mildly decreased 60–89
G3a Mildly to moderately decreased 45–59
G3b Moderately to severely decreased 30–44
G4 Severely decreased 15–29
G5 Kidney failure <15
Green, low risk (if no other markers of kidney disease, no CKD); yellow, moderately increased risk; 
orange, high risk; red, very high risk.Kidney International Supplements (2018) 8, 91–165 97
conve r s i on fac to r s www.kisupplements.orgCONVERSION FACTORS OF CONVENTIONAL UNITS TO SI UNITS
Conventional unit Conversion factor SI unit98 Kidney InCreatinine mg/dl 88.4 mmol/lNote: conventional unit  conversion factor ¼ SI unit.ALBUMINURIA CATEGORIES IN CKD
ACR (approximate equivalent)Category AER (mg/24 h)ternationTerms(mg/mmol) (mg/g)A1 <30 <3 <30 Normal to mildly increased
A2 30–300 3–30 30–300 Moderately increasedaA3 >300 >30 >300 Severely increasedbACR, albumin-to-creatinine ratio; AER, albumin excretion rate; CKD, chronic kidney disease.
aRelative to young adult level.
bIncluding nephrotic syndrome (albumin excretion usually > 2200 mg/24 h [ACR > 2200 mg/g; > 220 mg/mmol]).INTERPRETATION OF HCV ASSAYS
Anti-HCV HCV-NAT InterpretationPositive Positive Acute or chronic HCV infection depending on the clinical context
Positive Negative Resolution of HCV infection (i.e., successfully treated or spontaneously cleared)
Negative Positive Early acute HCV infection; chronic HCV in the setting of immunosuppressed state; false
anti-HCV negative or false HCV-NAT positive
Negative Negative Absence of HCV infectionAnti-HCV, HCV antibody; HCV, hepatitis C virus; NAT, nucleic acid testing.al Supplements (2018) 8, 91–165
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APRI aspartate aminotransferase–platelet ratio
index
ASN American Society of Nephrology
AUC area under the curve
BSI bloodstream infection
CDC Centers for Disease Control and
Prevention
CI conﬁdence interval
CKD chronic kidney disease
CKD G4
CKD G5
chronic kidney disease GFR category 4
chronic kidney disease GFR category 5
CKD-EPI Chronic Kidney Disease Epidemiology
Collaboration
CNI calcineurin inhibitor
CPG clinical practice guideline
CrCl creatinine clearance
DAA direct-acting antiviral
DOPPS Dialysis Outcomes and Practice Patterns
Study
EASL European Association for the Study of the
Liver
eGFR estimated glomerular ﬁltration rate
ERT evidence review team
ESKD end-stage kidney disease
FDA Food and Drug Administration
GFR glomerular ﬁltration rate
GN glomerulonephritis
GRADE Grading of Recommendations Assessment,
Development and Evaluation
GT genotype
HAV hepatitis A virus
HBcAb antibody to hepatitis B core antigen
HBsAb antibody to hepatitis B surface antigen
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCC hepatocellular carcinoma
HCV hepatitis C virus










NAT nucleic acid test(ing)
NS5A nonstructural protein 5A







RCT randomized controlled trial
RR relative risk
SVR (weeks) sustained virologic response (at statedweeks)
US United States
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SECTION I: USE OF THE CLINICAL PRACTICE GUIDELINE
This Clinical Practice Guideline document is based upon literature searches last conducted in May 2017, supplemented with
additional evidence through July 2018. It is designed to assist decision making. It is not intended to deﬁne a standard of care,
and should not be interpreted as prescribing an exclusive course of management. Variations in practice will inevitably and
appropriately occur when clinicians consider the needs of individual patients, available resources, and limitations unique to an
institution or type of practice. Health care professionals using these recommendations should decide how to apply them to their
own clinical practice.
SECTION II: DISCLOSURE
Kidney Disease: Improving Global Outcomes (KDIGO) makes every effort to avoid any actual or reasonably perceived conﬂicts
of interest that may arise from an outside relationship or a personal, professional, or business interest of a member of the Work
Group. All members of the Work Group are required to complete, sign, and submit a disclosure and attestation form showing
all such relationships that might be perceived as or are actual conﬂicts of interest. This document is updated annually and
information is adjusted accordingly. All reported information is published in its entirety at the end of this document in the
Work Group members’ Biographic and Disclosure section, and is kept on ﬁle at KDIGO.
Disclaimer: The ﬁndings and conclusions in this report are those of the authors and do not necessarily represent the ofﬁcial
position of the US Centers for Disease Control and Prevention.Copyright © 2018, KDIGO. Published by Elsevier on behalf of the International Society of Nephrology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Single copies may be made for personal use as allowed by national copyright laws. Special rates are available for educational
institutions that wish to make photocopies for nonproﬁt educational use. No part of this publication may be reproduced,
amended, or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any
information storage and retrieval system, without explicit permission in writing from KDIGO. Details on how to seek
reprints, permission for reproduction or translation, and further information about KDIGO’s permissions policies can be
obtained by contacting Danielle Green, Executive Director, at danielle.green@kdigo.org.
To the fullest extent of the law, neither KDIGO, Kidney International Supplements, nor the authors, contributors, or editors
assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or
otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.100 Kidney International Supplements (2018) 8, 91–165
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Kidney International Supplements (2018) 8, 91–165; http://dx.doi.org/10.1016/j.kisu.2018.06.001With the growing awareness that chronic kidney disease
(CKD) is an international health problem, Kidney Disease:
Improving Global Outcomes (KDIGO) was established in
2003 with its stated mission to “improve the care and out-
comes of kidney disease patients worldwide through pro-
moting coordination, collaboration, and integration of
initiatives to develop and implement clinical practice
guidelines.”
The high prevalence of hepatitis C virus (HCV) in the CKD
population was recognized once diagnostic testing became
available in the early 1990s, as was its transmission within
dialysis units. A series of publications subsequently identiﬁed
the adverse consequences of HCV infection in the CKD
population as well as its detrimental effect on recipient and
graft outcomes following kidney transplantation. Although
screening of blood products for HCV reduced its acquisition by
blood transfusion, the unique aspects of its epidemiology in the
CKD population were apparent. Studies also established that
transmission was frequent in dialysis patients and typically
reﬂected insufﬁcient attention to body ﬂuid precautions. Also
confounding the management of HCV in the CKD population
was an absence of biochemical liver dysfunction in most
HCV-infected hemodialysis patients, which contributed to the
lack of recognition of its presence and clinical signiﬁcance. An
additional difﬁculty was the lack of effective and tolerable
antiviral agents to treat HCV in patients with CKD because
interferon, especially in combination with ribavirin, had
considerable toxicity. Furthermore, interferon was implicated
in graft dysfunction in kidney transplant recipients.
KDIGO convened a group of experts in this area to
develop guideline recommendations for the prevention,
diagnosis, and management of HCV in CKD a decade ago,
which resulted in the publication of the very ﬁrst KDIGO
guideline in 2008. Since then there have been major advances
in HCV management, particularly in antiviral therapy. As a
result, much of the hesitancy in advising therapy forKidney International Supplements (2018) 8, 91–165HCV-infected patients with CKD and following kidney
transplant has now disappeared. In addition, diagnostic
testing has evolved in chronic liver disease to the extent that
ﬁbrosis can now be assessed with noninvasive techniques such
as transient elastography. Because of these advances in di-
agnostics and therapeutics, it was deemed appropriate to
undertake a comprehensive review and update of the KDIGO
HCV guideline in patients with kidney disease. It has been
KDIGO’s philosophy to provide recommendations based on
the best available clinical evidence without direct consider-
ation of costs, as they vary widely across countries. The recent
Lancet Commission on Essential Medicines articulated the
importance and challenges of providing access to safe, effec-
tive, and affordable essential medicines, including treatments
for combating HCV.1 In this vein, the World Health Orga-
nization has issued its ﬁrst global report to offer practical
steps to expand access for such treatments.2
We thank Michel Jadoul, MD, and Paul Martin, MD, for
leading this important initiative, and we are especially grateful
to the Work Group members who provided their time and
expertise to this endeavor. In addition, this Work Group was
ably assisted by colleagues from the independent evidence
review team led by Ethan Balk, MD, MPH, Craig Gordon,
MD, MS, Amy Earley, BS, and Mengyang Di, MD, PhD, who
made this guideline possible.
In keeping with KDIGO’s policy for transparency and
rigorous public review during the guideline development
process, its scope and the draft guideline were both made
available for open commenting. The feedback received was
carefully considered by the Work Group members who crit-
ically reviewed the public input and revised the guideline as
appropriate for the ﬁnal publication.
David C. Wheeler, MD, FRCP
Wolfgang C. Winkelmayer, MD, ScD
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www.kisupplements.org abs t r a c tAbstractKidney InternatioThe Kidney Disease: Improving Global Outcomes (KDIGO) 2018 Clinical Practice Guideline for the
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease rep-
resents a complete update of the prior guideline published in 2008. This guideline is intended to
assist the practitioner caring for patients with hepatitis C virus (HCV) and chronic kidney disease
(CKD), including those who are on chronic dialysis therapy and individuals with a kidney
transplant. Speciﬁcally, the topic areas for which new recommendations are issued include
detection and evaluation of HCV in CKD; treatment of HCV infection in patients with CKD;
management of HCV-infected patients before and after kidney transplantation; prevention of
HCV transmission in hemodialysis units; and diagnosis and management of kidney diseases
associated with HCV infection. Development of this guideline update followed an explicit process
of evidence review and appraisal. Treatment approaches and guideline recommendations are
based on systematic reviews of relevant studies, and appraisal of the quality of the evidence and
the strength of recommendations followed the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) approach. Limitations of the evidence are discussed, with
areas of future research also presented.
Keywords: chronic kidney disease; cryoglobulinemia; dialysis; direct-acting antivirals; glomerular
diseases; hemodialysis; hepatitis C virus; infection control; guideline; KDIGO; kidney trans-
plantation; liver testing; nosocomial transmission; screening; systematic review
CITATIONnal SuIn citing this document, the following format should be used: Kidney Disease: Improving
Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 Clinical Practice
Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic
Kidney Disease. Kidney Int Suppl. 2018;8:91–165.pplements (2018) 8, 91–165 103
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Chapter 1: Detection and evaluation of HCV in CKD
1.1 Screening patients with CKD for HCV infection2
1041.1.1: We recommend screening all patients for HCV infection at the time of initial evaluation of CKD (1C).
1.1.1.1: We recommend using an immunoassay followed by nucleic acid testing (NAT) if immunoassay is
positive (1A).
1.1.2: We recommend screening all patients for HCV infection upon initiation of in-center hemodialysis or upon
transfer from another dialysis facility or modality (1A).
1.1.2.1: We recommend using NAT alone or an immunoassay followed by NAT if immunoassay is positive
(1A).
1.1.3: We suggest screening all patients for HCV infection upon initiation of peritoneal dialysis or home hemodi-
alysis (2D).
1.1.4: We recommend screening all patients for HCV infection at the time of evaluation for kidney transplantation
(1A).1.2 Follow-up HCV screening of in-center hemodialysis patients
1.2.1: We recommend screening for HCV infection with immunoassay or NAT in in-center hemodialysis patients
every 6 months (1B).1.2.1.1: Report any new HCV infection identiﬁed in a hemodialysis patient to the appropriate public health
authority (Not Graded).
1.2.1.2: In units with a new HCV infection, we recommend that all patients be tested for HCV infection and the
frequency of subsequent HCV testing be increased (1A).
1.2.1.3: We recommend that hemodialysis patients with resolved HCV infection undergo repeat testing every 6
months using NAT to detect possible re-infection (1B).1.2.2: We suggest that patients have serum alanine aminotransferase (ALT) level checked upon initiation of in-center
hemodialysis or upon transfer from another facility (2B).
1.2.2.1: We suggest that hemodialysis patients have ALT level checked monthly (2B).1.3 Liver testing in patients with CKD and HCV infection
1.3.1: We recommend assessing HCV-infected patients with CKD for liver ﬁbrosis (1A).
1.3.2: We recommend an initial noninvasive evaluation of liver ﬁbrosis (1B).
1.3.3: When the cause of liver disease is uncertain or noninvasive testing results are discordant, consider liver biopsy
(Not Graded).
1.3.4: We recommend assessment for portal hypertension in CKD patients with suspected advanced ﬁbrosis (F3–4)
(1A).
1.4 Other testing of patients with HCV infection
1.4.1: We recommend assessing all patients for kidney disease at the time of HCV infection diagnosis (1A).1.4.1.1: Screen for kidney disease with urinalysis and estimated glomerular ﬁltration rate (eGFR) (Not Graded).
1.4.2: If there is no evidence of kidney disease at initial evaluation, patients who remain NAT-positive should un-
dergo repeat screening for kidney disease (Not Graded).
1.4.3: We recommend that all CKD patients with a history of HCV infection, whether NAT-positive or not, be
followed up regularly to assess progression of kidney disease (1A).
1.4.4: We recommend that all CKD patients with a history of HCV infection, whether NAT-positive or not, be
screened and, if appropriate, vaccinated against hepatitis A virus (HAV) and hepatitis B virus (HBV), and
screened for human immunodeﬁciency virus (HIV) (1A).
Chapter 2: Treatment of HCV infection in patients with CKD
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Kidney In.1.2: We recommend that the choice of speciﬁc regimen be based on HCV genotype (and subtype), viral load, prior
treatment history, drug–drug interactions, glomerular ﬁltration rate (GFR), stage of hepatic ﬁbrosis, kidney
and liver transplant candidacy, and comorbidities (1A).
.1.3: Treat kidney transplant candidates in collaboration with the transplant center to optimize timing of therapy
(Not Graded).2.2: We recommend that patients with GFR ‡ 30 ml/min per 1.73 m2 (CKD G1–G3b) be treated with any licensed direct-
acting antiviral (DAA)-based regimen (1A).
2.3: Patients with GFR < 30 ml/min per 1.73 m2 (CKD G4–G5D) should be treated with a ribavirin-free DAA-based
regimen as outlined in Figure 1.
2.4: We recommend that all kidney transplant recipients infected with HCV be evaluated for treatment (1A)..4.1: We recommend treatment with a DAA-based regimen as outlined in Figure 1 (1A).
.4.2: We recommend that the choice of regimen be based on HCV genotype (and subtype), viral load, prior
treatment history, drug–drug interactions, GFR, stage of hepatic ﬁbrosis, liver transplant candidacy, and
comorbidities (1A).
.4.3: We recommend avoiding treatment with interferon (1A).
.4.4: We recommend pre-treatment assessment for drug–drug interactions between the DAA-based regimen and
other concomitant medications including immunosuppressive drugs in kidney transplant recipients (1A).
2.4.4.1: We recommend that calcineurin inhibitor levels be monitored during and after DAA treatment (1B).ey function HCV
genotype 












 G5 PD n/a (reasonable to follow proposed regimens for HD)
1a Sofosbuvir with ledipasvir,
daclatasvir or simeprevir  
D2nirivabir/rivubsofoSB1
Glecaprevir/pibrentasvir c 1C
1b Sofosbuvir with ledipasvir,
daclatasvir or simeprevir 
1B
Glecaprevir/pibrentasvir c 1C
2, 3, 5, 6 Glecaprevir/pibrentasvir c 1D Sofosbuvir/daclatasvir/ribavirin d 2D
4 Sofosbuvir with ledipasvir,




 < 30 ml/min per
m2) including
TRb
 ≥ 30 ml/min per
m2)
Ritonavir-boosted paritaprevir, ombitasvir, and
dasabuvir (also known as PrOD or 3D regimen)
with ribavirin  
Ritonavir-boosted paritaprevir, ombitasvir, and
dasabuvir (also known as ProD or 3D regimen)
1 | Recommended direct-acting antiviral (DAA) treatment regimens for patients with chronic kidney disease (CKD) G4–G5D and
transplant recipients (KTRs), by hepatitis C virus (HCV) genotypea. Duration of therapy for all above regimens is usually 12 weeks
ders should consult Association for the Study of Liver Diseases (AASLD) or European Association for the Study of the Liver guidelines for
uidance. aWe recommend that CKD patients with glomerular ﬁltration rates (GFRs) $ 30 ml/min per 1.73 m2 (CKD G1T–G3bT) be treated
y licensed DAA regimen. bThere is little published evidence to guide treatment regimens in KTRs with GFR < 30 ml/min per 1.73 m2
4T–G5T). Regimens in KTRs should be selected to avoid drug–drug interactions, particularly with calcineurin inhibitors. cBased on Reau et
suggested in AASLD guidelines (https://www.hcvguidelines.org/). CKD G, chronic kidney disease (GFR category); HD, hemodialysis; n/a,
a or evidence available; PD, peritoneal dialysis.
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106.5.1: If hepatitis B surface antigen [HBsAg] is present, the patient should undergo assessment for HBV therapy (Not
Graded).
.5.2: If HBsAg is absent but markers of prior HBV infection (HBcAb-positive with or without HBsAb) are detected,
monitor for HBV reactivation with serial HBV DNA and liver function tests during DAA therapy (Not Graded).Chapter 3: Preventing HCV transmission in hemodialysis units
3.1: We recommend that hemodialysis facilities adhere to standard infection control procedures including hygienic
precautions that effectively prevent transfer of blood and blood-contaminated ﬂuids between patients to prevent
transmission of blood-borne pathogens (see Table 1) (1A).1 | Infection control practices (“hygienic precautions”) particularly relevant for preventing HCV transmission
er hand hygiene and glove changes, especially between patient contacts, before invasive procedures, and after contact with blood and
ntially blood-contaminated surfaces/supplies
er injectable medication preparation practices following aseptic techniques and in an appropriate clean area, and proper injectable medication
inistration practice
ough cleaning and disinfection of surfaces at the dialysis station, especially high-touch surfaces
uate separation of clean supplies from contaminated materials and equipment.1.1: We recommend regular observational audits of infection control procedures in hemodialysis units (1C).
.1.2: We recommend not using dedicated dialysis machines for HCV-infected patients (1D).
.1.3: We suggest not isolating HCV-infected hemodialysis patients (2C).
.1.4: We suggest that the dialyzers of HCV-infected patients can be reused if there is adherence to standard infection
control procedures (2D).3.2: We recommend that hemodialysis centers examine and track all HCV test results to identify new cases of HCV in-
fections in their patients (1B)..2.1: We recommend that aggressive measures be taken to improve hand hygiene (and proper glove use), injection
safety, and environmental cleaning and disinfection when a new case of HCV is identiﬁed that is likely to be
dialysis-related (1A).3.3: Strategies to prevent HCV transmission within hemodialysis units should prioritize adherence to standard infection
control practices and should not primarily rely upon the treatment of HCV-infected patients (Not Graded).
Chapter 4: Management of HCV-infected patients before and after kidney transplantation
4.1 Evaluation and management of kidney transplant candidates regarding HCV infection
4.1.1: We recommend kidney transplantation as the best therapeutic option for patients with CKD G5 irrespective of
presence of HCV infection (1A).
4.1.2: We suggest that all HCV-infected kidney transplant candidates be evaluated for severity of liver disease and
presence of portal hypertension (if indicated) prior to acceptance for kidney transplantation (2D).4.1.2.1: We recommend that HCV-infected patients with compensated cirrhosis (without portal hypertension)
undergo isolated kidney transplantation (1B).
4.1.2.2: We recommend referring HCV-infected patients with decompensated cirrhosis for combined liver-
kidney transplantation (1B) and deferring HCV treatment until after transplantation (1D).4.1.3: Timing of HCV treatment in relation to kidney transplantation (before vs. after) should be based on donor type
(living vs. deceased donor), wait-list times by donor type, center-speciﬁc policies governing the use of kidneys
from HCV-infected deceased donors, HCV genotype, and severity of liver ﬁbrosis (Not Graded).
4.1.3.1: We recommend that all HCV-infected patients who are candidates for kidney transplantation be
considered for DAA therapy, either before or after transplantation (1A).
4.1.3.2: We suggest that HCV-infected kidney transplant candidates with a living kidney donor can be
considered for treatment before or after transplantation according to HCV genotype and anticipated
timing of transplantation (2B).
4.1.3.3: We suggest that if receiving a kidney from an HCV-positive donor improves the chances for trans-
plantation, the HCV NAT–positive patient can undergo transplantation with an HCV-positive kidney
and be treated for HCV infection after transplantation (2B).Kidney International Supplements (2018) 8, 91–165
www.kisupplements.org summary o f re commenda t ion s ta tement s4.2 Use of kidneys from HCV-infected donors
4.2.1: We recommend that all kidney donors be screened for HCV infection with both immunoassay and NAT (if NAT
is available) (1A).
4.2.2: We recommend that transplantation of kidneys from HCV NAT-positive donors be directed to recipients with
positive NAT (1A).
4.2.3: After the assessment of liver ﬁbrosis, HCV-positive potential living kidney donors who do not have cirrhosis
should undergo HCV treatment before donation; they can be accepted for donation if they achieve sustained
virologic response (SVR) and remain otherwise eligible to be a donor (Not Graded).
4.3 Use of maintenance immunosuppressive regimens
4.3.1: We suggest that all conventional current induction and maintenance immunosuppressive regimens can be used
in HCV-infected kidney transplant recipients (2C).
4.4 Management of HCV-related complications in kidney transplant recipients
4.4.1: We recommend that patients previously infected with HCV who achieved SVR before transplantation be tested
by NAT 3 months after transplantation or if liver dysfunction occurs (1D).
4.4.2: Untreated HCV-positive kidney transplant recipients should have the same liver disease follow-up as HCV-
positive non-transplant patients, as outlined in the American Association for the Study of Liver Diseases
(AASLD) guidelines (Not Graded).




Kidney In4.4.3.1: We suggest that patients who develop new-onset proteinuria (either urine protein-to-creatinine ratio >
1 g/g or 24-hour urine protein > 1 g on 2 or more occasions) have an allograft biopsy with immu-
noﬂuorescence and electron microscopy included in the analysis (2D).4.4.4: We recommend treatment with a DAA regimen in patients with post-transplant HCV-associated glomerulo-
nephritis (1D).
Chapter 5: Diagnosis and management of kidney diseases associated with HCV infection
5.1: We recommend that a kidney biopsy be performed in HCV-infected patients with clinical evidence of glomerular
disease (Not Graded).
5.2: We recommend that patients with HCV-associated glomerular disease be treated for HCV (1A).
.2.1: We recommend that patients with HCV-related glomerular disease showing stable kidney function and/or non-
nephrotic proteinuria be treated initially with DAA (1C).
.2.2: We recommend that patients with cryoglobulinemic ﬂare, nephrotic syndrome, or rapidly progressive kidney
failure be treated, in addition to DAA treatment, with immunosuppressive agents with or without plasma
exchange (1C).
.2.3: We recommend immunosuppressive therapy in patients with histologically active HCV-associated glomerular
disease who do not respond to antiviral therapy, particularly those with cryoglobulinemic kidney disease (1B).
5.2.3.1: We recommend rituximab as the ﬁrst-line immunosuppressive treatment (1C).ternational Supplements (2018) 8, 91–165 107
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Patients receiving maintenance hemodialysis and subgroups
of CKD patients not yet on dialysis are known to have a high
prevalence of HCV infection. The reasons for testing CKD
patients for HCV infection include early detection and
treatment of HCV infection, diagnostic evaluation of the
cause of CKD, identiﬁcation of infection control lapses in
hemodialysis centers, and guidance on decisions surrounding
kidney transplantation care.
1.1.1: We recommend screening all patients for HCV
infection at the time of initial evaluation of CKD
(1C).1081.1.1.1: We recommend using an immunoassay fol-
lowed by nucleic acid testing (NAT) if
immunoassay is positive (1A).1.1.2: We recommend screening all patients for HCV
infection upon initiation of in-center hemodialysis
or upon transfer from another dialysis facility or
modality (1A).1.1.2.1: We recommend using NAT alone or an
immunoassay followed by NAT if immuno-
assay is positive (1A).1.1.3: We suggest screening all patients for HCV infection
upon initiation of peritoneal dialysis or home he-
modialysis (2D).
1.1.4: We recommend screening all patients for HCV
infection at the time of evaluation for kidney
transplantation (1A).
Rationale
1.1.1: We recommend screening all patients for HCV infec-
tion at the time of initial evaluation of CKD (1C).1.1.1.1: We recommend using an immunoassay fol-
lowed by nucleic acid testing (NAT) if
immunoassay is positive (1A).Any CKD patient who has a risk factor for HCV infection
should be tested.4 Additionally, HCV testing is warranted for
the evaluation of CKD because: (i) the prevalence of HCV
infection may be higher in patients with CKD not yet on
dialysis than in the general population;5,6 (ii) HCV infection
increases the risk of developing CKD;7 and (iii) HCV infec-
tion can accelerate progression of CKD.8–10
Diagnosis of HCV infection relies on various assays.11,12
Serological assays that detect HCV antibody (anti-HCV) are
based on enzyme immunoassays or chemoluminescenceimmunoassays. Anti-HCV tests are unable to distinguish
between resolved HCV infection and current HCV infection.
Detection of HCV viremia relies on NAT technologies.
Qualitative and quantitative HCV RNA methods are available
and have similar limits of detection (10–20 international units
[IU]/ml). HCV antigen tests that detect core antigen alone or
in combination with other HCV proteins have the potential to
be less costly than NAT, but their limit of detection is higher
(equivalent to about 150–3000 IU/ml).11,13–15
The most usual strategy for diagnosis of HCV infection
consists of initial screening with an inexpensive serological
assay and, if the assay is positive, subsequent NAT. However,
in high prevalence settings or very high risk groups, imme-
diate NAT is an appropriate alternative.
1.1.2: We recommend screening all patients for HCV
infection upon initiation of in-center hemodialysis
or upon transfer from another dialysis facility or
modality (1A).1.1.2.1: We recommend using NAT alone or an
immunoassay followed by NAT if immuno-
assay is positive (1A).The prevalence of HCV infection in patients undergoing
hemodialysis (CKD G5 on dialysis) is higher than in the general
population16,17 andhas been associatedwith the number of years
onehas beenonhemodialysis. Patient-to-patient transmissionof
HCV infection in outpatient hemodialysis centers has occurred
repeatedly despite widespread knowledge of this risk and pub-
lished guidelines for prevention. Identiﬁcation of HCV trans-
mission within a dialysis facility should prompt immediate
reevaluation of infection control practices and determination of
appropriate corrective action (see Chapter 3).18–22 The majority
of persons with HCV infection are asymptomatic, making
screening necessary to detect infection in high-risk populations,
particularly in hemodialysis patients in whom signs or symp-
toms of acute HCV infection are rarely recognized. Screening of
maintenance hemodialysis patients for HCV infection is rec-
ommended by the United States (US) Centers for Disease
Control and Prevention (CDC) and also the US Preventive
Services Task Force.23,24 Goals of screening in this patient pop-
ulation include early detection of HCV infection, treatment of
infection, and detection of dialysis-related transmission. HCV
screening is indicated in patients starting in-center maintenance
hemodialysis and also in patients who transfer from another
dialysis facility or modality. In dialysis units with a high preva-
lence of HCV, initial testing with NATshould be considered. An
anti-HCV–negative, HCV RNA–positive (i.e., NAT-positive)
proﬁle strongly suggests acute HCV infection.Kidney International Supplements (2018) 8, 91–165
www.kisupplements.org chap te r 1Samples collected to test for HCV by NAT should be
drawn before dialysis, because hemodialysis sessions reduce
viremia level, although the mechanism remains unclear.25
1.1.3: We suggest screening all patients for HCV infection
upon initiation of peritoneal dialysis or home he-
modialysis (2D).
HCV transmission has typically been described in the
context of in-center hemodialysis. In this setting, blood
contamination on the hands of staff members or of medica-
tions, supplies, and equipment can contribute to HCV trans-
mission. The current risk of health care–related HCV infection
among patients who receive peritoneal dialysis or home he-
modialysis has not been quantiﬁed. Many of these patients will
require in-center hemodialysis at some point during their care,
andmay be at risk of acquiringHCV infection during that time.
Screening of peritoneal dialysis and home hemodialysis pa-
tients should be considered upon initiation of dialysis to
document baseline HCV infection status. If these patients
transiently receive in-center hemodialysis, they should undergo
HCV infection screening as per the recommendations for in-
center hemodialysis patients, with consideration of continued
screening until 6 months after the completion of in-center
hemodialysis (and transition to a different modality).
1.1.4: We recommend screening all patients for HCV
infection at the time of evaluation for kidney
transplantation (1A).
Kidney transplantation candidates should be tested for
HCV infection during evaluation for transplantation. Deter-
mination of HCV status in recipients is essential for optimal
management and potentially for acceptance of kidneys from
HCV-infected donors (see Chapter 4).1.2 Follow-up HCV screening of in-center
hemodialysis patients
1.2.1: We recommend screening for HCV infection with
immunoassay or NAT in in-center hemodialysis
patients every 6 months (1B).Kidney In1.2.1.1: Report any new HCV infection identiﬁed in a
hemodialysis patient to the appropriate
public health authority (Not Graded).
1.2.1.2: In units with a new HCV infection, we
recommend that all patients be tested for
HCV infection and the frequency of subse-
quent HCV testing be increased (1A).
1.2.1.3: We recommend that hemodialysis patients
with resolved HCV infection undergo repeat
testing every 6 months using NAT to detect
possible re-infection (1B).1.2.2: We suggest that patients have serum alanine
aminotransferase (ALT) level checked upon initia-
tion of in-center hemodialysis or upon transfer
from another facility (2B).ternational Supplements (2018) 8, 91–1651.2.2.1: We suggest that hemodialysis patients have
ALT level checked monthly (2B).Rationale
1.2.1: We recommend screening for HCV infection with
immunoassay or NAT in in-center hemodialysis
patients every 6 months (1B).1.2.1.1: Report any new HCV infection identiﬁed in a
hemodialysis patient to the appropriate public
health authority (Not Graded).
1.2.1.2: In units with a new HCV infection, we
recommend that all patients be tested for
HCV infection and the frequency of subse-
quent HCV testing be increased (1A).
1.2.1.3: We recommend that hemodialysis patients
with resolved HCV infection undergo repeat
testing every 6 months using NAT to detect
possible re-infection (1B).Patients who are not infected with HCV should be
screened for presence of new infection every 6 months.23 This
recommendation includes anti-HCV–negative patients and
anti-HCV–positive, HCV RNA–negative patients screened
initially by immunoassay, as well as HCV RNA–negative pa-
tients screened initially by NAT. Patients who are anti-HCV–
positive and HCV RNA–negative (i.e., NAT-negative) have
resolved infection but remain at risk for re-infection if
exposed.26 Therefore, these patients should also undergo
repeat screening. For dialysis patients who are anti-HCV–
positive and HCV NAT–negative, screening for HCV rein-
fection should be conducted every 6 months using NAT.
The purpose of the repeat screening is to identify new in-
fections (i.e., newly acquired infections) that could represent
transmission within the dialysis center. The baseline HCV
testing results should be reviewed for any patient who has a
positive HCV screening test result to determine whether there
was a change in infection status indicating a new infection, and
results must be communicated to the patient. Any patient with
a current infection, whether new or pre-existing, should be
linked to HCV care and considered for antiviral therapy.
Acute HCV infection in a hemodialysis patient should be
reported to the appropriate public health authority. Reporting
may be mandated by law, as in the US, where a documented
negative HCVantibody or NAT laboratory test result followed
within 12 months by a positive HCV test result (test conver-
sion) must be reported to public health authorities.27 Acute
HCV infection in a hemodialysis patient should be investigated
and considered health care–related until proven otherwise.28
Behavioral risk factors, along with dialysis and nondialysis
health care exposures, should be evaluated by public health
authorities. Molecular sequencing of HCV RNA from other
patients in the facility may help to identify a source.22,29–31
Acute HCV infection should also prompt immediate
evaluation of all other patients in the same facility to identify
additional cases. The status of all patients should be reviewed
at the time a new infection is identiﬁed, and all patients109
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HCV infection. The frequency of repeat screening should also
be increased for a limited time: for example, monthly testing
for 3 months, followed by testing again in 3 months, and then
resumption of screening every 6 months if no additional in-
fections are identiﬁed.20,23 This strategy can help to identify
delayed seroconversions (from the same exposure period as
the index case) or other cases resulting from recurrent
breaches. Use of this strategy has led to the detection of
additional new cases in several reported outbreaks.22,32
For anti-HCV–positive patients with chronic HCV infection
who become HCV NAT–negative with a sustained virologic
response (SVR) toHCV therapy, initiateNATscreening 6months
after documentation of SVR. SVR is determined based on results
of NAT testing$ 12 weeks after the conclusion of therapy.
For patients with spontaneous resolution of acute HCV
infection as documented by a negative test for HCV RNA at$ 6
months after the onset of acute infection, NATscreening should
begin 6 months after documented resolution of infection.
1.2.2: We suggest that patients have serum alanine
aminotransferase (ALT) level checked upon initia-
tion of in-center hemodialysis or upon transfer
from another facility (2B).1101.2.2.1: We suggest that hemodialysis patients have
ALT level checked monthly (2B).A baseline serum ALT test, followed by monthly testing,
in susceptible patients has been recommended to enable
early detection of new HCV infection in hemodialysis pa-
tients.23 Newly infected patients may have an increase in
ALT levels prior to antibody conversion, which should
prompt additional evaluation. If an unexplained elevation
(i.e., to greater than upper-limit normal) of ALT occurs, the
patient should be tested for HCV infection. The exact pre-
dictive value of ALT screening for detection of HCV infec-
tion has been assessed in a single study and found to be
moderate.33 However, ALTmonitoring is an inexpensive way
to ensure that hemodialysis patients are assessed for possible
acquisition of infection between regular antibody or NAT
screenings. Because few hemodialysis patients with a new
HCV infection report symptoms or have symptoms docu-
mented in their dialysis medical records, ALT levels are also
often used retrospectively to deﬁne the likely exposure
period for patients who acquired infection. Thus, monthly
ALT levels are valuable to help narrow the focus of an HCV
case investigation to the most likely exposure and source.
The value of monthly ALT testing in patients who have
resolved HCV infection has not been studied.
1.3 Liver testing in patients with CKD and HCV
infection
1.3.1: We recommend assessing HCV-infected patients
with CKD for liver ﬁbrosis (1A).
1.3.2: We recommend an initial noninvasive evaluation of
liver ﬁbrosis (1B).1.3.3: When the cause of liver disease is uncertain or
noninvasive testing results are discordant, consider
liver biopsy (Not Graded).
1.3.4: We recommend assessment for portal hypertension
in CKD patients with suspected advanced ﬁbrosis
(F3–4) (1A).
Rationale
Evaluation of liver ﬁbrosis in HCV-infected patients with
CKD. In the prior Kidney Disease: Improving Global Outcomes
(KDIGO) HCV guideline published in 2008,34 liver biopsy had
been considered the gold standard to assess liver ﬁbrosis in
patients with CKD, including candidates for transplantation
and transplant recipients. The primary objective of liver biopsy
in patients with advanced CKD had been to diagnose cirrhosis.
Because of the risk of liver-related mortality after kidney
transplantation, cirrhosis had been considered a contraindi-
cation to kidney transplantation alone and led to consideration
of combined liver-kidney transplantation.
Current evidence suggests that biochemical noninvasive
markers (FibroTest/FibroMeter, aspartate aminotransferase–
platelet ratio index [APRI], Forns, or FIB-4 index) and
morphological evaluation (liver stiffness by elastography) may
have comparable accuracy in evaluating liverﬁbrosis in patients
with CKD G4–5 as in the general population.35 Noninvasive
methods, especially elastography, are sufﬁciently reliable to
detect extensive ﬁbrosis and/or cirrhosis (F3–F4)36,37 though
noninvasive tests other than elastography may be less accurate
(Supplementary Tables S1 and S2). Furthermore, although
serious complications of liver biopsy are uncommon, patients
are often reluctant to consider it, and its validity may be
diminished by sampling as well as interpretation errors. Liver
biopsy use in HCV-infected patients generally has declined.
Because SVR can now be anticipated in the vast majority of
patients treated for HCV, the management of the HCV-infected
kidney transplant candidate, even with cirrhosis, has evolved.
SVR is associated with sustained and long-lasting suppression of
necroinﬂammation and may even result in regression of
cirrhosis, potentially resulting in decreased disease-related
morbidity and improved survival.38 Even in the absence of
regression of cirrhosis, kidney transplantation alone is feasible
in the absence of major complications of portal hypertension,
just like in patients with hepatitis B virus (HBV)–related
cirrhosis.39
Thus, the role of liver biopsy in evaluation of liver ﬁbrosis in
HCV-infected patients with CKD G4–5 will evolve given the
high SVR rates obtained with current DAA regimens. Deﬁning
the severity of cirrhosis involves assessment for clinically sig-
niﬁcant portal hypertension (hepatic-vein wedge-pressure
gradient of$ 10mmHg).40Methods include upper endoscopy,
noninvasive radiological evaluation, or direct portal pressure
measurement. Based on the Baveno VI consensus,41 portal
hypertension is very unlikely (and hence an upper endoscopy
can be avoided with > 90% reliability) in patients with
compensated cirrhosis but elastography < 20 kPa and plateletKidney International Supplements (2018) 8, 91–165
www.kisupplements.org chap te r 1count > 150,000/mm3. Whether this approach is also valid for
patients on hemodialysis remains unknown.
In summary, all HCV-infected patients with kidney failure
should undergo a noninvasive biochemical and/or morpho-
logical evaluation to stage ﬁbrosis and determine the role of
antiviral therapies (see Chapter 2) and to facilitate the choice
of kidney or combined liver-kidney transplantation in
cirrhotic patients. When results between biochemical and
morphological evaluation are discordant or when liver
comorbidities are suspected, liver biopsy is suggested.42
1.4 Other testing of patients with HCV infection
Although HCV infection predominantly causes liver disease,
it is also associated with extrahepatic manifestations including
kidney disease.43 HCV has been shown to infect both hepa-
tocytes and lymphocytes; thus, lymphoproliferative disorders
such as lymphoma and mixed cryoglobulinemia are linked to
HCV infection.44 HCV has also been implicated in de-
rangements of multiple organ systems including cardiovas-
cular, endocrine, muscular, nervous, ocular, respiratory,
skeletal, cutaneous, and urinary systems. In addition, HCV
can have a deleterious impact on psychosocial status.45
The relationship between HCV infection and CKD is com-
plex. HCV infection and CKD are prevalent in the general
population and associated in various ways: patients on chronic
hemodialysis are at increased risk of acquiring HCV, and some
types of kidney disease are precipitated by HCV infection.
Conventional risk factors for CKD such as aging, diabetes,
hypertension, andmetabolic syndrome do not fully explain the
current frequency of CKD in the adult general population of
developed countries. In addition to these conventional risk
factors, accumulating evidence in the last decade has implicated
HCV infection as a cause of kidney disease. HCV co-infection
has also been implicated as a risk factor for CKD in HIV-in-
fected patients.46 Ameta-analysis7 of observational studies47–55
demonstrated a relationship between anti-HCV–positive
serologic status and an increased incidence of CKD in the adult
general population, with an adjusted hazard ratio (HR) of 1.43
(95% conﬁdence interval [CI]: 1.23–1.63). Based on current
information, patients with HCV infection should be regarded
as being at increased risk of CKD, regardless of the presence of
conventional risk factors for kidney disease.
1.4.1: We recommend assessing all patients for kidney
disease at the time of HCV infection diagnosis (1A).Kidney In1.4.1.1: Screen for kidney disease with urinalysis and
estimated glomerular ﬁltration rate (eGFR)
(Not Graded).1.4.2: If there is no evidence of kidney disease at initial
evaluation, patients who remain NAT-positive
should undergo repeat screening for kidney disease
(Not Graded).
1.4.3: We recommend that all CKD patients with a his-
tory of HCV infection, whether NAT-positive or
not, be followed up regularly to assess progression
of kidney disease (1A).ternational Supplements (2018) 8, 91–1651.4.4: We recommend that all CKD patients with a his-
tory of HCV infection, whether NAT-positive or
not, be screened and, if appropriate, vaccinated
against hepatitis A virus (HAV) and hepatitis B
virus (HBV), and screened for human immuno-
deﬁciency virus (HIV) (1A).
Rationale
1.4.1: We recommend assessing all patients for kidney
disease at the time of HCV infection diagnosis (1A).1.4.1.1: Screen for kidney disease with urinalysis and
estimated glomerular ﬁltration rate (eGFR)
(Not Graded).The prevalence of CKD, deﬁned by a reduction in eGFR and/
or increased urinary albumin excretion,56 exceeds 10% in the
adult general population, according to numerous population-
based studies. The prevalence of low GFR alone is around 5% to
6%but increases sharplywith older age. Testing forCKDappears
logical in HCV-infected individuals, as many authors have sug-
gested a potential role of HCV infection as a cause of CKD.
However, epidemiologic supporting data regarding the preva-
lence of CKD in HCV-infected patients were until recently
limited and used variable criteria for the deﬁnition of CKD; the
demographic/clinical characteristics of the representative patient
population were variable as well. According to 3 studies per-
formed in the US,47,52,55 the unadjusted prevalence of low GFR
(<60 ml/min per 1.73m2) ranged at baseline between 5.1% and
8.0% among middle-aged anti-HCV–seropositive individuals.
The unadjusted prevalence of renal insufﬁciency (serum creati-
nine>1.5mg/dl [>133mmol/l]) in one large studyof anti-HCV-
seropositive veterans from the US was 4.8%.57 In another large
cohort of HCV-positive, HIV-positive patients from North
America, the unadjusted frequency of lowGFR (<60ml/minper
1.73 m2) at baseline ranged between 3.7% and 4.0%.58
Kidney involvement in HCV infection was ﬁrst recognized
more than 2 decades ago; however, the association between
HCV and CKD (low GFR or presence of proteinuria) in the
adult general population was controversial until a few years
ago. An increasing body of evidence has recently highlighted
the detrimental impact of HCV infection on the risk of CKD
(Supplementary Tables S3 and S4). One meta-analysis7 re-
ported an HR of 1.43 (95% CI: 1.23–1.63) between positive
HCV serologic status and increased incidence for CKD, while
another recent study59 demonstrated that patients with HCV
had a 27% increased risk of CKD compared with patients
without HCV. This study also revealed that HCV-positive
patients experienced a 2-fold higher risk of mem-
branoproliferative glomerulonephritis (MPGN) and a nearly
17-fold higher risk of cryoglobulinemia. Effective antiviral
treatments have been shown to reduce risk for development
of CKD by 30%. Cohort studies performed in patients with
HIV and HCV co-infection,10 patients with diabetes,8,60 and
patients with biopsy-proven chronic glomerulonephritis
(GN)9 have conﬁrmed a signiﬁcant relationship between anti-
HCV–positive serologic status and accelerated progression of111
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greater in patients with CKD before reaching end-stage kid-
ney disease (ESKD) than in a healthy population.5,6 Among
liver transplant recipients infected with HCV who were
treated with antiviral therapy, SVR led to improved eGFR in
those with CKD G2 (GFR 60–89 ml/min per 1.73 m2) before
treatment.61 HCV co-infection is a risk factor for increased
health care resource utilization in HIV-infected individuals in
the US; a multivariate Poisson model showed that HCV co-
infection was associated with higher frequency of emergency
department visits: adjusted relative risk (RR) 2.07 (95% CI:
1.49–2.89). In particular, emergency department visits related
to kidney disease were much more common among co-
infected patients (37%) than among those with HIV infection
alone (10%).62 Another meta-analysis of observational
studies63 reported a relationship between positive anti-HCV
serologic status and an increased risk of reduced GFR among
HIV-infected individuals, with an adjusted HR of 1.64 (95%
CI: 1.28–2.0), compared with those having HIV infection
alone.
1.4.2: If there is no evidence of kidney disease at initial
evaluation, patients who remain NAT-positive
should undergo repeat screening for kidney disease
(Not Graded).
The recommendation to repeat testing for proteinuria or
GFR in anti-HCV–positive, HCV NAT–positive patients
comes from epidemiologic data. In one study, serial mea-
surements of eGFR and proteinuria were obtained in a large
cohort of US metropolitan residents. The prevalence of CKD
was greater among anti-HCV–positive, HCV NAT–positive
patients compared with matched anti-HCV–negative controls
(9.1% vs. 5.1%, P ¼ 0.04).64 In addition, using data from the
Third National Health and Nutrition Examination Survey, at
least 2 studies have observed an increased risk of albuminuria
in patients with HCV.65,66 Classically, HCV infection pre-
disposes to cryoglobulinemic MPGN; however, HCV-positive
individuals may also be at risk for kidney injury related to
decompensated cirrhosis, injection drug use, and HIV or
HBV co-infection. Overall, multiple studies have now shown
that HCV infection is associated with an increased risk of
developing CKD, as summarized in a recent meta-analysis.7 It
is possible that accelerated atherosclerosis also contributes to
the increased risk of developing kidney disease among HCV-
infected individuals.67
1.4.3: We recommend that all CKD patients with a history
of HCV infection, whether NAT-positive or not, be
followed up regularly to assess for progression of
kidney disease (1A).
Although studies are heterogeneous and some controversy
persists,68 overall, HCV-infected patients appear to be at greater
risk for incidence and progression of kidney disease and require
monitoring as outlined in the KDIGO CKD guideline.56 In the
Women’s Interagency HIV study, anti-HCV–positive serologic
statuswas independently associatedwith a net decrease in eGFR112of approximately 5%per year (95%CI: 3.2–7.2) comparedwith
women who were seronegative.69
Of note, antiviral therapy for HCV signiﬁcantly improves
hepatic and extrahepatic outcomes in the general population70,71
and among patients co-infectedwithHIVandHCV.72 Six studies
have addressed the impact of interferon (IFN)-based regimens
on the progression of CKD.64,73–77 Five multivariate ana-
lyses64,73–76 suggested that treatment of HCV infection may
improve renal survival per se. In a nationwide cohort study from
Taiwan, patients who had received antiviral treatment (pegylated
IFN plus ribavirin [RBV]) had a calculated 8-year cumulative
incidence of ESKD of 0.15% versus 1.32% in untreated patients
(P < 0.001).75 Multivariate-adjusted Cox regression revealed
that antiviral treatment was associated with lower risks of ESKD
(HR: 0.15; 95% CI: 0.07–0.31). Antiviral treatment was also
associated with an adjusted HR of 0.77 (95% CI: 0.62–0.97) for
acute coronary syndrome, and 0.62 (95% CI: 0.46–0.83) for
ischemic stroke.75 These favorable associations were not
observed in patients treated for less than 16 weeks, suggesting
that shorter-duration therapy was inadequate.
In a study on 650 Japanese patients with liver cirrhosis,73
multivariate Cox proportional hazards analysis showed that
failure to achieve SVR was a predictor of development of CKD,
with an adjusted HR of 2.67 (95% CI:1.34–5.32). In a hospital-
based study from the US, 552 HCV-infected patients were
evaluated, and 159 received IFN therapy during a 7-year follow-
up. Multivariate logistic regression indicated that a history of
IFN treatment was a signiﬁcant independent negative predictor
forCKD (odds ratio [OR]: 0.18; 95%CI: 0.06–0.56).64 Finally, a
recentmeta-analysis of controlled and uncontrolled studies (11
studies; n ¼ 225 patients) that evaluated efﬁcacy and safety of
antiviral treatment for HCV-related glomerular disease found
that the summary estimate of the mean decrease in serum
creatinine levels was 0.23 mg/dl (20 mmol/l) (95% CI: 0.02–
0.44) after IFNa-based therapy.78
1.4.4: We recommend that all CKD patients with a history
of HCV infection, whether NAT-positive or not, be
screened and, if appropriate, vaccinated against
HAV and HBV, and screened for human immuno-
deﬁciency virus (HIV) (1A).
HCV is a blood-borne pathogen and shares routes of
transmission with HBV and HIV. Although hepatitis A virus
(HAV) infection is frequently mild in healthy individuals,
superinfection with HAV and HBV in patients with liver
disease (including chronic HCV) may result in signiﬁcant
morbidity and mortality.79 Thus, as HAV80 and HBV81 are
vaccine-preventable infections, appropriate vaccination
should be encouraged, although response rates to vaccination
are diminished in patients with advanced CKD.
Research recommendations
 Studies are needed to examine HCV antigen testing as an
alternative to NAT to diagnose HCV viremic infection.
 The clinical utility of HCV antigen immunoassays and anti-
gen and antibody combination assays should be determined.Kidney International Supplements (2018) 8, 91–165
www.kisupplements.org chap te r 1 The predictive value of different levels of ALT for identi-
fying HCV infection and the additive value of ALTscreening
to the current generation of immunoassays or NAT testing
should be investigated. Data should already exist to address
this question among dialysis providers that perform routineKidney International Supplements (2018) 8, 91–165screening of their patients. The utility of ALT testing after
resolved HCV infection should be studied.
 With the availability of effective treatments for HCV, the
role of DAAs in preventing and slowing the progression of
CKD in HCV-infected population should be assessed.113
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with CKDThe recommendations are presented below by GFR category.
GFR can be measured GFR or estimated GFR. If eGFR is
used, we suggest using the creatinine-based Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) formula or
the creatinine and cystatin C-based CKD-EPI formula.82
Because multiple studies from the general population
have found a strong correlation between mortality and
SVR,83 regulatory agencies such as the US Food and Drug
Administration (FDA) have generally accepted SVR response
as a surrogate endpoint for trials used in their drug approval
process.84 The FDA recently replaced SVR at 24 weeks after
cessation of therapy (SVR24) with SVR at 12 weeks
(SVR12). Although there are no data demonstrating that
SVR12 reduces mortality in CKD, a meta-analysis showed
that SVR24 predicted mortality not only in the general
population, but also in patients with cirrhosis and patients
with HIV co-infection.85 Currently, duration of therapy for
DAA regimens is usually 12 weeks but may change in the
future.
For most CKD patients, as in the general population, the
potential beneﬁts of antiviral treatment outweigh potential
harms.86 However, some patients may not be expected to live
long enough to beneﬁt from therapy (e.g., those with meta-
static cancer). The Work Group was hesitant to specify a
minimum life expectancy that would justify treatment, given
the inaccuracy of predictions and the need to individualize
this decision. However, as noted in the American Association
for the Study of Liver Diseases/Infectious Diseases Society of
America (AASLD/IDSA) guidance, little evidence exists to
support initiation of HCV treatment in patients with a limited
life expectancy (<12 months).87
IFN is often poorly tolerated in advanced CKD (CKD G4–
G5) patients who have prolonged IFN exposure due to
decreased renal clearance. RBV is also associated with adverse
events. Hemolytic anemia induced by RBV is especially
common in patients with CKD G3b–G5 and can be severe.
The RBV dose needs to be reduced in patients with advanced
CKD, but dose reductions can only be approximated. An
initial starting dose of 200 mg daily is typical but does not
preclude development of anemia, despite initiation or
increased dosing of erythropoiesis stimulating agents (ESAs).
Because DAAs are effective, well-tolerated, and often do not
require dose reductions in those with CKD, it is clearly
desirable to avoid IFN completely in all patients and to
minimize use of RBV in patients with advanced CKD.1142.1: We recommend that all CKD patients infected with
HCV be evaluated for antiviral therapy (1A).2.1.1: We recommend an interferon-free regimen
(1A).
2.1.2: We recommend that the choice of speciﬁc
regimen be based on HCV genotype (and
subtype), viral load, prior treatment history,
drug–drug interactions, glomerular ﬁltra-
tion rate (GFR), stage of hepatic ﬁbrosis,
kidney and liver transplant candidacy, and
comorbidities (1A).
2.1.3: Treat kidney transplant candidates in
collaboration with the transplant center to
optimize timing of therapy (Not Graded).2.2: We recommend that patients with GFR ‡ 30 ml/min per
1.73 m2 (CKD G1–G3b) be treated with any licensed
direct-acting antiviral (DAA)-based regimen (1A).
2.3: Patients with GFR < 30 ml/min per 1.73 m2 (CKD G4–
G5D) should be treated with a ribavirin-free DAA-
based regimen as outlined in Figure 1.
2.4: We recommend that all kidney transplant recipients
infected with HCV be evaluated for treatment (1A).2.4.1: We recommend treatment with a DAA-based
regimen as outlined in Figure 1 (1A).
2.4.2: We recommend that the choice of regimen be
based on HCV genotype (and subtype), viral
load, prior treatment history, drug–drug in-
teractions, GFR, stage of hepatic ﬁbrosis, liver
transplant candidacy, and comorbidities (1A).
2.4.3: We recommend avoiding treatment with
interferon (1A).
2.4.4: We recommend pre-treatment assessment
for drug–drug interactions between the
DAA-based regimen and other concomitant
medications including immunosuppressive
drugs in kidney transplant recipients (1A).
2.4.4.1: We recommend that calcineurin in-
hibitor levels be monitored during
and after DAA treatment (1B).
2.5: All treatment candidates should undergo testing for
HBV infection prior to therapy (Not Graded).2.5.1: If hepatitis B surface antigen [HBsAg] is
present, the patient should undergo assess-
ment for HBV therapy (Not Graded).Kidney International Supplements (2018) 8, 91–165
Kidney function HCV
genotype 












CKD G5 PD n/a (reasonable to follow proposed regimens for HD)
1a Sofosbuvir with ledipasvir,
daclatasvir or simeprevir  
D2nirivabir/rivubsofoSB1
Glecaprevir/pibrentasvir c 1C
1b Sofosbuvir with ledipasvir,
daclatasvir or simeprevir 
1B
Glecaprevir/pibrentasvir c 1C
2, 3, 5, 6 Glecaprevir/pibrentasvir c 1D Sofosbuvir/daclatasvir/ribavirin d 2D
4 Sofosbuvir with ledipasvir,








(GFR ≥ 30 ml/min per
1.73 m2)
Ritonavir-boosted paritaprevir, ombitasvir, and
dasabuvir (also known as PrOD or 3D regimen)
with ribavirin  
Ritonavir-boosted paritaprevir, ombitasvir, and
dasabuvir (also known as ProD or 3D regimen)
Figure 1 | Recommended direct-acting antiviral (DAA) treatment regimens for patients with chronic kidney disease (CKD) G4–G5D and
kidney transplant recipients (KTRs), by hepatitis C virus (HCV) genotypea. Duration of therapy for all above regimens is usually 12 weeks
but readers should consult Association for the Study of Liver Diseases (AASLD) or European Association for the Study of the Liver guidelines for
latest guidance. aWe recommend that CKD patients with glomerular ﬁltration rates (GFRs) $ 30 ml/min per 1.73 m2 (CKD G1T–G3bT) be treated
with any licensed DAA regimen. bThere is little published evidence to guide treatment regimens in KTRs with GFR < 30 ml/min per 1.73 m2
(CKD G4T–G5T). Regimens in KTRs should be selected to avoid drug–drug interactions, particularly with calcineurin inhibitors. cBased on Reau et
al.3 dAs suggested in AASLD guidelines (https://www.hcvguidelines.org/). CKD G, chronic kidney disease (GFR category); HD, hemodialysis; n/a,
no data or evidence available; PD, peritoneal dialysis.
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Kidney Inter2.5.2: If HBsAg is absent but markers of prior HBV
infection (HBcAb-positive with or without
HBsAb) are detected, monitor for HBV
reactivation with serial HBV DNA and liver
function tests during DAA therapy (Not
Graded).Rationale
CKD G1–G3b (GFR $ 30 ml/min per 1.73 m2). For mild to
moderate decreases in kidney function, patients with CKD can
generally be treated as per evidence-based guidelines for the
general population. Currently in the US, the AASLD/IDSA
guidelines recommend few dosage modiﬁcations for people
with mild to moderate reductions in GFR. For CKD G1–G3b
(GFR $ 30 ml/min per 1.73 m2), no dosage adjustment is
required when using daclatasvir (60 mg); daily ﬁxed-dose
combination of elbasvir (50 mg) and grazoprevir (100 mg);
daily ﬁxed dose combination of glecaprevir (300 mg) and
pibrentasvir (120 mg); ﬁxed dose combination of sofosbuvirnational Supplements (2018) 8, 91–165(400 mg) with either ledipasvir (90 mg) or velpatasvir
(100 mg); simprevir (150 mg); ﬁxed-dose combination of
sofosbuvir (400 mg), velpatasvir (100 mg), and voxilaprevir
(100 mg); or sofosbuvir (400 mg). At the time of publication,
regimens including velpatasvir have not been formally
approved for use in patients with CKD G1–G3 in some juris-
dictions, however.
The 2018 European Association for the Study of the Liver
(EASL) guideline42 also recommends no dosage modiﬁcations
of DAAs for CKD G1–G3 patients, but recommends that
these patients should be carefully monitored.
In summary, for patients with CKD G1–G3 the choice of
DAA is not restricted. However, it must be stressed that
recommended drugs and dosage are constantly evolving, and
clinicians should consult the latest guidelines from AASLD
(https://www.hcvguidelines.org/unique-populations/renal-
impairment) or EASL (http://www.easl.eu/research/our-
contributions/clinical-practice-guidelines) for the most
up-to-date treatment information.115
chap te r 2 www.kisupplements.orgCKD G4–G5 and G5D (Advanced CKD: GFR < 30 ml/min per
1.73 m2 and those on hemodialysis). DAAs have variable
renal elimination; thus, advanced CKD, if present, is an
important determinant in the choice of agent. Until recently,
patients with advanced CKD had limited options for HCV
therapy. Importantly sofosbuvir, which had been the corner-
stone of most DAA regimens, is predominantly renally cleared
(80%) and is licensed for use only in individuals with GFR$ 30
ml/min per 1.73 m2 (CKD G1–G3b).
A regimen combining a nonstructural protein 5A (NS5A)
replication complex inhibitor (elbasvir) and a new-generation
nonstructural protein NS3/4A protease inhibitor (grazoprevir)
has been licensed for patients infected with HCV genotypes
(GTs) 1 and 4, with safety and efﬁcacy data available in patients
with advanced CKD. Both agents are metabolized by CYP3A
and primarily (>90%) excreted in feces with minimal renal
clearance (<1%). Although pharmacokinetic analyses show
that area under the curves (AUCs) are higher in individuals
with advanced CKD requiring hemodialysis (up to 46% higher
compared with individuals with normal kidney function),
these changes in exposure to the drugs are not considered
clinically relevant.88 Of note, Reddy et al.89 identiﬁed 32 pa-
tients with CKD G3a/G3b included in trials with grazoprevir
and elbasvir and found no evidence of deterioration of kidney
function as a result of treatment with these agents.
Grazoprevir is a substrate of OATP1B1/3, and co-admin-
istration with drugs that inhibit OATP1B1/3 (such as ena-
lapril, statins, digoxin, some angiotensin-receptor blockers)
may result in increased levels of grazoprevir that may lead to
clinically signiﬁcant hyperbilirubinemia. Elbasvir and grazo-
previr are substrates of CYP3A, and co-administration with
strong CYP3A inducers (such as rifampin, phenytoin, and
St John’s wort) is contraindicated, as it may result in
decreased plasma concentrations and potentially reduced
antiviral activity of both agents. The Hepatitis Drug
Interactions website from the University of Liverpool (http://
www.hep-druginteractions.org) or another reliable expert
source should be accessed to determine the risk and man-
agement recommendations for drug–drug interactions.
In contrast to sofosbuvir, agents such as grazoprevir-
elbasvir, paritaprevir-ritonavir-ombitasvir with or without
dasabuvir, simeprevir, daclatasvir as well as glecaprevir/
pibrentasvir can be safely used in CKD G4 and G5 patients
(Supplementary Tables S5 and S6). Data on several regimens
have been published in patients with advanced CKD (CKD
G4–G5D). In the C-SURFER trial, a phase 3 placebo-
controlled, randomized, multicenter trial, 12-week treatment
with grazoprevir and elbasvir was evaluated in HCV GT1–
infected patients with advanced CKD (81% with eGFR < 15
ml/min per 1.73 m2 [CKD G5] and 76% on hemodialysis
[CKD G5D]), including 6% of patients with cirrhosis).90 The
majority of them were infected with GT1a (52%), and 80%
were treatment-naïve. SVR12 was 99% (95% CI: 95.3–100.0;
115 of 116), with 1 relapse 12 weeks after end of treatment
with no signiﬁcant difference between GTs 1a and 1b, nor
between those undergoing hemodialysis and those with116advanced CKD not on dialysis therapy. Tolerability was
excellent. The most common adverse events ($10% fre-
quency) were headache, nausea, and fatigue, and were com-
parable in the treatment versus control arms. The frequencies
of hemoglobin levels < 8.5 g/dl (< 85 g/l) were also com-
parable between treated and untreated groups (4.5% and
4.4%, respectively), and similar proportions of patients in
both groups required treatment with ESAs. Renal events such
as a rise in serum creatinine and/or blood urea nitrogen,
change in eGFR, and need to start hemodialysis were com-
parable between both groups.90,91 These RCT results have
recently been conﬁrmed in a real-world French cohort
study.92 The combination of ritonavir-boosted paritaprevir
with ombitasvir and dasabuvir (“PrOD” or 3D regimen) has
been evaluated in a small single-arm study as well as in
observational cohorts demonstrating excellent efﬁcacy in
patients infected with HCV GT1 and CKD G4 and G5.93 RBV
may be required when using the PrOD regimen in patients
infected with HCV GT1a. However, even with a reduced dose
of 200 mg RBV daily, further dosing reduction was required
in half of the treated patients despite the use of ESAs.94
Virological factors that may impact response to HCV
therapy especially in GT1a-infected patients include the
presence of resistance-associated variants.95 Resistance testing
may not be available in some centers, and if use of RBV is not
feasible due to baseline anemia, extension of therapy with
grazoprevir/elbasvir to 16 weeks for patients infected with
HCVGT1a should be considered. In HCVGT1a patients with
high viral load (>800,000 IU/ml), prolonging duration of
therapy to 16 weeks and the use of RBV, if possible, to avoid a
reduction in SVR12 (from 99% with RBV to 88% without in
1 study) is suggested.96
In the RUBY II trial presented at the 2016 AASLD Annual
Meeting, dialysis patients with HCV GT1a were treated with
ritonavir-boosted paritaprevir, ombitasvir, and dasabuvir, and
those infected with GT4 were treated with the ﬁrst 2 agents
without dasabuvir. RBV was not included in the regimen. Of
the 13 treated subjects, 12 achieved SVR (92%). The
remaining patient who discontinued antiviral therapy elected
to undergo kidney transplantation.97 All components of the
combination regimen containing ombitasvir, paritaprevir, ri-
tonavir, and dasabuvir (used in GT1 and without dasabuvir in
GT4) are predominantly excreted in the feces, with <11%
renal clearance; thus, pharmacokinetics are not signiﬁcantly
altered in advanced CKD (CKD G4–G5), and no dose
adjustment is recommended. In a single-arm, multicenter
study of treatment-naïve adults with HCV GT1 infection
without cirrhosis and with CKD G4 or G5, 20 patients were
treated with this regimen for 12 weeks. Patients with HCV
GT1a infection also received RBV (n ¼ 13), whereas those with
GT1b infection did not (n ¼ 7). Eighteen of the 20 patients
achieved SVR12 (90%; 95% CI: 69.9–97.2), but 1 treatment
failure was nonvirological (death after the end of the treatment
unrelated to the treatment). The only patient who relapsed was
a GT1-infected patient with advanced liver ﬁbrosis on hemo-
dialysis. Adverse events were primarily mild or moderate, andKidney International Supplements (2018) 8, 91–165
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RBV therapy was interrupted in nine patients due to anemia; 4
received ESAs. No blood transfusions were required.94
Similar to other protease inhibitors (simeprevir and par-
itaprevir), grazoprevir is contraindicated in decompensated
patients with Child-Turcotte-Pugh class B or C due to
diminished hepatic metabolism and risk of adverse event,
particularly hepatic toxicity.
In practice, no dose adjustment for kidney function is
needed with NS5A inhibitors such as daclatasvir and protease
inhibitors such as simeprevir.
Prior to the recent introduction of glecaprevir-pibrentas-
vir, a sofosbuvir-based regimen had been the only option for
patients with CKD G4 and G5 infected with HCV GTs 2, 3, 5,
and 6, particularly those with cirrhosis and those with a
history of prior nonresponse to IFN-based therapies. How-
ever, the glecaprevir-pibrentasvir regimen is pan-genotypic,
with no dose reduction necessary for diminished GFR. In the
EXPEDITION-4 trial, which included 104 patients with CKD
G4–G5 and HCV GTs 1–6 of whom 82% were receiving he-
modialysis therapy,98 subjects received the combination of
glecaprevir, a protease inhibitor, and pibrentasvir, an NS5A
inhibitor, for 12 weeks. Forty-two percent of subjects had been
treated previously, including 2 who had received sofosbuvir-
based therapy; 19% of patients had compensated cirrhosis.
SVR12 was 98%; of the 2 patients who did not achieve SVR, 1
received only 4 weeks of therapy and the other died of an
unrelated cause shortly after completion of therapy. Detection
of resistance-associated variants, present in 29% of subjects,
did not impact SVR, although HCV GT 3 patients with prior
therapy failure had been excluded from inclusion.
We recognize that preferred regimens such as grazoprevir-
elbasvir and glecaprevir-pibrentasvir for CKD G4–G5D pa-
tients may not be available in some countries or regions, and
sofosbuvir-based regimens may be all that is available despite
the fact that they are not licensed for use in CKD G4–G5D
patients. Sofosbuvir undergoes extensive hepatic metabolism
and is biotransformed to the pharmacologically active
nucleotide analog uridine-triphosphate (SOF-007TP) which,
once dephosphorylated, results in the formation of the pre-
dominant sofosbuvir inactive metabolite GS-331007 (SOF-
007). SOF-007 is mainly eliminated through the renal route,
and the 4-hour hemodialysis extraction ratio is about 53%.99
For creatinine clearance (CrCl) < 30 ml/min, pharmacoki-
netics data showed marked plasma overexposure of sofos-
buvir (AUC0-IFN 171% higher), and particularly SOF-007
(AUC0-IFN 451% higher) after a single dose of 400 mg, as
compared with subjects with normal kidney function.100
Despite these pharmacokinetics studies, there are pre-
liminary data with sofosbuvir-based regimen in CKD patients
suggesting that sofosbuvir with a daily or 3-times weekly
regimen is safe and well tolerated in HCV-infected patients,
most with cirrhosis, who require hemodialysis.100–107 In a
recent prospective study, 2 dosing regimens, sofosbuvir full
dose (400 mg daily, n ¼ 7) and 3 times a week (n ¼ 5) after
hemodialysis with simeprevir, daclatasvir, ledipasvir, or RBV,Kidney International Supplements (2018) 8, 91–165were compared in hemodialysis patients.105 While both groups
showed higher SOF-007 plasma concentrations than those
previously reported in patients with normal kidney function,
plasma concentrations of sofosbuvir or its inactive metabolite
SOF-007 did not accumulate with either regimen between
hemodialysis sessions or throughout the treatment course.
Additional experience with reduced sofosbuvir doses, such
as 200 mg daily or 400 mg 3 times weekly, suggests that while
very well tolerated, these suboptimal doses may lead to
inferior SVR rates. In one study, Gane et al. presented results
for 10 patients with advanced CKD (9 infected with HCV
GT1 and 1 with HCV GT3, all with CrCl < 30 ml/min)
receiving sofosbuvir, 200 mg daily, combined with RBV, 200
mg daily.100 This schedule resulted in 6 relapses in HCVGT1-
infected patients. In 2 case reports, Perumpail et al. reported
the successful treatment of 2 liver transplant patients on he-
modialysis therapy who received sofosbuvir, 200 mg and 400
mg daily, respectively, with simeprevir at standard dose.103,104
Bhamidimarri et al.106 evaluated 2 different schedules in 15
patients with advanced CKD (n ¼ 3) or requiring hemodi-
alysis (n ¼ 12). Eleven patients received sofosbuvir, 200 mg
daily, and 4 patients received sofosbuvir, 400 mg 3 times
weekly, all with simeprevir at a standard dose. Two relapses
occurred, one in each group. Finally, preliminary results from
another case series in 11 patients requiring hemodialysis
receiving sofosbuvir, 400 mg daily, and simeprevir reported
no relapse.102 Very recently, a larger study (n ¼ 50) also
suggested that sofosbuvir-based antiviral therapy, with a
reduced dose of sofosbuvir, is reasonably safe and effective for
the treatment of HCV patients with ESKD, including hemo-
dialysis patients.108
Use of full-dose off-label use of sofosbuvir daily has been
reported in HCV patients on dialysis and in those at high risk
of treatment failure such as those with cirrhosis, previously
pretreated or nonresponders and those infected with GT3.
Such patients should be closely monitored, with clinical,
biological, and cardiac assessment.109
A related and unresolved issue is whether use of sofosbuvir
in patients with advanced CKD may accelerate its progression.
Most of the studies that examined this issue were conducted
in patients with moderate CKD. Gonzalez-Parra and col-
leagues110 observed a signiﬁcant mean decrease in GFR of 9
ml/min per 1.73 m2 in 35 patients treated with a sofosbuvir-
based regimen with a baseline GFR of 30 to 60 ml/min per
1.73 m2, whereas no signiﬁcant decline in GFR occurred in 8
patients treated with the PrOD regimen. Rosenblatt et al.111
also reported that in a series of 90 patients, a baseline CrCl
< 60 ml/min predicted a decline in kidney function with
sofosbuvir therapy. Saxena et al. also observed a decline in
kidney function in 73 patients with a baseline eGFR # 45 ml/
min per 1.73 m2 treated with sofosbuvir.107 Mallet et al.,112 in
a retrospective study of 814 HCV patients mostly with base-
line eGFR $ 60 ml/min per 1.73 m2, reported a mean eGFR
decrease of 2.6 and 1.7 ml/min per 1.73 m2 over a maximum
of 37 months in patients treated with sofosbuvir-based and















(Genotypes 2, 3: 1B;
Genotypes 5, 6: 2D)
Algorithm 1 | Treatment scheme for chronic kidney disease (CKD) G1–G5D. Recommendation grading is provided for each speciﬁc
treatment regimen and hepatitis C virus (HCV) genotype. CKD G, chronic kidney disease, GFR category; DAA, direct-acting antiviral; GFR,
glomerular ﬁltration rate; NAT, nucleic acid testing.
chap te r 2 www.kisupplements.orget al.113 recently reported that in patients with CKD G3a–G3b
who received sofosbuvir-based regimens, HCV cure was
associated with a 9.3 ml/min per 1.73 m2 improvement in
eGFR during the 6-month post-treatment follow-up period.
Despite these conﬂicting ﬁndings, if a sofosbuvir-based
regimen is selected, monitoring of kidney function should be
performed with serial serum creatinine measurements during
therapy, although it is unclear whether dose reduction or
withdrawal is indicated if GFR declines further.
Algorithm 1 summarizes the recommended choice of
DAAs according to the level of kidney function and HCV GT.
The Work Group recognizes that not all preferred regimens
are available in all jurisdictions, and as such we have also
recommended alternate regimens to provide further potential
treatment options. There is no evidence to support speciﬁc
DAA regimens in patients on peritoneal dialysis, but it is
reasonable to follow guidance for patients on hemodialysis.114
In summary, we recommend that patients with CKD G4–
G5 and G5D be treated with a RBV-free DAA-based regimen.
Glecaprevir-pibrentasvir has pan-genotypic efﬁcacy including
in patients with prior sofosbuvir treatment and cirrhosis.
Grazoprevir-elbasvir and the PrOD regimen are also approved
for use in CKD G4–G5 and G5D patients with GTs 1 and 4.
Although there are studies reporting the use of sofosbuvir in
patients with CKD G4–G5D, in jurisdictions where there is
availability of well-tolerated regimens (i.e., grazoprevir-
elbasvir and glecaprevir-pibrentasvir), its use is not recom-
mended given the limited information about its safety in this
population. Our guidance is in general concordance with
those provided by AASLD (https://www.hcvguidelines.org/
unique-populations/renal-impairment) and EASL (http://118www.easl.eu/research/our-contributions/clinical-practice-
guidelines), but given that recommended drugs and dosage
are constantly evolving, clinicians should consult these re-
sources for the most up-to-date treatment information.
Kidney transplant recipients: CKD G1T–G5T (see also Chapter
4). Although published data on DAAs in kidney transplant
recipients are less abundant,115 the study results seem as
satisfactory as those observed in liver transplant recipients
(Supplementary Tables S7 and S8). In a recent trial
comparing 12 and 24 weeks of sofosbuvir and ledipasvir in
114 kidney transplant recipients infected with HCV GTs 1
and 4 (96% GT1) with an eGFR of 40 ml/min per 1.73 m2 or
greater (median eGFR 56 ml/min per 1.73 m2), the therapy
was very well tolerated, and SVR rates were close to 100%
without differences between arms, suggesting that a 12-week
regimen is also indicated in kidney transplant recipients.116
Smaller cohort studies recently also reported excellent re-
sults in kidney transplant recipients with sofosbuvir-based
regimens.117–119 Sofosbuvir/velpatasvir has also been shown
to be highly effective and well tolerated in liver transplant
recipients with GTs 1–4 and may be considered for kidney
transplant recipients in the future, although at the present,
efﬁcacy and safety data for the latter group are lacking.120
Reau et al.3 have recently described the use of glecapravir/
pibrentasvir in 100 organ transplant recipients, 20 of whom
had received a kidney transplant with high SVR and excel-
lent tolerability.
In transplant recipients, drug–drug interactions with
immunosuppressive agents may result in increased or
diminished plasma levels of immunosuppressive agents, withKidney International Supplements (2018) 8, 91–165
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(Genotypes 2, 3: 1B;
Genotypes 5, 6: 2D)
Algorithm 2 | Treatment scheme for kidney transplant recipients (KTRs). Recommendation grading is provided for each speciﬁc treatment
regimen and hepatitis C virus (HCV) genotype. Chronic kidney disease (CKD) G, CKD glomerular ﬁltration rate (GFR) category (sufﬁx T denotes
transplant recipient); NAT, nucleic acid testing.
www.kisupplements.org chap te r 2consequent risk of toxicity or graft rejection, respectively. For
instance, concurrent use of elbasvir-grazoprevir and cyclo-
sporine is not recommended, as it results in a 15-fold increase
in grazoprevir AUC and 2-fold increase in elbasvir AUC.
Elbasvir-grazoprevir increases levels of tacrolimus by 43%;
thus, close monitoring of levels is indicated, and dose re-
ductions of tacrolimus may be needed. Other protease in-
hibitors such as simeprevir and paritaprevir have similar
drug–drug interactions with cyclosporine, tacrolimus, and
everolimus. There are no signiﬁcant drug–drug interactions
with these protease inhibitors and mycophenolate mofetil
(MMF). No signiﬁcant interactions between NS5A and po-
lymerase inhibitors such as sofosbuvir and calcineurin in-
hibitors (CNIs) have been described, but close monitoring of
immunosuppressive drugs is mandatory because changes in
liver metabolism concurrent with HCV eradication may
require modiﬁcation of immunosuppressive drug doses.
Overall, drug–drug interactions are an important factor
in the choice of a DAA regimen. Protease inhibitors are
associated with signiﬁcant risk for drug–drug interactions,
particularly in patients who are treated with immunosup-
pressive agents such as CNIs and mTOR inhibitors.93,121Kidney International Supplements (2018) 8, 91–165Nonstructural protein 5B (NS5B) inhibitors such as sofos-
buvir or NS5A inhibitors such as ledipasvir and daclatasvir
are associated with a low risk of drug–drug interaction with
CNIs and mTOR inhibitors, but may have interactions with
other concomitant medications. The Hepatitis Drug In-
teractions website from the University of Liverpool (http://
www.hep-druginteractions.org) or another reliable expert
source should be accessed to determine the risk and man-
agement recommendations for drug–drug interactions.
Waiting times for deceased donor kidney transplantation are
very long in many parts of the world, and many transplant
candidates die while waiting for a deceased donor transplant.
(see Chapter 4). Survival after transplantation is generally better
than survival on dialysis including for HCV-infected patients.
With access to DAA, it may be better to receive a kidney trans-
plant fromanHCV-positive donor than to face a longwait for an
HCV-negative kidney. It has been suggested that an HCV-pos-
itive transplant candidate should forego treatment of HCVuntil
after kidney transplantation, to allow receipt of a kidney
transplant from an HCV-positive deceased donor. Adoption of
this strategy would expand the deceased donor organ pool as
well as diminish wait times as suggested by Kucirka et al.122119
chap te r 2 www.kisupplements.orgIf an HCV-negative transplant candidate has a potential
living donor who is HCV NAT–positive, then it seems
reasonable for the donor to be treated for HCV, and donate the
kidney after SVR has been achieved. Because the probability of
SVR is very high, and the time it takes to achieve SVR is only 12
weeks, this strategy makes intuitive sense even if there are no
supporting data. The potential donor also requires careful
evaluation of severity of liver disease. Another consideration is
the use of a kidney from an HCV NAT–positive donor in an
HCV-negative recipient with prompt DAA treatment after
transplant, as recently reported by Goldberg et al.123 and
Durand et al.124 in 2 encouraging small case series. This
approach requires further study before it can be endorsed.
In summary, kidney transplant recipients with GFR $ 30
ml/min per 1.73 m2 (CKD G1T–G3bT) and HCV GTs 1 or 4
can utilize sofosbuvir-based regimens and glecaprevir-
pibrentasvir. For those with HCV GTs 2, 3, 5, and 6, we
recommend glecaprevir-pibrentasvir. For kidney transplant
recipients with GFR < 30 ml/min per 1.73 m2 (CKD G4T–
G5T), the same regimens proposed for patients with CKD
G4–G5D apply (i.e., grazoprevir-elbasvir for GTs 1 and 4 and
glecaprevir-pibrentasvir for all GTs). Our guidance is in
general concordance with those provided by AASLD (https://
www.hcvguidelines.org/unique-populations/kidney-transplant)
and EASL (http://www.easl.eu/research/our-contributions/
clinical-practice-guidelines), but given that recommended
drugs and dosage are constantly evolving, clinicians should
consult these resources for the most up-to-date treatment
information. Algorithm 2 summarizes the recommended
choice of DAAs for kidney transplant recipients according to
the level of kidney function and HCV GT.
Reactivation of HBV infection after DAA therapy. A number
of reports have recently described apparent reactivation of
HBV infection in individuals following successful therapy of
HCV infection with DAA-based therapy.125,126 This has120prompted an FDAwarning.127 As part of routine evaluation of
patients with HCV and CKD, serum markers of HBV infec-
tion (i.e., hepatitis B surface antigen [HBsAg) and HBV DNA)
should be obtained prior to antiviral therapy. Initiation of
therapy with an oral HBV suppressive agent is recommended
if criteria for HBV therapy are met, based on initial testing
prior to HCV therapy or during follow-up after HCV. If
HBsAg is initially absent but markers of prior HBV infection
(positive antibody to hepatitis B core antigen [HBcAb-posi-
tive] with or without antibody to hepatitis B surface antigen
[HBsAb]) are detected, patients should be monitored for
HBV reactivation with serial HBV DNA and liver function
tests during DAA therapy (see also https://www.hcvguidelines.
org/evaluate/monitoring).Research recommendations
 Further studies should be conducted on whether RBV is
required after kidney transplantation in some speciﬁc
groups such as prior nonresponders infected with HCV
GT1a. Treatment of NS5A-resistant variants after kidney
transplantation should also be evaluated.
 Optimal timing of antiviral therapy before or after trans-
plantation in candidates for kidney transplantation should
be clariﬁed. Because the time to transplantation with kid-
neys from deceased donors is unpredictable, delaying
treatment carries higher vascular, metabolic, and malig-
nancy risks as well as the risk of drug–drug interactions
with CNIs after transplantation. As such, treatment before
transplantation may be more appropriate. However, in re-
gions where the prevalence of anti-HCV–positive donors is
high, post-kidney transplant therapy should be considered.
 Use of organs from HCV-positive donors for HCV-negative
recipients with DAA therapy needs to be further explored.
 The impact of treating HCV infection on CKD progression
should be further investigated.Kidney International Supplements (2018) 8, 91–165
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hemodialysis units3.1: We recommend that hemodialysis facilities adhere to
standard infection control procedures including hy-
gienic precautions that effectively prevent transfer of
blood and blood-contaminated ﬂuids between patients
to prevent transmission of blood-borne pathogens







Kidney Inter3.1.1: We recommend regular observational audits
of infection control procedures in hemodi-
alysis units (1C).
3.1.2: We recommend not using dedicated dialysis
machines for HCV-infected patients (1D).
3.1.3: We suggest not isolating HCV-infected he-
modialysis patients (2C).
3.1.4: We suggest that the dialyzers of HCV-
infected patients can be reused if there is
adherence to standard infection control
procedures (2D).3.2: We recommend that hemodialysis centers examine and
track all HCV test results to identify new cases of HCV
infections in their patients (1B).3.2.1: We recommend that aggressive measures be
taken to improve hand hygiene (and proper
glove use), injection safety, and environ-
mental cleaning and disinfection when a new
case of HCV is identiﬁed that is likely to be
dialysis-related (1A).3.3: Strategies to prevent HCV transmission within hemo-
dialysis units should prioritize adherence to standard
infection control practices and should not primarily
rely upon the treatment of HCV-infected patients (Not
Graded).
Rationale
The prevalence of HCV infection in hemodialysis patients is
usually higher than in the general population.128 HCV preva-
lence rates range from about 4%–9% in most high-income
countries, but is signiﬁcantly higher in other countries,Infection control practices (“hygienic precautions”) par
hand hygiene and glove changes, especially between patient cont
ally blood-contaminated surfaces/supplies
injectable medication preparation practices following aseptic techn
tration practice
gh cleaning and disinfection of surfaces at the dialysis station, esp
te separation of clean supplies from contaminated materials and e
national Supplements (2018) 8, 91–165particularly those in the Middle East, North and Sub-Sahara
Africa, Asia, and Eastern Europe16,129,130,131 (Table 2). Rates also
vary during times of social crisis, war, or economic down-
turn.132–134 According to a recent systematic review of studies in
hemodialysis patients basedondata up to 2006, the overall global
incidence rate of HCV infection was 1.47 per 100 patient-years:
4.44 per 100 patient-years in low- to middle-income countries,
and 0.99 per 100 patient-years in high-income countries.135
HCV is easily transmitted parenterally, primarily through
percutaneous exposure to blood. Dramatic reductions were
noted in the incidence following introduction of screening for
HCV in blood donors and reduction in blood transfusion
requirements following introduction of ESAs,136 leaving
nosocomial transmission as the main method of spread of
HCV in dialysis units. Several studies have conﬁrmed noso-
comial transmission in dialysis units using epidemiologic and
phylogenetic data obtained by viral sequencing.21,34,137–140
These data are further supported by the observation of
decline in infection rates following routine implementation of
infection control practices and virological follow-up to detect
anti-HCV using sensitive, speciﬁc new-generation serological
tests.17,141 A multicenter survey revealed that prevalence of
anti-HCV positivity for a Belgian cohort of hemodialysis
patients (n ¼ 1710) dropped steadily from 13.5% in 1991 to
6.8% in 2000, and the same survey revealed signiﬁcant drops
in other European countries including France (42% to 30%),
Italy (28% to 16%), and Sweden (16% to 9%).141 Table 2
provides an overview of HCV prevalence in hemodialysis
patients as summarized from some recent studies.
Nevertheless, more than 50% of all health care–associated
HCV outbreaks from 2008 to 2015 reported to the CDC
occurred in hemodialysis settings.142 As a result, the CDC
recently provided guidance on improving infection control
practices to stop HCV transmission in dialysis units.143
Infection control. Infection control lapses responsible for
HCV transmission contribute to transmission of other
pathogens; hence implementation of improvement efforts willticularly relevant for preventing HCV transmission
acts, before invasive procedures, and after contact with blood and




Table 2 | Recent reported HCV prevalence in hemodialysis patients
Country N Year of testing HCV prevalence (%) Source
Australia-New Zealand 393 2012 3.8 DOPPS 5147
Belgium 485 2012 4.0 DOPPS 5147
Brazil 798 2011 8.4 Rodrigues de Freitas148
Canada 457 2012 4.1 DOPPS 5147
China 1189 2012 9.9 DOPPS 5147
Cuba 274 2009 76 Santana149
Egypt – 2007–2016 50 Ashkani-Esfahan149a
France 501 2012 6.9 DOPPS 4147
Germany 584 2012 4.5 DOPPS 5147
Gulf Cooperation Council 910 2012 19.3 DOPPS 5147
India 216 2012 16 NephroPlus
1050 2013 11
3068 2014 8
Iran – 2006–2015 12 Ashkani-Esfahan149a
Iraq – 2008–2015 20 Ashkani-Esfahan149a
7122 2015 10
7673 2016 9
Italy 485 2012 11.5 DOPPS 5147
Japan 1609 2012 11.0 DOPPS 5147
Jordan – 2007–2015 35 Ashkani-Esfahan149a
Lebanon 3769 2010–2012 4.7 Abou Rached150
Libya 2382 2009–2010 31.1 Alashek151
Nigeria 100 2014 15 Ummate152
Palestine – 2010–2016 18 Ashkani-Esfahan149a
Romania 600 2010 27.3 Schiller153
Russia 486 2012 14.0 DOPPS 5147
Saudi Arabia – 2007 19 Ashkani-Esfahan149a
Senegal 106 2011 5.6 Seck154
Syria – 2009 54 Ashkani-Esfahan149a
Spain 613 2012 8.9 DOPPS 5147
Sweden 426 2012 6.0 DOPPS 5147
Turkey 383 2012 7.0 DOPPS 5147
United Kingdom 397 2012 4.6 DOPPS 5147
United States 2977 2012 7.3 DOPPS 5147
DOPPS, Dialysis Outcomes and Practice Patterns Study; HCV, hepatitis C virus.
Table 3 | Factors and lapses in infection control practices
associated with transmission of HCV infection in dialysis units
 Preparation of injections in a contaminated environment (including at
patient treatment station)
 Reuse of single-dose medication vial for more than 1 patient
 Use of mobile cart to transport supplies or medications to patients
 Inadequate cleaning or disinfection of shared environmental surfaces
between patients
 Failure to separate clean and contaminated areas
 Failure to change gloves and perform hand hygiene between tasks or
patients
 Hurried change-over processes
 Low staff-to-patient ratio
HCV, hepatitis C virus.
chap te r 3 www.kisupplements.orghave broader salutary effects. Most importantly, HCV trans-
mission can be prevented effectively through adherence to
currently recommended infection control practices. There are
no reports of transmission of HCV in dialysis units that had
all infection control practices in place. Publication bias is
unlikely to explain this observation. Additionally, in the
experience of the authors, centers that have had HCV trans-
mission identiﬁed and that subsequently responded with
increased attention to appropriate infection control practices
have not had continued transmission. This observation ap-
plies to unpublished outbreaks and transmission events.
Three systematic reviews have examined the reasons
behind transmission of HCV in hemodialysis units.34,140,144
Root cause analysis of conﬁrmed nosocomial out-
breaks22,29,31,145,146 has revealed lapses in infection control to
be associated with transmission of HCV infection between
patients in dialysis units. For several reasons, including the
long latency period of HCV infection, the number of dialysis
treatments occurring during a patient’s likely exposure period
(based on multiple treatments per week), and sparse docu-
mentation of details in the dialysis treatment record,
retrospective investigation to determine an exact cause of
dialysis-related HCV acquisition is challenging. Rarely, the122exact cause can be surmised using epidemiologic and mo-
lecular virology data. More often, transmission is documented
among patients in the same clinic, who lack other common
exposures and/or risk factors, and lapses in infection control
are identiﬁed in the clinic that could logically lead to trans-
mission (Table 3). Other causes of infection such as under-
going dialysis during travel to developing countries, and
nondialysis health care exposures (e.g., procedures performed
in a common vascular access surgical center) can occur andKidney International Supplements (2018) 8, 91–165
www.kisupplements.org chap te r 3are considered before concluding that transmission occurred
in the dialysis unit.
Mishandling of parenteral medications has been impli-
cated frequently in transmission. Medication vials can
become contaminated with HCV when accessed with used
needles or syringes, or through environmental or touch
contamination of the vial diaphragm by health care personnel
hands. The US CDC’s One & Only Campaign on safe injection
practices (http://www.oneandonlycampaign.org/) should help
address the former issue by promoting single use of syringes.
The latter issue concerning contamination is more likely to
occur when medications are stored or prepared in contami-
nated areas and blood-contaminated items are handled in
close proximity. Sharing of multidose heparin or other
medication vials or spring-triggered devices for glucose
monitoring can lead to transmission. Inadequate cleaning and
disinfection of shared environmental surfaces also increases
risk of transmission. This may include failure to adequately
clean and disinfect external surfaces of hemodialysis ma-
chines, treatment chairs, and other surfaces in the treatment
station, and failure to clean blood spills.
It should be emphasized that blood contamination of
environmental surfaces and equipment both at the patient
treatment station and outside the immediate treatment area
can be present, even in the absence of visible blood. HCV
RNA has been detected on external surfaces of dialysis ma-
chines, a dialysate connector, on a shared waste cart, and in
hand washings of dialysis personnel.155–161 Blood that is
visible or not visible to the naked eye, as evidenced by
chemical tests, has also been detected on dialysis treatment
station surfaces that underwent routine cleaning procedures
following an outbreak of HCV.21 HCV can persist in an in-
fectious state for at least 16 hours, and potentially much
longer, on surfaces at room temperature.160,162 Hand hygiene
also plays an important role in prevention of nosocomial
transmission.163 Lack of adherence to standard practices, such
as hand-washing and glove use and removal practices, has
been documented in several audits. In most HCVoutbreaks in
US hemodialysis centers reported to the CDC, multiple lapses
in infection control were identiﬁed, involving practices such
as hand hygiene and glove use, injectable medication
handling, and environmental surface disinfection.142
Petrosillo et al.164 conducted a multicenter study in 58 Italian
hemodialysis centers and found that the adjusted risk of trans-
mission was correlated with dialysis in units with a high preva-
lence of HCV-infected patients at baseline and those with a low
personnel-patient ratio. A study of 87 US hemodialysis centers
similarly found that baseline HCV prevalence of greater than
10%, low staff-to-patient ratio, and $2-year duration of treat-
ment in the facility were independently associatedwith frequency
ofHCV infections that were likely to be acquired in the facility.165
Implementation of infection control practices can be
advanced by establishing a list of evidence-based in-
terventions, such as those recommended by the CDC, and
regularly assessing and reinforcing adherence to practice
through observational audits. Infection control practices thatKidney International Supplements (2018) 8, 91–165may be most critical to improve (based upon observation of
breaches in outbreak situations that are likely to transmit
HCV) are shown in Table 1. The CDC has checklists and
audit tools to assist facilities in implementing and assessing
many of these practices.166
Isolation. Isolating HCV-infected patients (or patients
awaiting HCV screening results) during hemodialysis is
deﬁned as physical segregation from others for the express
purpose of limiting direct or indirect transmission of HCV.
The traditional deﬁnition of contact isolation is that used for
HBV infections in hemodialysis centers (i.e., dedicated room,
machine, equipment, gowns, and personnel). However,
“isolation” as considered for HCV control has involved
multiple varied approaches and policies, including the use of
a dedicated dialysis machine, personnel, room, or shift, and/
or other barrier precautions (e.g., aprons, gowns, or gloves)
by health care professionals attending these patients.
Whereas the complete isolation of HBV-infected patients
(by room, thus including machine, equipment, and staff) has
proven invaluable in halting the nosocomial transmission of
HBV within hemodialysis units,167 there are multiple reasons
that argue against recommending isolation of HCV-positive
patients:168
(i) Isolation purely for HCV will have no impact on trans-
mission of other infections. Segregation of patients can
create a false sense of reassurance around practices that
could easily result in bloodstream infections (BSIs) or
transmission of multi-drug resistant organisms or other
blood-borne pathogens.
(ii) Segregating patients on the basis of HBVand HCV would
create four separate cohorts, which creates a signiﬁcant
logistic challenge. The treatment of HCV infection in
dialysis patients raises an additional logistical difﬁculty of
how to cohort patients undergoing therapy.
(iii) Isolating only on HCV infection status may expose the
isolated patient to infection with a second HCV GT.
(iv) HCV seroconversion may be delayed for several months
in newly infected hemodialysis patients and serological
testing cannot be relied on to exclude recent infection.169
(v) Starting and maintaining isolation is likely to impose
large costs on already expensive dialysis programs.
The evidence for the use of isolation of HCV-infected
patients during hemodialysis is weak, based on very low-
quality evidence (Supplementary Tables S9 and S10). The
KDIGO 2008 HCV guideline34 stated that hemodialysis units
should ensure implementation of and adherence to strict
infection control procedures designed to prevent transmission
of blood-borne pathogens, including HCV, but isolation of
HCV-infected patients was not recommended as an alterna-
tive to strict infection control procedures (unless in cases of
continued health care–acquired transmission, where a local
isolation policy may be deemed necessary).
A recent Cochrane review170 examined the impact of
isolation as a strategy for controlling transmission of HCV
infection in hemodialysis units. Of the 123 full-text articles123
chap te r 3 www.kisupplements.orgidentiﬁed, the authors could ﬁnd only 1 randomized
controlled trial (RCT).171 This cluster RCT included a total of
12 hemodialysis centers (593 patients) assigned to either
dedicated hemodialysis machines for HCV-infected patients
or no dedicated machines. Two follow-up periods were
included in the study, and each was 9 months long. Staff was
educated on standard infection control practices. Although
the original article reported a signiﬁcant reduction in the
proportion of new infections in the second follow-up period
among the facilities using dedicated versus nondedicated
machines (calculated using chi-square test), based on a more
standard risk ratio analysis, the Cochrane review concluded
that the use of dialysis machines dedicated for HCV-infected
individuals, as compared with the use of nondedicated ma-
chines made no difference in terms of reducing the incidence
of HCV infection during the follow-up period. In addition,
the quality of evidence was rated as “very low” due to several
methodological issues.
Other studies examining isolation as a means of reducing
HCV transmission reported a reduction of transmission, but
they were observational and had very poor-quality evidence
with methodological challenges.172–174 The isolation policies
studied included implementing the isolation or cohorting of
infected patients in a separate room; using exclusive ma-
chines; or employing dedicated machines, room, and staff.
Most studies have adopted a “before-and-after” design,
and compared their results with their own historical
controls.175–178 Thus, it is unclear whether the reported
improvement resulted from the isolation policy or rather
from the simultaneous raising of awareness and reinforce-
ment of the application of hygienic precautions. Furthermore,
in some studies, there might be other contributing factors
such as changes in baseline prevalence and injection safety
and hygienic practices over time.
In contrast to these studies, a DOPPS (Dialysis Outcomes
and Practice Patterns Study) multicenter study and an Italian
multicenter study both concluded that isolation did not
protect against transmission of HCV in hemodialysis pa-
tients,16,164 and some prospective observational studies have
shown reduction of transmission after adoption of universal
precautions.179 A prospective observational study showed a
reduction in the annual incidence of HCV seroconversion
from 1.4% to 0% after the reinforcement of basic hygienic
precautions, without any isolation measures.180
The CDC does not recommend the isolation of HCV-
infected patients in its infection-prevention guidelines.23
The UK Renal Association also states that patients with
HCV do not need to be dialyzed in a segregated area;
however, more experienced staff should be assigned. They
further recommend that if nosocomial transmission con-
tinues to occur despite reinforcement and audit of the pre-
cautions, a local segregation policy may be deemed
necessary.181 The European Best Practice Work Group
considers implementation of universal hygienic measures to
be the standard of care.182124Finally, several experts and guidelines acknowledge that
because transmission can be effectively prevented by adher-
ence to currently recommended practices, considering isola-
tion of seropositive patients indicates a failure of adherence to
the current standard and would have a negative impact on the
implementation and reinforcement of basic hygienic mea-
sures in the unit as a whole.
Dedicated dialysis machines. Evidence of HCV transmission
through internal pathways of the modern single-pass dialysis
machine has not been demonstrated.34 Transmission would
require the virion to cross the intact dialyzer membrane,
migrate from the drain tubing to the fresh dialysate circuit,
and pass again through the dialyzer membrane of a second
patient. However, the virus does not cross the intact mem-
brane, and even in the event of a blood leak, transmission
would require HCV to reach fresh dialysate used for a sub-
sequent patient and enter the blood compartment for that
patient through back-ﬁltration across the dialyzer membrane,
a highly unlikely scenario. Almost all the studies included in
the various systematic reviews have conclusively excluded
transmission via the internal dialysis pathway. In a few cases, a
role for the dialysis circuit could not be excluded, but the
environmental surfaces are more likely to have contributed to
transmission.21
Receiving dialysis next to, rather than sharing the same
dialysis machine with, an HCV-infected patient has been
found to be a risk factor for HCV acquisition.183 In outbreak
investigations with phylogenetic viral sequencing analysis,
transmission is sometimes documented from an infected
patient to a subsequent patient treated at the same station on
the next shift, and also from an infected patient to patients
treated in nearby stations during the same or subsequent
shifts, which indicates transmission independent of the ma-
chine. Hurried and incomplete disinfection of external ma-
chine surfaces and other surfaces at the station (e.g., side
table, dialysis chair, blood pressure cuff, or prime waste
container) are lapses commonly identiﬁed in these outbreaks.
In some investigations, transmission involving the dialysis
machine was essentially ruled out.137 In several studies
included in the systematic reviews of HCV transmission,
nosocomial spread was documented despite the existence of a
policy of dedicated machines. Taken together, this informa-
tion conﬁrms that contamination of dialysis machine com-
ponents cannot be the sole contributor to transmission, and
may have little to no role in HCV spread. While contaminated
external surfaces of dialysis machines might facilitate HCV
spread, other surfaces in the dialysis treatment station are
likely to have the same impact, diminishing the purported
value of using dedicated machines. Similar to the concern
about the risks of isolating dialysis patients with HCV, it
should be stressed that using dedicated machines may trigger
the perception that there is no longer a risk of nosocomial
HCV transmission and thus reduce the attention devoted by
hemodialysis staff members to body ﬂuid precautions.Kidney International Supplements (2018) 8, 91–165
Table 4 | Hygienic precautions for hemodialysis (dialysis machines)
Deﬁnitions
 The “transducer protector” is a ﬁlter (normally a hydrophobic 0.2-mm ﬁlter) that is ﬁtted between the pressure-monitoring line of the extracorporeal
circuit and the pressure-monitoring port of the dialysis machine. The ﬁlter allows air to pass freely to the pressure transducer that gives the reading
displayed by the machine, but it resists the passage of ﬂuid. This protects the patient from microbiologic contamination (as the pressure-
monitoring system is not disinfected) and the machine from ingress of blood or dialysate. An external transducer protector is normally ﬁtted to
each pressure-monitoring line in the blood circuit. A back-up ﬁlter is located inside the machine. Changing the internal ﬁlter is a technical job.
 A “single-pass machine” is a machine that pumps the dialysate through the dialyzer and then to waste. In general, such machines do not allow ﬂuid
to ﬂow between the drain pathway and the fresh pathway except during disinfection. “Recirculating” machines produce batches of ﬂuid that can
be passed through the dialyzer several times.
Transducer protectors
 External transducer protectors should be ﬁtted to the pressure lines of the extracorporeal circuit.
 Before commencing dialysis, staff should ensure that the connection between the transducer protectors and the pressure-monitoring ports is tight,
as leaks can lead to wetting of the ﬁlter.
 Transducer protectors should be replaced if the ﬁlter become wet, as the pressure reading may be affected. Using a syringe to clear the ﬂooded
line may damage the ﬁlter and increase the possibility of blood passing into the dialysis machine.
 If wetting of the ﬁlter occurs after the patient has been connected, the line should be inspected carefully to see if any blood has passed through
the ﬁlter. If any ﬂuid is visible on the machine side, the machine should be taken out of service at the end of the session so that the internal ﬁlter
can be changed and the housing disinfected.
 Some blood tubing sets transmit pressure to the dialysis machine without a blood-air interface, thus eliminating the need for transducer
protectors.
External cleaning
 After each session, the exterior of the dialysis machine and all surfaces in the dialysis treatment station should be cleaned with a low-level
disinfectant if not visibly contaminated. Pay particular attention to high-touch surfaces that are likely to come into contact with the patient (e.g.,
arm rests or blood pressure cuff) or staff members’ hands (e.g., machine control panel).
 Disinfection of external machine surfaces should not commence until the patient has left the dialysis treatment station. A complete (unit-wide)
patient-free interval between shifts might facilitate more thorough cleaning and disinfection of the unit.
 If a blood spillage has occurred, the exterior should be disinfected with a commercially available tuberculocidal germicide or a solution containing
at least 500 p.p.m. hypochlorite (a 1:100 dilution of 5% household bleach) if this is not detrimental to the surface of dialysis machines. Advice on
suitable disinfectants, and the concentration and contact time required, should be provided by the manufacturer.
 If blood or ﬂuid is thought to have seeped into inaccessible parts of the dialysis machine (e.g., between modules or behind the blood pump), the
machine should be taken out of service until it can be dismantled and disinfected.
Disinfection of the internal ﬂuid pathways
 It is not necessary for the internal pathways of a single-pass dialysis machines to be disinfected between patients, even in the event of a blood leak.
Some facilities may still opt to disinfect the dialysate-to-dialyzer (Hansen) connectors before the next patient.
 Machines with recirculating dialysate should always be put through an appropriate disinfection procedure between patients.
www.kisupplements.org chap te r 3Reuse. During the reuse procedure, patient-to-patient
transmission can take place if the dialyzers or blood port caps
are switched between patients and not sterilized effectively or
if there is spillage of contaminated blood or mixing of reused
dialyzers during transport. These situations can be eliminated
by adherence to standard hygienic precautions and appro-
priate labeling. Two large studies have not identiﬁed reuse as a
risk factor for HCV transmission,180,184 whereas a weak as-
sociation was shown in 1 study, likely due to unmeasured
confounders.185
Management of a dialyzer membrane defect leading to blood
leak. As HCV is transmitted by percutaneous exposure to
blood from an infected person, effective implementation of
the dialysis precautions recommended in the 2008 KDIGO
HCV guideline34 and by the CDC should prevent nosocomial
transmission. The risk that the virus leaving the dialyzer could
be trapped in the Hansen connector and transferred to the
fresh dialysate side through accidental misconnection is
vanishingly low, hence the CDC does not recommend
disinfection of “single-pass” machines between treatments on
the same day, even when a blood leak has occurred.23 The
2008 KDIGO HCV guideline, however, recommendsKidney International Supplements (2018) 8, 91–165disinfection of both the internal ﬂuid pathways and the
Hansen connectors before the next patient if a leak has
occurred as a matter of abundant caution, and justiﬁed it
based on the rarity of such events34 (Table 4). We reafﬁrm our
previous recommendation.
Audits. Audits and use of surveillance data to implement
prevention steps are critical to any infection control program.
Routine observational audits of various infection control
practices, combined with feedback of results to clinical staff,
allows for regular assessment of actual practices and identi-
ﬁcation of gaps. Data from audits can facilitate immediate
interventions to correct practice and should also inform
broader quality improvement efforts, including unit-wide
staff education and retraining. In the US, most dialysis centers
use infection control audit tools (including tools developed by
the CDC or the dialysis company) as part of their continuous
quality improvement process.
Although there are no RCTs that examined the impact of
audits on transmission of HCV infection in dialysis units,
observational studies as part of quality improvement programs
have shown reduction in the rates of BSIs following imple-
mentation of regular audits and an evidence-based intervention125
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event and denominator data to the National Healthcare Safety
Network and received guidance from the CDC. The feedback
included advice on chlorhexidine use for catheter exit site care,
staff training and competency assessments focused on catheter
care and aseptic technique, hand hygiene and vascular access
care audits, and feedback of infection and adherence rates to
staff. Modeled rates decreased 32% (P < 0.01) for BSIs and
54% (P < 0.001) for access-related BSIs.186 In a follow-up
study, the reduction in access-related BSI rates was sustained
for 4 years after the initial intervention implementation.187 The
over-representation of hospital-based centers and lack of a
control group limit generalization of these data. However, the
ongoing simpliﬁcation of audit tools for ease of reporting with
the use of information technology—as used in this study—
precludes the need of infection control professionals on site,
and leaves little justiﬁcation to not recommend implementa-
tion of audits. Moreover, the scope of such audits goes beyond
measuring 1 particular outcome, such as HCV transmission,
and permits wider implementation of infection control
measures.
Audits done in other dialysis center studies routinely show
suboptimal adherence to hygienic practices. A Spanish study
showed that gloves were used on 93% of occasions, and hands
were washed only 36% of the time after patient contact and
only 14% of the time before patient contact.188 In a 2002 US
survey, only 53% of US outpatient ESKD facilities reported
preparing injected medications in a dedicated room or area
separated from the treatment area; 25% prepared these
medications at a medication cart or other location in the
treatment area, and 4% prepared medications at the dialysis
station.184 A survey of 420 dialysis personnel from 45 facilities
reported on hand hygiene practices and knowledge regarding
HCV infection risk.189 At these facilities, percentages of
dialysis staff reported to always wash their hands and change
gloves during the following activities were: 47% when going
from one patient treatment station to another, 55% between
administering intravenous medications to different patients,
and 57% immediately before starting patients on dialysis.
Other studies have shown similar ﬁndings.
Observational audits of hygienic precautions that were
carried out in outbreak investigations have identiﬁed a
range of problems, including lack of basic hand hygiene,
failure to change gloves when touching the machine
interface, or when urgently required to deal with bleeding
from a ﬁstula; carrying contaminated blood circuits
through the ward unbagged; lack of routine decontamina-
tion of the exterior of machines and other surfaces even
when blood spillages had occurred; and failure to change
the internal transducer protector when potentially
contaminated. On the other hand, when hygienic practice
was reviewed through interviewing staff after an outbreak
rather than by observation, no obvious breaches in pro-
cedure could be identiﬁed.
The frequency at which routine audits of infection control
procedures should be carried out will depend on audit type,126staff turnover and training, and on the results of previous
audits. When setting up a new program, audits should be at
intervals of no greater than 6 months to enable staff to gain
experience with the process and ensure that any remedial
actions taken have been effective. The CDC recommends that
audits be performed as often as monthly to establish and
constantly reinforce recommended practices. Observational
audits should be conducted on various days of the week and
different shifts to capture all staff, and should include
particularly busy times of day such as shift changes. These
factors and the number of opportunities (e.g., for hand hy-
giene) and procedures (e.g., injectable medication adminis-
tration) observed will determine the representativeness of the
results.
The CDC website (http://www.cdc.gov/dialysis/prevention-
tools/audit-tools.html) has a number of audit tools and
checklists intended to promote CDC-recommended practices
for infection prevention in hemodialysis facilities. The audit
tools and checklists can be used by individuals when assessing
staff practices. They can also be used by facility staff themselves
to help guide their practices. In some centers, audit tools have
been shared with patients, who are asked to assess staff practice
as a means of engaging patients in the infection control efforts
of the facility and improving the culture of safety in units.190
Patients should be educated on correct practices and should
feel empowered to speak up when they observe a breach in
hand hygiene or other staff practice.
It is known that hand hygiene practices improve when
study participants are aware they are under observation. In
one study, video monitoring of hand hygiene (performed via
review of video surveillance footage) was shown to be a more
accurate method than direct observation.191 Video surveil-
lance for hand hygiene adherence should be considered, and
other innovative approaches to monitoring staff adherence
to recommended infection control practices should be
explored.
Screening. Screening for HCV infection is essential to
identifying transmission in hemodialysis units. The CDC
recommends that all maintenance hemodialysis patients be
screened for anti-HCV and ALT level upon admission and
that anti-HCV testing be repeated semiannually and ALT
testing be repeated monthly for susceptible patients.192 This is
discussed in Chapter 1. Detection of seroconversions should
prompt an aggressive evaluation of infection control practices
to correct lapses and prevent additional cases from occurring
(Table 5).28 Importantly, HCV screening should not be used
as a substitute for regular infection control audits.
Infrastructure requirements. Audit data show that despite
the existence of guidelines to prevent transmission of in-
fections in hemodialysis units, their implementation remains
suboptimal, leading to a large preventable burden of in-
fections that not only adversely impacts clinical outcomes, but
imposes large costs on the health care system. Experience
from public health interventions shows that interventionsKidney International Supplements (2018) 8, 91–165
Table 5 | Steps to initiate concurrently and undertake following identiﬁcation of a new HCV infection in a hemodialysis patient
(adapted from CDC Health Alert28)
A. Report the infection to appropriate public health authority.
 Assess risk factors of the affected patient in conjunction with public health.
B. Determine HCV infection status of all patients in the hemodialysis unit.
 Test all patients treated in the center for HCV infection (Chapter 1) unless they are already known to have active infection. Follow-up and testing of
patients who were treated in the center and those subsequently transferred or discharged may be warranted.
C. Conduct a thorough root cause analysis of the infection and address infection control lapses.
 Perform rigorous assessments of staff infection control practices to identify lapses. This should minimally include assessments of hand hygiene and
glove change practices; injectable medication preparation, handling, and administration; and environmental cleaning and disinfection practices.
 Share ﬁndings with all staff members and take action to address lapses. Staff education and retraining may be necessary.
 Consider hiring a consultant with infection prevention expertise to provide recommendations for improvement of practices and work ﬂow and/or
to help implement actions to address identiﬁed lapses.
 Conduct regular audits to ensure improved adherence to recommended practice.
 Demonstrations of cleaning adequacy such as use of Glo Germ (Moab, UT) or luminol might be helpful for staff education.
D. Communicate openly with patients.
 Inform all patients of the reason for additional HCV testing and the results of their HCV tests.
 If transmission within the center is suspected or conﬁrmed, inform all patients of this. Patients should also be made aware of steps being taken to
assess and improve practices.
CDC, Centers for Disease Control and Prevention; HCV, hepatitis C virus.
www.kisupplements.org chap te r 3that depend on behavior change require large effort, which
can undermine their impact. In contrast, making systemwide
changes, such as imposition of regulations and creating an
environment that discourages unhealthy behavior, is likely to
have greater impact. This impact has been shown in many
ﬁelds such as smoking cessation and containing HIV infec-
tion.193 Examples in the dialysis ﬁeld include endorsement of
dialysis event BSI measure by the US National Quality Forum,
and implementation of the Medicare Quality Initiative.
Recommendation of uniform validated measures such as those
used by the National Healthcare Safety Network are critical forTable 6 | Strategies to support adherence to infection control re
 It is important for the designers of dialysis units to create an environment th
washing facilities must be provided, and the machines and shared space sh
jurisdictions specify the area around a hemodialysis machine.
 The unit should ensure that there is sufﬁcient time between shifts for effe
surfaces.
 The unit should locate supplies of gloves at enough strategic points to en
 When selecting new equipment, ease of disinfection should be considere
 There are indications from the literature that the rate of failure to implem
been associated with hepatitis C outbreaks. Certain jurisdictions specify a sp
of all staff should be required (e.g., in the US, technicians provide most dire
changing staff-to-patient ratios, or introducing a cohort of new staff, shoul
requirements.
 Resource problems should be handled by carrying out a risk assessment an
penetrated the pressure-monitoring system of a machine but the unit has
protector can be inserted between the blood line and the contaminated sy
problem.







http://www.who.int/gpsc/5may/hh_guide.pdf (See Figure 9 of document a
CDC, Centers for Disease Control and Prevention; US, United States; WHO, World Healt
Kidney International Supplements (2018) 8, 91–165comparisons and to facilitate interventions. Other systemwide
changes that are likely to have a beneﬁcial impact on infection
prevention and control practices include increasing staff-to-
patient ratios and instituting staff training and education re-
quirements. Physical infrastructure changes to facilities might
also be beneﬁcial—for example, establishing minimum space
requirements between treatment stations, creating walls around
individual treatment stations to establish separate rooms
instead of large open spaces, and using walls to separate clean
and dirty processes (e.g., separate room for medication prep-
aration). Such possibilities should be explored, along withcommendations in hemodialysis centers
at makes infection control procedures easy to implement. Adequate hand-
ould make it easy for staff to visualize individual treatment stations. Certain
ctive decontamination of the exterior of the machine and other shared
sure that staff has no difﬁculty obtaining gloves in an emergency.
d.
ent hygienic precautions increases with understafﬁng. Understafﬁng has
eciﬁc nurse-to-patient ratio (e.g., 1:4 in France). Formal health care training
ct hemodialysis care but lack standardized training). Dialysis units that are
d review the implications on infection control procedures and educational
d developing local procedures. For example, if blood is suspected to have
no on-site technical support and no spare machines, an extra transducer
stem so that the dialysis can continue until a technician can attend to the







Table 7 | Key hygienic precautions for hemodialysis staffa
Deﬁnitions
 A “dialysis station” is the space and equipment within a dialysis unit that is dedicated to an individual patient. This may take the form of a well-
deﬁned cubicle or room, but there is usually no material boundary separating dialysis stations from each other or from the shared areas of the
dialysis unit.
 A “potentially contaminated” surface is any item of equipment at the dialysis station that could have been contaminated with blood, or ﬂuid
containing blood, since it was last disinfected, even if there is no visual evidence of contamination.
Education
 A program of continuing education covering the mechanisms and prevention of crossinfection should be established for staff caring for he-
modialysis patients.
 Staff should demonstrate infection control competency for the tasks they are assigned. Infection control competencies (e.g., use of aseptic
techniques) should be assessed upon hire and at least yearly thereafter.
 Appropriate information on infection control should also be given to nonclinical staff, patients, caregivers, and visitors. Patients should be
encouraged to speak up when they observe an infection control practice that is concerning to them.
Hand hygiene
 Staff should wash their hands with soap or an antiseptic hand-wash and water, before and after contact with a patient or any equipment at the
dialysis station. An alcohol-based hand rub may be used instead when their hands are not visibly contaminated.
 In addition to hand washing, staff should wear disposable gloves when caring for a patient or touching any potentially contaminated surfaces at
the dialysis station. Gloves should always be removed when leaving the dialysis station.
 Patients should also clean their hands with soap and water, or use an alcohol-based hand rub or sanitizer, when arriving at and leaving the dialysis
station.
Injection safety
 Medication preparation should be done in a designated clean area.
 All vials should be entered with a new needle and a new syringe, which should be discarded at point of use.
 Medications should be administered aseptically, after wearing a disposable glove and disinfecting the injection port with an antiseptic.
 Hand hygiene must be performed before and after administration of injection.
 All single-dose vials must be discarded and multidose vials, if used, should not be stored or handled in the immediate patient care area.
Equipment management (for management of the dialysis machine, see Table 4)
 Single-use items required in the dialysis process should be disposed of after use on 1 patient.
 Nondisposable items should be disinfected after use on 1 patient. Items that cannot be disinfected easily (e.g., adhesive tape and tourniquets)
should be dedicated to a single patient and discarded after use.
 The risks associated with use of physiologic monitoring equipment (e.g., blood pressure monitors, weight scales, and access ﬂow monitors) for
groups of patients should be assessed and minimized. Blood pressure cuffs should be dedicated to a single patient or made from a light-colored,
wipe-clean fabric.
 Medications and other supplies should not be moved between patients (e.g., on carts or by other means). Medications provided in multiple-use
vials, and those requiring dilution using a multiple-use diluent vial, should be prepared in a dedicated central area and taken separately to each
patient. Items that have been taken to the dialysis station should not be returned to the preparation area.
 After each session, all potentially contaminated surfaces at the dialysis station should be wiped clean with a low-level disinfectant if not visibly
contaminated. Surfaces that are visibly contaminated with blood or ﬂuid should be disinfected with a commercially available tuberculocidal
germicide or a solution containing at least 500 p.p.m. hypochlorite (a 1:100 dilution of 5% household bleach).
Waste and specimen management
 Needles should be disposed of in closed, unbreakable containers, which should not be overﬁlled. A “no-touch” technique should be used to drop
the needle into the container, as it is likely to have a contaminated surface. If this is difﬁcult due to the design of the container, staff should
complete patient care before disposing of needles.
 All blood and other biologic specimen handling should occur away from dedicated clean areas, medications, and clean supplies.
 The used extracorporeal circuit should be sealed as effectively as possible before transporting it from the dialysis station in a ﬂuid-tight waste bag
or leak-proof container for disposal. Avoid draining or manipulating the used circuit. If it is necessary to drain the circuit to comply with local
regulatory requirements, or to remove any components for reprocessing, this should be done in a dedicated area away from the treatment and
preparation areas.
aIn addition to standard precautions.
chap te r 3 www.kisupplements.orgstrategies to improve work ﬂow and reduce unnecessary staff
maneuvers that add to the already substantial number of oc-
casions during dialysis care when glove change and hand hy-
giene are warranted. As such, regulatory and accrediting
agencies should issue and/or incorporate recommendations to
favor compliance with basic infection control practices in
dialysis units, and efforts to make the desired infection control
behavior the simplest or most logical approach to care pro-
cesses should be pursued (Table 6). Table 7 provides a sum-
mary of important hygienic precautions for hemodialysis
center staff to follow.128Treatment of HCV infection as a means for prevention of
transmission. With the availability of DAAs, there is a possi-
bility that dialysis units might take recourse to starting HCV-
infected patients on these agents with the hope that this will
cure the infection and prevent transmission to uninfected pa-
tients. Several studies have shown that facility prevalence of
HCV infection is associated with incidence of infection. Thus,
it stands to reason that successful treatment of patients could
reduce the likelihood of HCV spread in dialysis centers.
However, it should be noted that transmission can occur even
in centers with very low HCV prevalence.139 A study thatKidney International Supplements (2018) 8, 91–165
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that HCV prevalence inﬂuenced incidence (as did staff-to-
patient ratio), but the compliance rate with hand hygiene
and glove change between patients was a much stronger
determinant of transmission.163 Thus, even in the setting of
low HCV prevalence, rigorous adherence to infection control
practices is necessary. HCV prevention programs that focus
solely on treatment of patients are likely to have a deleterious
effect on observance of routine infection control practices,
leading to paradoxically increased risk of transmission.
Furthermore, reliance on HCV treatment to prevent trans-
mission goes against the principle of treating patients
primarily for their individual beneﬁt. Use of treatment alone as
an infection control measure might place patients at increased
risk of HCV and other blood-borne infections from other
sources.
Implementation issues. Despite such strong data, adher-
ence to recommended practices remains suboptimal, often
due to misconceptions of the dialysis staff. A survey of 420
dialysis personnel from 45 hemodialysis facilities showed
that only 35% of dialysis personnel strongly believed that
patients were at risk of acquiring HCV infection in the
hemodialysis facility. In contrast, 46% strongly perceived
themselves to be at risk of acquiring HCV infection through
occupational exposure.189 Personnel also were much more
likely to report knowing how to protect themselves from
acquiring a blood-borne pathogen infection than knowing
how to protect their patients. On the basis of their obser-
vational results, which included high compliance with glove
use (93%) in contrast to poor hand hygiene compliance
(36%), Arenas et al.188 similarly concluded that dialysis
personnel had greater concern for patient-to-staff trans-
mission and lacked awareness of their role in facilitating
pathogen transmission to patients. These data support the
need for improved training and education to address
knowledge gaps, as well as other initiatives focused on
optimizing adherence to recommended infection control
practices (Table 7). As mentioned above, implementation is
more likely when guidelines are accompanied by changes in
regulations.Kidney International Supplements (2018) 8, 91–165Research recommendations
 Further observation studies should be conducted to ascer-
tain features of facilities that do not have incident cases
(e.g., stafﬁng, physical layout, policies and practices, and
baseline prevalence).
 Large, multicenter long-term RCTs of good quality are
required to answer the questions concerning the beneﬁts and
harms of isolatingHCV-positive patients during hemodialysis.
These studies should ideally evaluate costs, patient perceptions,
and complications associated with isolation. These studies
should ensure the physical separation of either the center or
room, or separation by treatment shift; these programs should
have strict isolation strategies in place that include staff. Studies
should randomize centers to either the standard of care (i.e.,
efforts to adhere to recommended infection control practices)
or the standard of care plus isolation; they should describe the
infection control efforts and compliance rates in both sets of
centers, and should ensure data assessors are blinded to the
interventions. The above-suggested trials remain of interest
because HCV therapies may not be universally available,
affordable, or prioritized for all hemodialysis patient pop-
ulations. In particular, we need innovative, effective strategies
to improve infection control, and it is still important to over-
come barriers to identiﬁcation and treatment of all infected
patients (e.g., costs and reimbursement for screening and
treatment regimens) in hemodialysis centers; this has impli-
cations for improved infection control practices for other
endemic and emerging infections even if HCV is eradicated
from hemodialysis patient populations.
 Studies should determine whether isolation of HCV-posi-
tive patients inﬂuences rates of transmission of HCV or
other infections.
 The costs and impact of improved facility stafﬁng strategies,
including higher staff-to-patient ratios, on HCV trans-
mission should be further evaluated.
 Future research should examine standard measures for
detecting dialysis-associated HCV infection that do not
require viral sequencing and phylogenetic analysis.
 Future research should devise innovative approaches that
accurately measure infection control processes at a reason-
able cost.129
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before and after kidney transplantationHCV infection remains more prevalent in CKD G5 patients
compared with the general population. Although HCV
infection can cause HCV-associated glomerular disease
resulting in CKD G5D (ESKD),128,194 kidney transplant
candidates may also have acquired HCV infection within a
dialysis unit195 or may have been infected when they had
received a previous transplant or were transfused in the era
before systematic screening for HCV.194,196,197 Because of the
deleterious effects of HCV infection in dialysis and kidney
transplant patients, evaluation of disease severity and need for
antiviral therapy is crucial.198–204 Screening for HCV in kid-
ney transplant candidates has been addressed in Chapter 1.
4.1 Evaluation and management of kidney
transplant candidates regarding HCV infection
4.1.1: We recommend kidney transplantation as the best
therapeutic option for patients with CKD G5 irre-
spective of presence of HCV infection (1A).
4.1.2: We suggest that all HCV-infected kidney transplant
candidates be evaluated for severity of liver disease
and presence of portal hypertension (if indicated)
prior to acceptance for kidney transplantation (2D).1304.1.2.1: We recommend that HCV-infected patients
with compensated cirrhosis (without portal
hypertension) undergo isolated kidney
transplantation (1B).
4.1.2.2: We recommend referring HCV-infected
patients with decompensated cirrhosis for
combined liver-kidney transplantation
(1B) and deferring HCV treatment until
after transplantation (1D).4.1.3: Timing of HCV treatment in relation to kidney
transplantation (before vs. after) should be based
on donor type (living vs. deceased donor), wait-list
times by donor type, center-speciﬁc policies gov-
erning the use of kidneys from HCV-infected
deceased donors, HCV genotype, and severity of
liver ﬁbrosis (Not Graded).
4.1.3.1: We recommend that all HCV-infected pa-
tients who are candidates for kidney
transplantation be considered for DAA
therapy, either before or after trans-
plantation (1A).
4.1.3.2: We suggest that HCV-infected kidney
transplant candidates with a living kidneydonor can be considered for treatment
before or after transplantation according
to HCV genotype and anticipated timing
of transplantation (2B).
4.1.3.3: We suggest that if receiving a kidney from
an HCV-positive donor improves the
chances for transplantation, the HCV
NAT–positive patient can undergo trans-
plantation with an HCV-positive kidney
and be treated for HCV infection after
transplantation (2B).Rationale
4.1.1: We recommend kidney transplantation as the best
therapeutic option for patients with CKD G5 irre-
spective of presence of HCV infection (1A).
Several studies have shown that kidney transplantation is
the best therapeutic option for patients with ESKD
(Supplementary Tables S11 and S12). Survival is signiﬁcantly
greater in CKD G5 patients who have undergone kidney
transplantation compared with those who have remained on
the waiting list irrespective of recipient age and/or comor-
bidities.205,206 As in the uninfected population, in patients
with HCV it has also been clearly shown that survival is
signiﬁcantly lower in dialysis patients than in kidney trans-
plant recipients.198,207,208 Thus, eligible patients should be
considered for kidney transplantation regardless of their HCV
status. In addition, the DAAs for HCV treatment in dialysis
and kidney transplant patients (see Chapter 2) allow suc-
cessful HCV clearance in nearly all patients before or after
transplantation. Patients who achieve SVR before trans-
plantation do not relapse after transplantation, despite the use
of potent immunosuppressive drugs.209,210
Although the survival of patients with persistent HCV
replication after kidney transplantation is inferior compared
with HCV-negative kidney transplant patients,200,201,204 it
remains higher than if they had remained on dial-
ysis.198,207,208 Graft survival is also signiﬁcantly decreased in
HCV-positive kidney transplant patients compared with
HCV-negative patients (Supplementary Tables S13 and
S14).200–202,204,211,212 Although liver ﬁbrosis progression in
HCV-infected kidney transplant patients is variable, devel-
opment of cirrhosis and hepatocellular carcinoma (HCC)
has been reported.213–216 As HCC typically develops only
in HCV-infected patients with stage 3 or 4 ﬁbrosis,Kidney International Supplements (2018) 8, 91–165
www.kisupplements.org chap te r 4surveillance for HCC should be offered if extensive ﬁbrosis is
present.
4.1.2: We suggest that all HCV-infected kidney transplant
candidates be evaluated for severity of liver disease
and presence of portal hypertension (if indicated)
prior to acceptance for kidney transplantation (2D).Kidney Inter4.1.2.1: We recommend that HCV-infected patients
with compensated cirrhosis (without portal
hypertension) undergo isolated kidney
transplantation (1B).
4.1.2.2: We recommend referring HCV-infected pa-
tients with decompensated cirrhosis for
combined liver-kidney transplantation (1B)
and deferring HCV treatment until after
transplantation (1D).HCV-positive patients who are candidates for kidney
transplantation should be evaluated for the presence of
cirrhosis using either a noninvasive ﬁbrosis-staging method
or, on occasion, a liver biopsy. The choice of method is dis-
cussed in Chapter 1. In addition, measurement of hepatic-
vein wedge-pressure gradient is useful when deciding whether
single kidney transplantation or simultaneous liver-kidney
transplantation should be proposed. Absence of varices on
endoscopy and portal pressure gradient < 10 mm Hg suggests
that cirrhosis is compensated.
In patients with compensated cirrhosis without portal
hypertension, isolated kidney transplantation is recom-
mended. HCV clearance halts the progression of liver disease
and may even induce regression of liver ﬁbrosis.217 The
Consensus Conference Group on simultaneous liver-kidney
transplantation proposed that combined liver-kidney trans-
plantation should be performed if patients have decom-
pensated cirrhosis and/or severe portal hypertension.218
Severe portal hypertension has been deﬁned as a hepatic-
vein wedge-pressure gradient of $ 10 mm Hg.40 The Portal
Hypertension Collaborative Group stated that hepatic
venous-pressure gradient predicts clinical decompensation in
patients with compensated cirrhosis.219 Patients with cirrhosis
who, despite having achieved SVR, have major hepatic com-
plications such as ascites, hepatic encephalopathy, or wors-
ening hepatocellular function should be evaluated for
combined liver-kidney transplantation.
4.1.3: Timing of HCV treatment in relation to kidney
transplantation (before vs. after) should be based on
donor type (living vs. deceased donor), wait-list
times by donor type, center-speciﬁc policies gov-
erning the use of kidneys from HCV-infected
deceased donors, HCV genotype, and severity of
liver ﬁbrosis (Not Graded).
4.1.3.1: We recommend that all HCV-infected pa-
tients who are candidates for kidney trans-
plantation be considered for DAA therapy,
either before or after transplantation (1A).national Supplements (2018) 8, 91–1654.1.3.2: We suggest that HCV-infected kidney
transplant candidates with a living kidney
donor can be considered for treatment
before or after transplantation according
to HCV genotype and anticipated timing
of transplantation (2B).
4.1.3.3: We suggest that if receiving a kidney from
an HCV-positive donor improves the chan-
ces for transplantation, the HCV NAT–
positive patient can undergo trans-
plantation with an HCV-positive kidney
and be treated for HCV infection after
transplantation (2B).Until recently, only IFN-based therapy was available to
treat HCV infection. The use of IFN was contraindicated after
kidney transplantation (except in cases of ﬁbrosing cholestatic
hepatitis) because of its immunostimulatory properties,
which increase the risk of graft rejection.220 Hence, it was
recommended that candidates for kidney transplantation be
treated with IFN before transplantation.34 The use of DAAs
has completely changed this situation because HCV clearance
is feasible in the vast majority of patients before and after
kidney transplantation (see Chapter 2). The current issue is
timing of HCV therapy in relationship to transplantation.
Considerations for planning therapy include living versus
deceased donor, wait-list time by donor type, center-speciﬁc
policy for acceptance of organs from HCV-positive deceased
donors, speciﬁc HCV GT, and severity of liver ﬁbrosis (see
Algorithm 3). Other factors such as candidate sensitization
and patient preference can be also considered for choosing the
timing of treatment.
In patients with compensated cirrhosis without portal hy-
pertension, if living-donor kidney transplantation is antici-
pated without a long wait, HCV therapy can be deferred until
after transplantation. If living-donor kidney transplantation is
likely to be delayed more than 24 weeks (to allow 12 weeks of
therapy and 12 weeks of follow-up to prove SVR), then HCV
therapy can be offered before or after transplantation based on
speciﬁc HCV GT and proposed treatment regimen.
In a potential recipient with compensated cirrhosis
without portal hypertension and listed for kidney trans-
plantation from a deceased donor at a center where it is
possible to obtain a kidney allograft from an HCV-positive
donor without a long wait, the potential recipient can defer
antiviral therapy to allow receipt of an organ from an HCV-
positive donor.221 However, the patient needs to provide
written informed consent for this approach. In contrast, when
kidney allografts from HCV-positive donors are not or cannot
be used because of local policy, or when the anticipated time
to obtain a kidney from an HCV-negative donor is long, the
patient should be offered HCV therapy before
transplantation.
Twice-yearly surveillance for HCC is indicated in cirrhotic
patients. In addition, endoscopic surveillance for varices is
indicated. Evaluation for complications of cirrhosis is131
Living donor Deceased donor
HCV-infected candidates
for a kidney transplantation
Testing for liver fibrosis and
if indicated, portal hypertension
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Algorithm 3 | Proposed strategy in a hepatitis C virus (HCV)–infected kidney transplant candidate. SKLT, simultaneous kidney-liver
transplantation.
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therapy or not.
Speciﬁc HCV GTs may also inﬂuence timing of HCV
therapy, depending on the availability of individual drugs in
some countries. If the pan-genotypic glecaprevir-pibrentasvir
is available, the GT will not inﬂuence the timing of DAA
treatment. If glecaprevir-pibrentasvir is not available, as dis-
cussed in Chapter 2, DAAs (grazoprevir plus elbasvir, dacla-
tasvir plus asunaprevir, or 3D regimen) that are approved to
treat HCV infections in CKD G4–G5 patients are efﬁcacious
in GTs 1 and 4. For other GTs, only a sofosbuvir-based
therapy can be proposed. The off-label use of sofosbuvir-
based therapy at reduced doses in CKD G4–G5 patients with132GTs 2, 3, 5, or 6 has been reported, though it is not licensed
for patients with an GFR < 30 ml/min per 1.73 m2 (see
Chapter 2). Hence, in HCV-infected patients with GTs 2, 3, 5,
and 6, if possible, treatment should be postponed until after
transplantation.
4.2 Use of kidneys from HCV-infected donors
4.2.1: We recommend that all kidney donors be screened
for HCV infection with both immunoassay and
NAT (if NAT is available) (1A).
4.2.2: We recommend that transplantation of kidneys
from HCV NAT–positive donors be directed to
recipients with positive NAT (1A).Kidney International Supplements (2018) 8, 91–165
www.kisupplements.org chap te r 44.2.3: After the assessment of liver ﬁbrosis, HCV-positive
potential living kidney donors who do not have
cirrhosis should undergo HCV treatment before
donation; they can be accepted for donation if they
achieve sustained virologic response (SVR) and
remain otherwise eligible to be a donor (Not
Graded).
Rationale
4.2.1: We recommend that all kidney donors be screened
for HCV infection with both immunoassay and NAT
(if NAT is available) (1A).
In 1991Pereira et al. demonstrated thatHCVwas transmitted
by organ transplantation.196 Several experiences published soon
after the ﬁrst description on the transplantation of kidneys from
HCV RNA–positive donors corroborated unequivocally the
transmission of HCV infection by organ transplantation.222 For
this reason, organ procurement organizations and international
guidelines have strongly recommended that all organ donors
should be tested for HCV infection.34,223
The diagnosis of HCV infection is made by the detection
of anti-HCV by enzyme-linked immunosorbent assay.34,223
The majority of patients who are seropositive for anti-HCV
also have detectable HCV RNA in the serum. Performing
NAT as an emergency test in potential deceased donors is
optimal but is not widely available due to time con-
straints;34,223 thus, in many cases, only anti-HCV is tested in
potential organ donors prior to transplantation.
4.2.2: We recommend that transplantation of kidneys from
HCV NAT–positive donors be directed to recipients
with positive NAT (1A).
There has been a consensus that kidneys from HCV
NAT–positive donors should not be transplanted into anti-
HCV–negative recipients. Kidneys from donors with anti-
HCV who are HCV NAT–negative can generally be used
safely in negative anti-HCV patients. Nowak et al. recently
reported a case series of 21 anti-HCV–positive kidneys (20
donors) who were HCV NAT–negative. In no case did the
use of those kidneys lead to de novo HCV infection in HCV-
negative recipients.224 However, there have been isolated
cases of HCV transmission reported to Disease Transmission
Advisory Committee (DTAC) from HCV aviremic (i.e., anti-
HCV–positive and NAT-negative) donors; these are
currently under investigation, but the risk of transmission is
probably very low.225 The problem was and remains that the
demand for kidney transplantation clearly surpasses the
supply, and this is a particular concern in areas with a high
prevalence of HCV infection.34 Universally discarding kid-
neys from HCV-positive donors could lead to the loss of up
to 4.2% of organs.226 A recent retrospective study of 9290
donors for whom both anti-HCV and NAT data were
available estimated that using anti-HCV–positive, NAT-
negative donors at the same rate as anti-HCV–negative,Kidney International Supplements (2018) 8, 91–165NAT-negative donors could result in 48 more kidney do-
nors. Thus, there is a potential for expanding donor pools
by using organs from carefully selected anti-HCV–positive,
NAT-negative donors.227
A related issue was whether organs harvested from HCV
NAT–positive donors could be safely transplanted in HCV
NAT–positive recipients.222 An experience in Spain of trans-
planting kidneys with positive HCV antibodies into HCV-
positive recipients228,229 provided some initial insights. When
serum HCV RNA was retrospectively assessed in donor and
recipients (by NAT) it was recognized that some HCV-positive
recipients who were HCV NAT–negative had received organs
from HCV NAT–positive donors.229 As a result of these ﬁnd-
ings, Spanish groups modiﬁed their policy, limiting the use of
kidneys from HCV-positive donors to HCV NAT–positive re-
cipients. This strategy was supported by international guide-
lines.34,223 Therefore, the HCV RNA (i.e., NAT) status of the
donor is critical for optimal allocation of HCV-positive organs.
Several studies from the US (registry or hospital data) have
demonstrated that transplantation of kidneys from HCV-
positive donors into HCV-positive recipients reduces the
waiting time for transplantation,230–236 but is associated with
a small increased risk of death, graft loss, and severe liver
disease compared with HCV recipients who received kidneys
from HCV-negative donors.235 Notably, despite this increase
in risk, HCV-positive recipients transplanted with kidneys
from HCV-positive donors have a better chance of survival
than HCV-positive patients on the waiting list.232
Long-term results of transplantation with HCV-positive
donors into HCV-positive recipients have demonstrated that
donor anti-HCV seropositivity was not an independent risk
factor for patient survival, graft loss, and liver disease.237
These results were comparable to a single-center experience
in the US, showing that donor HCV status does not inﬂuence
graft, patient survival or eGFR in HCV-positive recipients.238
Recent data from the US have corroborated these ﬁndings and
demonstrated again that HCV patients who received kidneys
from HCV-positive donors spent less time on the waiting list,
which probably contributed to improved death-censored graft
survival compared with HCV recipients from HCV-negative
donors.239 The US experience using kidneys from HCV-
positive donor demonstrated that the beneﬁt of trans-
plantation is limited to HCV-positive recipients older than 50
years (Supplementary Table S15).240 Recently, it has been
shown that kidneys from anti-HCV–positive donors can be
considered for transplant into HCV-infected recipients fol-
lowed by early post-transplant treatment with DAA agents.241
Superinfection by another HCV GT can occur, and there-
fore matching donors and recipients according to their GT
could be the next step to improve the safety of this policy.242
However, with the current availability of highly effective DAA
regimens, matching by GTmay be less of a serious concern.226
Despite international recommendations34,223 currently
there is underutilization of HCV-positive organs for a variety
of reasons including concerns about HCV transmission, the
fear of legal liability, the lack of acceptance of HCV-positive133
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morbidities (e.g., long history of kidney disease and high
immunological risk). Kucirka et al. have reported that kidneys
from HCV-positive donors were 2.6 times more likely to be
discarded than those from HCV-negative donors.122
In summary, the use of kidneys from HCV NAT–positive
donors into HCV NAT–positive recipients (limiting the risk
of transmission without loss of organs from the donor pool),
is an acceptable approach. The capacity to use DAAs shortly
after transplantation should allow safe use of these organs.
Use of HCV NAT–positive kidneys for HCV NAT–positive
recipients has been included in the algorithms to establish the
policy of DAA therapy before or after transplantation.243,244
4.2.3: After the assessment of liver ﬁbrosis, HCV-positive
potential living kidney donors who do not have
cirrhosis should undergo HCV treatment before
donation; they can be accepted for donation if they
achieve sustained virologic response (SVR) and
remain otherwise eligible to be a donor (Not Graded).
Potential living donors with HCV infection should be
treated as in the general population. First, liver ﬁbrosis should
be assessed, and then, if there is no evidence of cirrhosis, they
can receive DAAs based on GT (see Chapter 2).
SVR can then be assessed at 12 weeks with monitoring of
kidney function and proteinuria during and after DAA ther-
apy. In the absence of severe hepatic ﬁbrosis, living donation
is then feasible.
The scarcity of donor organs for transplantation results in
long waiting times for kidney transplantation.34 In addition,
individual patient characteristics, such as high sensitization,
may contribute to delays in transplantation. Longer time on
hemodialysis and on wait-list may be an independent risk
factor for graft loss and mortality after transplantation. For
these reasons kidney transplantation with expanded criteria
donors has become a necessity.
A recent analysis of the US Organ Procurement and
Transplant Network database through 2012 demonstrated
inferior outcomes in HCV-negative recipients who had
received an HCV-positive donor compared with HCV-nega-
tive recipients transplanted with HCV-negative donors.245
This practice has been considered unacceptable.34,223 How-
ever, the availability of current DAAs for HCV infections has
led to a reconsideration of this prohibition.
Treatment with DAAs is an established common practice in
the general population and in liver transplant recipients.243
There is limited information about the use of DAAs in the
early period after kidney transplantation.241 Preliminary in-
formation using DAAs in long-functioning kidney transplant
patients with HCV infection indicates excellent SVR12 of 90%
to 100%.118,119 In liver transplantation, ﬁbrosing cholestatic
hepatitis has been successfully treated with DAAs.244 A clinical
trial using HCV-positive kidneys into HCV-negative recipients
has started very recently in Philadelphia.123 In this pilot study
(THINKER), 10 patients with negative anti-HCV were given134kidneys from donors whowere HCV-NAT–positive for GT1.At
day 3 post-transplantation, all patients had detectable HCV
RNA and were given grazoprevir-elbasvir. SVR12 was observed
in all patients.123 This novel strategy raises several questions
regarding what the optimal informed consent process should
be, the potential risk for viral complications, and the cost im-
plications of post-transplant use of DAAs.246 Encouraging re-
sults from another trial (EXPANDER-1) of kidneys from HCV
NAT–positive donors for HCV-negative recipients were also
reported,124 but until more information is available regarding
long-term safety of this approach, this practice should be
considered strictly investigational.
4.3 Use of maintenance immunosuppressive
regimens
4.3.1: We suggest that all conventional current induction
and maintenance immunosuppressive regimens
can be used in HCV-infected kidney transplant
recipients (2C).
Rationale
In HCV-infected kidney transplant recipients, viral load in-
creases after transplantation because immunosuppression
facilitates viral replication.34 Roth et al. reported an increased
rate of death by infection in HCV-positive patients in the ﬁrst
6 months after kidney transplantation, a period when the
impact of induction and high doses of maintenance immu-
nosuppression therapy is greatest.216 These data suggest
caution in the choice of immunosuppressive protocol in these
patients34 given the frequent high immunological risk proﬁle
of HCV-infected recipients.
Antibody induction, particularly antilymphocyte prepara-
tions, had been associated with an increased risk of devel-
oping liver disease in HCV-infected transplant recipients.196
However, several studies have suggested that the use of anti-
body induction has no detrimental effect on survival in HCV-
positive patients with post-transplantation chronic liver dis-
ease, even in African Americans (Supplementary Table
S16).247–250 In addition, the HR for death dropped from
2.51 over the ﬁrst 6 months after transplant to 0.32 during the
7- to 84-month posttransplant period, in the study using
induction therapy noted above.216
There are only limited data on the inﬂuence of steroids in
kidney transplant patients with HCV infection. In a US study,
mortality was not different among patients who received
steroids as part of immunosuppression protocol versus those
who did not.250 In the setting of liver transplantation,
discontinuation of steroids after surgery was associated with a
reduced rate of post-transplant diabetes.251 It is thus plausible
that steroid withdrawal after kidney transplantation in HCV-
positive selected patients could be beneﬁcial to reduce post-
transplant diabetes.
Concerning CNIs, there are no signiﬁcant differences in
outcomes with cyclosporine versus tacrolimus therapy in HCV-
infected transplant recipients.34However, it should be noted thatKidney International Supplements (2018) 8, 91–165
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positive patients treated with tacrolimus,252 and cyclosporine
inhibits HCV replication on cultured hepatocytes.253
Increased serum HCV RNA concentrations have been re-
ported in patients who received MMF in place of azathio-
prine.254 However, MMF is considered part of the standard
immunosuppression given to kidney transplant patients no
matter what their HCV status is.216 Published information on
clinical use of mTOR inhibitors (sirolimus and everolimus) in
kidney transplant patients with HCV is scarce, and therefore
the inﬂuence of mTOR inhibitors on HCV-positive patient
survival after kidney transplantation is unknown.
One important concern with new DAAs for the treatment
of HCV infection in kidney transplant patients is drug–drug
interaction with immunosuppressive agents. Indeed, cyclo-
sporine, tacrolimus, sirolimus, and everolimus are metabo-
lized in the liver by the cytochrome P450. Thus, for most
DAAs substrate competition can occur, inﬂuencing their
elimination. The use of currently licensed DAAs can affect
CNI levels and may require dose adjustment. As such, the
Work Group suggests that the Hepatitis Drug Interactions
website from the University of Liverpool (http://www.hep-
druginteractions.org) be consulted for the latest guidance
on potential drug–drug interactions prior to DAA use.
4.4 Management of HCV-related complications in
kidney transplant recipients
4.4.1: We recommend that patients previously infected
with HCV who achieved SVR before trans-
plantation be tested by NAT 3 months after
transplantation or if liver dysfunction occurs (1D).
4.4.2: Untreated HCV-positive kidney transplant re-
cipients should have the same liver disease follow-
up as HCV-positive non-transplant patients, as
outlined in the American Association for the Study
of Liver Diseases (AASLD) guidelines (Not Graded).
4.4.3: HCV-infected kidney transplant recipients should
be tested at least every 6 months for proteinuria
(Not Graded).Kidney Inter4.4.3.1: We suggest that patients who develop new-
onset proteinuria (either urine protein-to-
creatinine ratio > 1 g/g or 24-hour urine
protein > 1 g on 2 or more occasions) have
an allograft biopsy with immunoﬂuores-
cence and electron microscopy included in
the analysis (2D).4.4.4: We recommend treatment with a DAA regimen in
patients with post-transplant HCV-associated
glomerulonephritis (1D).
Rationale
4.4.1: We recommend that patients previously infected
with HCV who achieved SVR before trans-
plantation be tested by NAT 3 months after trans-
plantation or if liver dysfunction occurs (1D).national Supplements (2018) 8, 91–165Kidney transplantation outcomes in patients with HCV
without extensive ﬁbrosis who are successfully treated before
transplantation should be equivalent to those in uninfected
transplant recipients. With achievement of SVR, viral relapse
is unlikely, although kidney transplant recipients with unex-
plained hepatic dysfunction should undergo HCV and HBV
testing.
4.4.2: Untreated HCV-positive kidney transplant re-
cipients should have the same liver disease follow-
up as HCV-positive non-transplant patients, as
outlined in the American Association for the Study
of Liver Diseases (AASLD) guidelines (Not
Graded).
Kidney transplantation in patients with activeHCV infection
may be complicated by liver disease and also by extrahepatic
complications.194 These patients exhibited a lower graft and
patient survival and an increased risk of severe liver disease
compared with HCV-negative recipients.34,194,223,255 Therefore,
patients with persistent HCV RNA because of lack of treatment
before transplantation or due to failure of therapy before or after
transplantation should be considered for liver disease reevalu-
ation and re-treatment with DAAs. Preliminary publications of
the use of DAAs in kidney transplant patients have exhibited
SVRof almost 100%without important side effects.118,119More
recently, a trial compared 12 and 24 weeks of sofosbuvir and
ledipasvir in 114 kidney transplant recipients infectedwithHCV
GTs 1 and 4 (96%GT1) with an eGFR of 40ml/min per 1.73m2
or greater (median eGFR: 56 ml/min per 1.73 m2). The therapy
was very well tolerated, and SVR rates were close to 100%
without differences between arms, suggesting that a 12-week
regimen is also indicated in kidney transplant recipients.116
4.4.3: HCV-infected kidney transplant recipients should be
tested at least every 6 months for proteinuria (Not
Graded).4.4.3.1: We suggest that patients who develop new-
onset proteinuria (either urine protein-to-
creatinine ratio > 1 g/g or 24-hour urine
protein > 1 g on 2 or more occasions) have
an allograft biopsy with immunoﬂuores-
cence and electron microscopy included in
the analysis (2D).4.4.4: We recommend treatment with a DAA regimen in
patients with post-transplant HCV-associated
glomerulonephritis (1D).
HCV infection has been reported as a risk factor for the
development of proteinuria in kidney transplant recipients.256
Several glomerular lesions have been described after kidney
transplantation in HCV RNA–positive patients including
recurrent or de novo cryoglobulinemic or non-cry-
oglobulinemic MPGN,257 membranous nephropathy
(MN),258 acute transplant glomerulopathy,194 anti-cardiolipin
related thrombotic microangiopathy,259 and chronic trans-
plant glomerulopathy.260 MPGN and MN are the most135
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presentation is proteinuria with or without microhematuria,
or nephrotic syndrome. The pathogenesis of MPGN and MN
seems to be related to the deposition of immune complexes
containing HCV RNA in the glomerulus.34
After HCV NAT–positive patients have undergone kidney
transplantation, clinicians should screen for proteinuria and
microhematuria. In the case of urine protein-to-creatinine
ratio > 1 g/g or 24-hour urine protein (protein excretion rate)
greater than 1 g on 2 or more occasions, a graft biopsy is
indicated. Pathological examination should include immu-
noﬂuorescence and electron microscopy. In the case of sus-
pected transplant glomerulopathy, electron microscopy is
mandatory to make the differential diagnosis with HCV-
related MPGN.194,260
For HCV-related glomerular disease, DAA therapy is
indicated.261–270 In severe HCV-related cryoglobulinemic
MPGN, in addition to antiviral therapy with DAAs, rituximab
and, in severe cases, plasmapheresis should be considered.194
This is discussed in detail in Chapter 5.
Research recommendations
 Prospective studies should assess the best timing for HCV
treatment in kidney transplant candidates: before or after
transplantation?136 Studies should examine whether accepting a kidney from
an HCV-positive donor would reduce the time on the
waiting list. Further studies are required in different
countries because the prevalence of HCV in donors is
highly variable worldwide.
 Future research should evaluate the impact of delaying
HCV treatment on HCV-induced morbidity (e.g., liver
disease) and patient survival in HCV-positive kidney
transplant candidates who are not given DAA therapy
in order to be grafted with a kidney from a positive
donor.
 Prospective larger studies under investigational protocols
should be conducted to corroborate the encouraging pre-
liminary results obtained using kidneys from HCV-positive
donors for HCV-negative recipients treated with DAAs.
Studies should also examine the cost-effectiveness of this
policy with different DAA treatment strategies.
 SVR should be assessed in a large cohort of HCV-positive
patients who receive a kidney allograft from a positive
donor and who are given DAA therapy after trans-
plantation. In this setting, the optimal timing for starting
DAA therapy should be determined.
 In patients presenting with an HCV-associated kidney dis-
ease after transplant, the effect of DAAs on the kidney graft
should be assessed in a large series.Kidney International Supplements (2018) 8, 91–165
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diseases associated with HCV infectionIn addition to chronic liver disease, HCV infection also leads
to extrahepatic manifestations including kidney disease and
mixed cryoglobulinemia.271 Although chronic HCV infection
has been identiﬁed as an important cause of tubulo-intersti-
tial injury in a large case-control study,272 HCV-associated
glomerular disease is the most frequent type of kidney disease
associated with HCV.
HCV-induced glomerular disease occurs frequently in the
context of HCV-associated mixed cryoglobulinemia, a sys-
temic vasculitis characterized by involvement of small and,
less frequently, medium-size vessels.273–277 Mixed cry-
oglobulinemia represents 60% to 75% of all cryoglobulinemia
cases and is observed in connective tissue diseases and in-
fectious or lymphoproliferative disorders, all grouped under
the term “secondary mixed cryoglobulinemia.” After its
identiﬁcation, HCV has been recognized as the cause of 80%
to 90% of idiopathic mixed cryoglobulinemia.273,276 In gen-
eral, HCV is associated with type II mixed cryoglobulinemia
(cryoglobulins consisting of polyclonal IgG and monoclonal
IgM with rheumatoid factor activity), although it is also less
frequently associated with type III mixed cryoglobulinemia
(cryoglobulins consisting of polyclonal IgG and polyclonal
IgM). In the absence of an identiﬁed etiology (currently
<10% of mixed cryoglobulinemia), cryoglobulinemic vascu-
litis is deﬁned as essential or idiopathic.
Immune complex glomerular diseases such as MPGN are
the most frequent kidney diseases associated with chronic
HCV infection.274,275 The incidence of HCV-associated
glomerular disease is probably low even if the available in-
formation is scanty. In an autopsy series of 188 consecutive
patients with HCV infection, the frequency of MPGN was
11%, MN 2%, and mesangial proliferative GN 17%.278
A large survey has been conducted by El-Serag et al., who
carried out a hospital-based case-control study among US male
veterans from 1992 to 1999 and identiﬁed 34,204 patients
infected with HCV (cases) and 136,816 randomly selected
patients without HCV (controls).279 A greater fraction of
HCV-infected patients had porphyria cutanea tarda (0.77% vs.
0.06%, P < 0.0001), vitiligo (0.17% vs. 0.10%, P ¼ 0.0002),
lichen planus (0.30% vs. 0.13%, P < 0.0001), and cry-
oglobulinemia (0.57% vs. 0.05%, P< 0.0001). A greater rate of
MPGN (0.36% vs. 0.05%, P < 0.0001) but not MN (0.33% vs.
0.19%, P ¼ 0.86) was found among patients with HCV. Ac-
cording to a prospective Norwegian study, the rate of CKD G5
due to MPGN was 0.2%.280 It has been further shown that
anti-HCV seropositive status was more common in patientsKidney International Supplements (2018) 8, 91–165with non-cryoglobulinemic MPGN and MN (18%–20%) than
that observed in the general population of the same area (7%)
after correction for age.281 A large meta-analysis of 107,356
patients7 reported that anti-HCV–positive serology was an
independent risk factor for proteinuria in the adult general
population (adjusted OR: 1.51 [95% CI: 1.19–1.89)].65,66,282–
285 Another pooled analysis63 demonstrated that anti-HCV–
positive serology was an independent risk factor for protein-
uria among HIV-infected patients with an adjusted effect es-
timate of 1.23 (95% CI: 1.18–1.28).286–291
5.1: We recommend that a kidney biopsy be performed in
HCV-infected patients with clinical evidence of
glomerular disease (Not Graded).
5.2: We recommend that patients with HCV-associated
glomerular disease be treated for HCV (1A).5.2.1: We recommend that patients with HCV-
related glomerular disease showing stable
kidney function and/or non-nephrotic pro-
teinuria be treated initially with DAA (1C).
5.2.2: We recommend that patients with cry-
oglobulinemic ﬂare, nephrotic syndrome, or
rapidly progressive kidney failure be
treated, in addition to DAA treatment, with
immunosuppressive agents with or without
plasma exchange (1C).
5.2.3: We recommend immunosuppressive therapy
in patients with histologically active HCV-
associated glomerular disease who do not
respond to antiviral therapy, particularly
those with cryoglobulinemic kidney disease
(1B).




5.1: We recommend that a kidney biopsy be performed in
HCV-infected patients with clinical evidence of
glomerular disease (Not Graded).
The main clinical manifestations of glomerular disease in
HCV-infected patients are the presence of proteinuria and
microscopic hematuria with or without reduction in GFR. It
remains unclear why only a minority of patients with HCV
infection develop kidney abnormalities. Glomerular diseases137
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presence or absence of signiﬁcant liver disease; however, all
patients with HCV-associated glomerular disease show
detectable HCV RNA in serum.292,293
The main reasons for recommending a kidney biopsy in
patients with HCV infection and signs of glomerular disease
are not markedly different from the usual reasons prompting
a kidney biopsy for other glomerular diseases.294 Kidney
biopsy remains invaluable to assess the precise histological
picture of the disease and the probability that the observed
lesions are causally related to HCV-infection. Other glomer-
ular diseases (including diabetic nephropathy and other
types) are indeed not infrequently reported among patients
with HCV infection.295 In addition, the histology will provide
an assessment of the extent of active or hyperactive lesions
requiring urgent immunosuppressive treatment, and of
chronic lesions that are unlikely to be reversible under
immunosuppression. Thus, some patients might be spared
from immunosuppression in the presence of severe chronic
lesions when there is no extrarenal indication for
immunosuppression.294
The most common type of HCV-related GN is immune
complex-mediated MPGN usually in the context of type II
cryoglobulinemia. Distinctive features of cryoglobulinemic
GN, especially in patients with rapidly progressive deterio-
ration of kidney function, include intraglomerular deposits,
which are commonly seen in a subendothelial location,
sometimes occluding the capillary lumen (intraluminal
thrombi). Glomeruli may show prominent hypercellularity as
a result of inﬁltration of glomerular capillaries by mono-
nuclear and polymorphonuclear leucocytes. Glomeruli
frequently show accentuation of lobulation of the tuft archi-
tecture with a combination of increased matrix and mesangial
cells, capillary endothelial swelling, splitting of capillary
basement membrane, and accumulation of eosinophilic
material representing precipitated immune complexes or
cryoglobulins. The glomerular basement membrane often
shows double contours, which are caused by the interposition
of monocytes between the basement membrane and the
endothelium. On electron microscopy, large subendothelial
deposits are present. Vasculitis of small renal arteries is pre-
sent in 30% of cases.296
Of note, numerous intraluminal thrombi, vasculitis, or
both are more commonly observed in patients with an acute
nephritic syndrome and rapid progressive kidney failure.
Histological features of exudative or lobular MPGN are
associated with the occurrence of nephrotic and/or nephritic
syndromes, whereas mesangial proliferation is prevalent in
cases with intact kidney function and isolated proteinuria
and/or microscopic hematuria.296
Some investigators have reported cases of HCV-associated
MPGN without cryoglobulinemia.275 In these patients, the
clinical picture, histological features and laboratory data are
indistinguishable from “classical” idiopathic immune com-
plex-mediated MPGN. Both subendothelial and mesangial
immune complexes can be identiﬁed by electron microscopy138typically without a distinctive substructure. In both forms of
HCV-associated GN, immunoﬂuorescence commonly reveals
deposition of IgM, IgG, and C3 in the mesangium and
capillary walls.
MN is also observed in association with chronic HCV
infection.258 Whether this corresponds to a true association or
a coincidence is unclear. The clinical presentation, outcome,
and histopathology are similar to those observed in idiopathic
MN. On light microscopy, the characteristic ﬁnding is a
diffuse and uniform thickening of the glomerular basement
membrane without mesangial or endothelial proliferation.
Diffuse subepithelial immune deposits can be identiﬁed by
electron microscopy, and immunoﬂuorescence shows diffuse
and granular deposits of IgG, IgA, and C3.
Other glomerular diseases that have been occasionally re-
ported in association with chronic HCV infection are acute
proliferative GN, focal segmental glomerulosclerosis,297 IgA
nephropathy,298 thrombotic microangiopathy,259 rapidly
progressive nephritis,299 ﬁbrillary GN, and immunotactoid
glomerulopathy.300 However, these likely correspond to spo-
radic cases and their pathogenic link with HCV remains even
more uncertain than for MN.
The pathogenesis of glomerular disease associated with
HCV infection is not completely understood. It appears that
HCV binds and penetrates into the renal parenchymal cells
via the CD81 and SR-B1 receptors.301 HCV RNA has been
found in mesangial cells, tubular epithelial cells, and endo-
thelial cells of glomerular and tubular capillaries. The depo-
sition of immune complexes containing HCV proteins in the
glomerular basement membrane has been cited in the path-
ogenesis of HCV-associated MN.301 HCV-related granular
protein deposits located in the mesangium have been
observed in patients with HCV-related MPGN; they are
probably related to higher degrees of proteinuria.302 Viral
antigens have been found by immunohistochemistry,303 in
situ hybridization,303 and laser capture microdissection.304
5.2: We recommend that patients with HCV-associated
glomerular disease be treated for HCV (1A).
In view of the role of HCV in the pathogenesis of cry-
oglobulinemic GN, antiviral therapy has been used to achieve
clearance of HCV and ameliorate the renal injury. RCTs
remain sparse; the evidence on the impact of antiviral treat-
ment of HCV-related glomerular disease was until recently
limited and consisted mostly of anecdotal reports and small-
sized observational studies (Supplementary Tables S17 and
S18). Initial reports adopted monotherapy with conven-
tional IFN,305 but the combined regimen (pegylated IFN plus
RBV) superseded monotherapy.306 With the arrivals of DAAs,
IFN-based regimens are now considered obsolete, though
these antiviral studies306–308 provided valuable insight on the
etiological role of HCV in the pathogenesis of GN.
Some evidence supporting the antiviral therapy of HCV-
associated glomerular disease has been provided by a meta-
analysis of comparative studies of various study designsKidney International Supplements (2018) 8, 91–165
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HCV-induced GN.309 However, even with pooling of study
results, the effect of IFN (vs. corticosteroid therapy) on
reducing proteinuria is highly imprecise: OR 1.92; 95%
CI: 0.39–9.57. In a sensitivity analysis including only
controlled trials using standard IFN doses, the OR was 3.86
(95% CI: 1.44–10.3). Of note, in all patients with proteinuria
reduction, HCV RNA clearance was observed at the end of
antiviral therapy.309
In another meta-analysis,78 antiviral therapy based on
IFN-a decreased proteinuria in HCV-positive CKD patients.
At the end of antiviral therapy, the summary estimate of the
mean decrease in proteinuria was 2.71 g/24 hr (95% CI: 1.38–
4.04). The decrease in proteinuria following antiviral therapy
was associated with HCV RNA clearance. Serum creatinine
was not signiﬁcantly decreased with antiviral treatment;
however, stabilization of serum creatinine was achieved. Pa-
tients receiving combination with IFN plus RBV achieved a
higher SVR rate than did those with IFN monotherapy
regardless of HCV GT.
Additional anecdotal reports on the antiviral treatment of
HCV-associated glomerular disease in adults with native
kidneys have been published, and a large variety of histo-
logical lesions was found.310 According to an updated review,
a total of 36 reports based on 47 unique patients were
retrieved.311–317 The majority of these patients had
improvement of renal changes after clearance of HCV RNA,
and this conﬁrms the role of the virus in the pathogenesis of
the kidney disease. One report emphasized the spontaneous
remission of glomerular lesions; this cannot be excluded in
a few cases.318 Additional, albeit limited, information on
antiviral treatment of HCV-related glomerular disease in
kidney,257 liver,319–321 and liver/kidney transplanted popula-
tion322 and among pediatric individuals exists. Recombinant
IFN given for treatment of HCV may exacerbate proteinuria
in some patients with underlying glomerulopathies.323
Regardless of the regimens used (IFN-based or DAAs),
antiviral treatment of HCV-related glomerular disease has
limitations. First, the impact of antiviral therapy on the long-
term outcomes of kidney disease remains uncertain. Second,
the clinical beneﬁt in patients who reached SVR may be
transient and/or a dissociation between viral and renal
responses can occur.275,324–326 Two recent long-term (1- to
2-year) studies reported high rates of marked improvement
on various cryoglobulinemia-related manifestations after SVR
with DAAs, but conﬁrmed that relapses of vasculitis may
occur despite achieving SVR.327,328
5.2.1: We recommend that patients with HCV-related
glomerular disease showing stable kidney function
and/or non-nephrotic proteinuria be treated
initially with DAA (1C).
The development of kidney disease among patients with
mixed cryoglobulinemia has particular importance because
kidney involvement confers a poor prognosis to suchKidney International Supplements (2018) 8, 91–165patients.329–331 Clinically, HCV-associated mixed cry-
oglobulinemia is characterized by the triad of purpura,
arthralgia, and weakness. The natural history of HCV-
induced mixed cryoglobulinemia is clinically variable: some
patients have an indolent course while others develop vas-
culitic lesions in various organs including kidneys. Extrarenal
features of mixed cryoglobulinemia include neuropathy, he-
patomegaly, sicca syndrome, and central nervous system and
gut involvement. Overt pulmonary involvement is infrequent.
Although extrarenal signs of mixed cryoglobulinemia vascu-
litis usually precede the kidney manifestations, often by years,
in 29% of cases, kidney and extrarenal involvement are
concurrent.331 Kidney disease occurs in 8% to 58% of patients
with mixed cryoglobulinemia, and in a minority of cases can
be the ﬁrst manifestation of mixed cryoglobulinemia. Patients
with HCV-associated cryoglobulinemic glomerular disease
can present with nephritic syndrome, asymptomatic non-
nephrotic proteinuria or hematuria, and/or reduced GFR.
Acute nephritic and nephrotic syndrome can be a presenting
feature in 25% and 20% of patients, respectively. Arterial
hypertension is frequent (affecting >50% of patients at the
time of diagnosis) and is often resistant to antihypertensive
drugs; the severity of hypertension often mirrors the severity
of kidney disease.330 Around 10% of patients present oliguric
kidney failure.330,331
Type II mixed cryoglobulinemia is most common in the
fourth or ﬁfth decade of life, and usually is characterized by
periods of extrarenal symptoms alternating with periods of
quiescence.332 The exacerbation of extrarenal symptoms often
is associated with a ﬂare-up of kidney disease, but can occur
independently. Patients with cryoglobulinemic GN have a poor
prognosis, mainly because of a high incidence of infections,
end-stage liver disease, and cardiovascular diseases.330,331
RCTs are lacking to help establish evidence-based recom-
mendations to treat glomerular lesions associated with HCV
infection. Until this information is available, the treatment of
HCV-associated GN should probably be driven by the severity
of proteinuria and kidney failure.
Given that remission of hematuria, proteinuria, and
improvement of GFR in patients with HCV-associated GN
who obtained sustained HCV RNA clearance by DAAs has
been reported,261–270 antiviral therapy with DAA regimens
should be considered the ﬁrst-line choice in patients with
non-nephrotic proteinuria and relatively stable kidney func-
tion (Supplementary Tables S17 and S18). In addition, anti-
proteinuric agents such as angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers should be given.
Treatment including diuretics and antihypertensive agents
should be used to achieve target blood pressure recom-
mended in patients with CKD.
5.2.2: We recommend that patients with cryoglobulinemic
ﬂare, nephrotic syndrome, or rapidly progressive
kidney failure be treated, in addition to DAA
treatment, with immunosuppressive agents with or
without plasma exchange (1C).139
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patients with serious, life-threatening complications of mixed
cryoglobulinemia, such as MPGN, severe neuropathy, or
extensive skin disease. Cyclophosphamide has been selected
to improve kidney disease by reducing stimulation of B
lymphocytes and cryoglobulin synthesis; steroid pulses have
been given to treat glomerular inﬂammation, and plasma
exchange has been employed to remove circulating cry-
oglobulins from the plasma and consequently to reduce the
deposition of immune complexes to the kidneys.
In patients with nephrotic-range proteinuria and/or
rapidly progressive kidney failure and/or acute ﬂare of cry-
oglobulinemia, control of disease by immunosuppressive
agents, with or without plasma exchange (3 liters of plasma
thrice weekly for 2–3 weeks), should be considered before the
initiation of DAA therapy. Potential regimens include ritux-
imab (375 mg/m2 weekly for 4 weeks) with or without cor-
ticosteroids (see below), or cyclophosphamide (2 mg/kg/d for
2–4 months) plus methylprednisolone pulses 0.5 to 1 g/d for
3 days. According to the decision of the clinician, immuno-
suppressive regimen alone or combined therapy (immuno-
suppressive agents plus DAA therapy) is suggested as the
initial approach.
Until a few years ago, combined therapy with corticosteroids
and immunosuppressive agents—for example, treatment using
sequentially cyclophosphamide and azathioprine—has been
used while awaiting the response, if any, to antiviral therapy.
In one retrospective study, the clinical outcome of 105 pa-
tients with essential mixed cryoglobulinemia vasculitis and
renal involvement was evaluated throughout a median
follow-up of 72 months since kidney biopsy.330 Positive anti-
HCV serologic status was reported in 85% of patients. About
80% of patients underwent treatment with oral or pulse
intravenous steroids and/or cytotoxic agents, whereas 67%
were treated with plasma exchange. Despite this aggressive
treatment, patient survival was 49% at 10 years after kidney
biopsy, and only 14% of patients had long-term remission of
kidney disease.330 By multivariate analysis, age > 50 years,
purpura, splenomegaly, cryocrit levels> 10%, C3 plasma levels
< 54 mg/dl, and serum creatinine > 1.5 mg/dl (> 133 mmol/l)
were independent risk factors for death or dialysis.330 Other
case reports have also documented improvement following the
administration of a combination of steroids and antivirals (IFN
and RBV) or of the 3D regimen combined with plasmaphe-
resis, corticosteroids, and rituximab.333,334
5.2.3: We recommend immunosuppressive therapy in pa-
tients with histologically active HCV-associated
glomerular disease who do not respond to antiviral
therapy, particularly those with cryoglobulinemic
kidney disease (1B).1405.2.3.1: We recommend rituximab as the ﬁrst-line
immunosuppressive treatment (1C).Limited information exists on the use of DAAs in patients
with HCV-associated glomerular disease. Nine patients withsymptomatic mixed cryoglobulinemic disease (seven with
MPGN) and HCV GT1 underwent triple antiviral therapy
(pegylated IFN, RBV, and boceprevir [n ¼ 2] or telaprevir
[n ¼ 5] or sofosbuvir [n ¼ 2]).325,335 All patients reached
SVR, but serum cryoglobulins persisted in 3 patients; also, the
beneﬁts on renal signs were partial. MPGN remitted in 3
patients after further treatment with corticosteroids or cor-
ticosteroids plus rituximab.
More recently, encouraging results have been obtained
with IFN-free DAA regimens for HCV-related glomerular
disease; a small group of 7 patients with symptomatic mixed
cryoglobulinemia and GN (5 had a biopsy-proven MPGN and
2 were diagnosed clinically) underwent sofosbuvir-based
regimens (6 with sofosbuvir and simeprevir and 1 with
sofosbuvir and RBV).265 Only 1 patient was receiving ongoing
immunosuppression concurrent with antiviral therapy. All
patients had an improvement in eGFR and a reduction in
proteinuria, particularly in those whose onset of proteinuria
was recent. Also, in all patients HCV RNA was undetectable
by week 4 and remained undetectable while on treatment.
SVR was reached in 6 of 7 patients.
In another cohort of 44 consecutive patients with HCV-
associated mixed cryoglobulinemia, 4 patients had renal
involvement.263 The treatment of HCV-associated mixed
cryoglobulinemia with sofosbuvir-based DAA therapy
appeared to be highly effective (SVR12, 100%) and safe with
some improvement of kidney disease262,263 These studies
suggest that IFN-free therapies can give high viral and clinical
responses in a difﬁcult-to-treat condition such as HCV-
associated mixed cryoglobulinemia with renal involvement. In
fact, the SVR rates ranging between 83% and 100% are
comparable to the SVR12 rates reported with similar regi-
mens in other non-cryoglobulinemic real-world groups.
However, it is clear that we need larger and controlled studies
to conﬁrm these results. Combining DAA therapy with rit-
uximab and other immunosuppressants might be of value for
cases with severe or obstinate manifestations of cry-
oglobulinemic vasculitis.
Immunosuppressive therapies are suggested typically for
patients with HCV-associated mixed cryoglobulinemia
showing severe disease manifestations, such as progressive
glomerular disease. In addition to conventional immuno-
suppressants, which target inﬂammation at the glomerular
level, encouraging results have been obtained with rituximab,
a human-mouse chimeric monoclonal antibody that binds to
the B-cell surface antigen CD20 and selectively targets B
cells.336–341 Rituximab interferes with synthesis of cry-
oglobulins, monoclonal IgM, and renal deposition of immune
complexes. An important pathogenetic feature of mixed
cryoglobulinemia (including cryoglobulinemic GN) is
chronic stimulation of B lymphocytes by HCV and wide-
spread auto-antibody synthesis related to HCV-induced
lowering of cell activation threshold.
Two RCTs have demonstrated the superiority of rituximab
monotherapy as compared with conventional immunosup-
pressive therapy (i.e., corticosteroids, azathioprine,Kidney International Supplements (2018) 8, 91–165
www.kisupplements.org chap te r 5cyclophosphamide, methotrexate, and plasma exchange) for
the treatment of HCV-associated cryoglobulinemic vasculitis
in patients for whom prior IFN therapy failed to induce
disease remission, or in patients who were not eligible for IFN
therapy. Admittedly, only a minority of the included patients
showed renal involvement.339,341 Rituximab was well toler-
ated and was effective in 71.4% to 83% of patients with HCV-
associated cryoglobulinemic vasculitis. Frequent relapses may
occur after rituximab when B cells re-emerge in the periph-
eral blood; in addition, repeated rituximab infusions may
expose patients to opportunistic infections.
In a recent prospective, single-center study, 16 patients with
cryoglobulinemic nephropathy (diffuse MPGN and mixed
cryoglobulinemia) received rituximab at a dose of 375 mg/m2,
according to a “4 + 2” protocol (days 1, 8, 15, and 22 plus one
dose 1 and 2 months later).337 No other immunosuppressive
drugs were used. Safety and efﬁcacy of rituximab was evaluated
over a long-term follow-up (mean: 72.5 months). A signiﬁcant
improvement of cryoglobulinemic GN was found, starting
from the secondmonth after rituximab (serum creatinine from
2.1 1.7 mg/dl [186 150 mmol/l] to 1.5 1.6 mg/dl [133
141 mmol/l], P< 0.05; and 24-hour proteinuria from 2.3 2.1
to 0.9  1.9 g/24 hr, P < 0.05).337 No clinically relevant side
effects were recorded. Re-inductionwith rituximabwas carried
out in 9 patients who relapsed after a mean of 31.1 months,
again with beneﬁcial effects. In addition, complete remission of
pre-treatment active manifestations was observed in all cases of
purpuric lesions and non-healing vasculitic ulcers, and in 80%
of the peripheral neuropathies.
A point of caution is important as rituximab, which selec-
tively targets B cells, has been associated with severe infectious
complications including reactivation of HCV,342 or more
frequently, HBV. The risk of reactivation of HBV infection has
been added to the existing black box warning on the rituximab
label by the FDA in 2013.343 Infections with ominous course
after rituximab therapy have been observed in kidney trans-
plant recipients and in the non-transplant setting. However,
these complications were mostly observed in patients under
multiple immunosuppressive agents. Infectious episodes have
been frequently reported in a patient subgroup (age> 70 years,
GFR < 60 ml/min per 1.73 m2, and concomitant high-dose
corticosteroids) and were fatal in some patients.344 Cholestatic
liver disease due to HCV reactivation by rituximab has been
also observed after kidney transplant.342
In addition to conventional or selective immunosuppres-
sive agents, additional immunosuppressive agents, such as
MMF, should be evaluated. Preliminary evidence suggests that
MMF can be effective for maintaining remission of HCV-
associated cryoglobulinemic GN.345,346
In summary, a kidney biopsy should be performed in
HCV-positive patients with clinical evidence of glomerular
disease. Patients with mild or moderate forms of HCV-asso-
ciated GN with stable kidney function and/or non-nephrotic
proteinuria should be managed ﬁrst with a DAA regimen.Kidney International Supplements (2018) 8, 91–165Patients with severe cryoglobulinemia or severe glomerular
disease induced by HCV (i.e., nephrotic proteinuria or rapidly
progressive kidney failure) should be treated with immuno-
suppressive agents (generally with rituximab as the ﬁrst-line
agent) and/or plasma exchange in addition to DAA therapies.
Patients with HCV-related glomerular disease who do not
respond to or are intolerant of antiviral treatment should also
be treated with immunosuppressive agents. In all cases,
achievement of SVR after DAA treatment, changes in kidney
function, evolution of proteinuria, and side effects from
antiviral therapy must be carefully monitored. Treatment with
antiproteinuric agents such as angiotensin-converting enzyme
inhibitors and/or angiotensin-receptor blockers should be
given to patients with HCV-associated glomerular disease.
When appropriate, diuretics and antihypertensive drugs
should be administered to achieve recommended target blood
pressure goals for patients with CKD.
Research recommendations
 Occult HCV infection (detectable HCV RNA in peripheral
blood mononuclear cells and/or in serum after centrifuga-
tion) could be involved in the pathogenesis of glomerular
disease among patients negative for HCV RNA.347 We need
large-sized studies with appropriate technology to assess the
relationship between occult HCV and glomerular disease.
 The efﬁcacy and safety of DAA therapies and/or imumu-
nosuppressive agents for the treatment of HCV-associated
GN should be assessed, preferably in larger, controlled
clinical studies, with longer follow-up.
 The antiviral approach to the treatment of HCV-related
glomerular disease is expected to improve with IFN-free and
RBV-free regimens. However, some of these drugs are not
currently approved in patients with low GFR; hence, further
studies of various DAAs are warranted in late CKD/ESKD for
various GTs in patients with HCV-associated GN. Typically,
patients with HCV-related glomerular disease receive a high
number of concomitant drugs, including cytotoxic agents.
Potential drug–drug interaction is another challenge to cli-
nicians using DAA regimens for HCV-induced GN.
 The role of immunosuppressive agents in the management
of aggressive HCV-related glomerular disease (i.e.,
nephrotic syndrome, rapidly progressive decline of GFR)
needs to be further clariﬁed in light of the rapid antiviral
activity provided by DAA regimens.
 Numerous questions regarding the use of rituximab in
HCV-positive glomerular disease remain. For example,
what is the optimal timing and dosing of periodic ritux-
imab infusions for relapsers? The role of rituximab as ﬁrst-
line or rescue therapy needs to be deﬁned further.
 Severe infections after rituximab therapy frequently occur
in patients who are older than 50 years, have kidney disease,
and report concomitant use of high-dose corticosteroids.
Future studies should delineate how best to avoid infections
associated with immunosuppression regimens.141
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The overall aim of this project was to develop an evidence-based
clinical practice guideline (CPG) for the management of patients
with CKD as pertains to HCV infection. The guideline consists of
recommendation statements, rationale text, and a summary of sys-
tematically generated evidence on relevant pre-deﬁned clinical
topics. The general guideline development method is described
below.
Overview of process
The development process for the KDIGO 2018 CPG for the Preven-
tion, Diagnosis, Evaluation and Treatment of Hepatitis C in CKD
included the following steps:
 Appointing Work Group members and the evidence review team
(ERT)
 Discussing process, methods, and results
 Developing and reﬁning topics
 Identifying populations, interventions or predictors, and out-
comes of interest
 Selecting topics for systematic evidence review
 Standardizing quality assessment methodology
 Developing and implementing literature search strategies
 Screening abstracts and retrieving full-text articles on the basis of
pre-deﬁned eligibility criteria
 Creating data extraction forms
 Extracting data and performing critical appraisal of the literature
 Grading the methodology and outcomes in individual studies
 Tabulating data from individual studies into summary tables
 Grading quality of evidence for each outcome across studies, and
assessing the overall quality of evidence across outcomes with the
aid of evidence proﬁles
 Grading the strength of recommendations on the basis of the
quality of evidence and other considerations
 Finalizing guideline recommendations and supporting rationales
 Sending the guideline draft for public review in February 2017
 Editing the guideline
 Publishing the ﬁnal version of the guideline
The overall process for conducting the systematic reviews and
developing the CPG follow international standards, including those
from the Institute of Medicine.348,349
The Work Group Co-Chairs and the ERTmet for a 2-day meeting
to go over the guideline development process, evidence review
topics, and systematic review ﬁndings. Following this, the Work
Group, ERT, and KDIGO support staff met for 2 separate 2-day
meetings to ﬁnalize review topics, review the available evidence,
formulate recommendation statements, evaluate the quality of the
evidence and strength of recommendations, deliberate on rationale
for recommendations, and develop consensus.
Commissioning of Work Group and ERT. The KDIGO
Co-Chairs appointed the Work Group Co-Chairs, who then
assembled the Work Group of domain experts, including individuals
with expertise in adult nephrology, transplant nephrology, hepatol-
ogy, virology, infection control, and public health. The Brown
University Center for Evidence Synthesis in Health in Providence,142Rhode Island, was contracted as the ERT to conduct systematic ev-
idence review and provide expertise in guideline development
methodology. The ERT consisted of physician-methodologists with
expertise in nephrology and evidence-based clinical practice guide-
line development, and experienced research associates.
Deﬁning scope and topics. The Work Group Co-Chairs and the
ERT deﬁned the overall scope and goals of the guideline (including a
list of critical and important interventions and outcomes) and then
drafted a preliminary list of topics and key clinical questions. The list
of research and recommendation topics was based on the original
KDIGO guideline on HCV,34 which the ERT also had helped to
develop (when it was based at Tufts Medical Center in Boston, MA).
The Work Group and ERT further developed and reﬁned each topic
and its eligibility criteria, literature search strategies, and data
extraction forms (Table 8).
Establishing the process for guideline development. The ERT
performed systematic literature searches and organized abstract and
article screening. The ERT also coordinated the methodological and
analytical processes and deﬁned and standardized the methodology
for performing literature searches, data extraction, and summarizing
the evidence. The Work Group took the primary role of writing and
grading the recommendation statements and rationales and retained
ﬁnal responsibility for their content. The Work Group Co-Chairs
and the ERT prepared the ﬁrst draft of the scope-of-work document
as a series of open-ended questions to be considered by Work Group
members.
Formulating questions of interest. Questions of interest were
formulated according to the PICODD criteria (population, inter-
vention, comparator, outcome, study design, and duration of follow-
up). Details of the PICODD criteria are presented in Table 8.
Ranking of outcomes. The Work Group ranked outcomes of
interest on the basis of their importance for informing clinical de-
cision making (Table 9).
Literature searches and article selection. Systematic search
strategies were developed by the ERT with input from the Work
Group Co-Chairs. Modules were created for kidney disease, HCV,
and study designs. Searches were conducted in Medline, Embase,
Cochrane Central Register of Controlled Trials, and Cochrane
Database of Systematic Reviews. For topics covered in the 2008
KDIGO HCV CPG,34 searches were limited to 2008 and later to
capture new evidence. For new topics, searches were not limited by
publication date. The full literature search strategies are provided in
Supplementary Appendix A. In addition, the ERT searched for
existing relevant systematic reviews. The ﬁnal searches were con-
ducted in May 2017. The search yield was also supplemented by
focused searches for DAAs, conference abstracts from the 2016 and
2017 American Society of Nephrology (ASN) and AASLD meet-
ings, and articles provided by Work Group members through July
2018.
For selection of studies, all members of the ERT screened the
abstracts in duplicate using an open-source online screeningKidney International Supplements (2018) 8, 91–165
Table 8 | Systematic review topics and screening criteria
Hepatitis C treatment
Population CKD G3a–5 (including dialysis and transplant) or equivalent; HCV infection
Intervention DAA (except 1st generation: telaprevir, boceprevir), pegylated interferon  ribavirin, immunosuppression including induction
(in combination with DAA or as treatment of HCV-associated GN)
Comparator Active or control or none (single-arm studies)
Outcome Categorical: all-cause mortality, SVR (preferably 24-wk), hepatocellular carcinoma, graft loss, NODAT, QoL, adverse events
(including treatment discontinuation), pharmacokinetics/dynamics
Continuous (HCV-associated GN only): kidney function, proteinuria
Study design RCT, nonrandomized comparative studies, single-group studies; prospective (all topics) or retrospective (immunosuppression
or GN topics only). Interferon in dialysis: RCT only.
Minimum duration of
follow-up
HCV treatment studies: 12 weeks post-treatment; Other topics: no minimum
Minimum N of subjects $ 10; Immunosuppression topic: any, including case reports
Publication dates All: $ 2008 (plus studies in 2008 KDIGO CPG); interferon and dialysis topic: Cochrane review350 and $ 2012
Liver testing
Population Tests for cirrhosis: CKD (all stages); pre-transplant biopsy: CKD G4–G5 pre-transplantation (or equivalent)
Intervention/comparator Noninvasive liver testing, including upper endoscopy (for varices), liver biopsy
Outcome Noninvasive test performance characteristics, change in management strategy, patient mortality, graft loss
Design Any
Minimum N of subjects Noninvasive testing: N $ 10, pre-transplant biopsy: N $ 5
Publication dates Any
Dialysis isolation
Population Hemodialysis (patients or units)
Intervention Isolation, quarantine, etc.






Minimum N of subjects N $ 30 patients
Publication dates $ 2008 (plus studies in 2008 KDIGO CPG)
Early versus late transplantation
Population HCV-infected transplantation candidates
Intervention Transplantation (“now”)
Comparator Remaining on wait-list or awaiting HCV-negative status
Outcome Patient mortality, graft loss




Minimum N of subjects N $ 100
Publication dates $ 2008 (plus studies in 2008 KDIGO CPG)
HCV-infected donors
Population HCV-infected kidney transplant recipients
Intervention HCV-infected donors
Comparator HCV-negative donors
Outcome Patient mortality, graft loss




Minimum N of subjects N $ 100
Publication dates Any
Predictor analyses
Population Predictors of CKD progression: any (including general population) except CKD G5D (dialysis); HCV as predictor: kidney
transplant recipients
Predictor HCV-infection (untreated), other predictors of CKD progression (if HCV-infected)
Outcome CKD progression (change in GFR, SCr doubling, ESKD), proteinuria, patient mortality, graft loss, delayed graft function, kidney
pathology (HCV-associated GN)




Minimum N of subjects $ 100
Publication dates Predictors of CKD progression: any; HCV as predictor: $ 2008 (plus studies in 2008 KDIGO CPG)
2008 KDIGO CPG, 2008 KDIGO clinical practice guideline on hepatitis C34; CKD, chronic kidney disease; DAA, direct-acting antiviral; ESKD, end-stage kidney disease; GFR,
glomerular ﬁltration rate; GN, glomerulonephritis; HCV, hepatitis C virus; NODAT, new-onset diabetes after transplantation; QoL, quality of life; RCT, randomized controlled trial;
SCr, serum creatinine; SVR, sustained virologic response.
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Table 9 | Hierarchy of outcomes
Hierarchy Outcome
Critical importance Mortality, graft loss, ESKD
High importance SVR, treatment discontinuation due to adverse events, serious adverse events, CKD incidence, quality of life, HCV seroconversion,
test performance characteristics
Moderate importance HCV relapse, kidney function, proteinuria, HCV positivity, hepatocellular carcinoma
CKD, chronic kidney disease; ESKD, end-stage kidney disease; HCV, hepatitis C virus; SVR, sustained virologic response.
Figure 2 | Search yield. AASLD, American Association for the Study of Liver Diseases; ASN, American Society of Nephrology; CKD, chronic
kidney disease; GL, guideline; HCV, hepatitis C virus; KDIGO HCV CPG, Kidney Disease: Improving Global Outcomes hepatitis C virus clinical
practice guideline.
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www.kisupplements.org me thods fo r gu ide l i ne deve lopmentprogram, Abstrackr (http://abstrackr.cebm.brown.edu/). To establish
relevance and consensus among reviewers, the entire team screened
and achieved consensus on a series of initial batches of 100 abstracts.
A total of 8703 citations from the databases were screened, in
addition to 520 conference abstracts and 93 studies included in the
2008 KDIG HCV CPG (Figure 2). Journal articles reporting original
data or systematic reviews were selected for evidence review, based
on a priori criteria for eligible evidence. Of these, 487 were selected
for consideration for inclusion. In total, 125 studies met eligibility
criteria for extraction.
Data extraction. Data extraction was done by ERT research as-
sociates. Extracted data from each study was reviewed by another
ERT member to conﬁrm accuracy. The ERT designed forms to
capture data on design, methodology, eligibility criteria, study
participant characteristics, interventions, comparators, predictors,
outcomes, and results of individual studies. Methodology and out-
comes were also systematically assessed for risk of bias (see the
section on risk of bias assessment below) and recorded during the
data extraction process. Data were extracted into the online re-
pository SRDR (Systematic Review Data Repository); the data are
available for review at http://srdr.ahrq.gov/.
Summary tables. Summary tables were developed for each
reviewed topic. Summary tables contain outcomes of interest, rele-
vant population characteristics, description of intervention and
comparator (or predictor), results, and quality grading for each
outcome. Categorical outcomes and continuous outcomes were
tabulated separately.
Work Group members reviewed and conﬁrmed all summary
table data and quality assessments. Summary tables are available as
supplementary material at www.kisupplements.org.Table 10 | Work products for the guideline
Topics
1. HCV testing
1.1 Determining which CKD patients should be tested for HCV
1.2 HCV testing in CKD
1.3 Noninvasive versus invasive tests for cirrhosis in CKD
1.4 HCV as predictor of CKD progression
1.4 Other predictors of CKD progression
2. HCV treatment
2 HCV treatment (DAA, CKD nontransplant including hemodialysis)
2 HCV treatment (peg-interferon, hemodialysis)
2 HCV treatment (DAA, kidney transplant)
2 HCV treatment (interferon, kidney transplant)




4.1.1 Transplantation versus wait-list
4.1.1 HCV as predictor, patient mortality
4.1.1 HCV as predictor, graft loss
4.1.2 Pre-transplant liver biopsy
4.1.3 Timing of HCV treatment versus kidney transplantation
4.2 HCV-positive versus negative donor kidneys
4.3 DAA and immunosuppression interaction
4.4 HCV-related complications
5. HCV-associated glomerulonephritis
5.1 HCV-associated kidney disease prevalence
5.2 HCV-associated glomerulonephritis management
CKD, chronic kidney disease; DAA, direct-acting antiviral; GL, guideline; HCV, hepatitis C
aPlus 6 case reports on miscellaneous topics.
Kidney International Supplements (2018) 8, 91–165Evidence proﬁles. Evidence proﬁles were constructed to assess
the quality and record quality grades and descriptions of effect (or
association) for each outcome across studies, as well as the quality of
overall evidence and description of net beneﬁts or harms of the
intervention or comparator across all outcomes. These proﬁles aim
to make the evidence synthesis process transparent. Decisions in the
evidence proﬁles were based on data from the primary studies listed
in corresponding summary tables and on judgments of the ERT and
Work Group. When the body of evidence for a particular comparison
of interest consisted of 2 or fewer studies, the summary table pro-
vided the ﬁnal level of synthesis and an evidence proﬁle was not
generated. Each evidence proﬁle was initially constructed by the ERT
and then reviewed, edited, and approved by the Work Group. The
work products created by the ERT for summarizing the evidence
base are listed in Table 10, together with the number of included
studies.
Grading of quality of evidence for outcomes of individual
studies. Methodological quality (internal validity) refers to the
design, conduct, and reporting of outcomes of a clinical study. A
previously devised 3-level classiﬁcation system for quality assessment
was used to grade the overall study quality and quality of all relevant
outcomes in the study (Table 11). Grading of individual studies was
done by one of the reviewers, then conﬁrmed by another, with
discrepancies discussed in conference.
We based the methodological quality of each study on predeﬁned
criteria. For RCTs and other comparative studies, the ERT used the
Cochrane risk of bias tool,351 which asks about risk of selection bias,
performance bias, detection bias, attrition bias, reporting bias, and
other potential biases. For observational studies, we also used
selected questions from the Newcastle Ottawa Scale about compa-
















 (based on GL 2) 
+ 8 
+ 4 
 (not searched) 
+ 5 
+ 13 +
virus; peg, pegylated; PK, pharmacokinetic.
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Table 11 | Classiﬁcation of study quality
Good quality Low risk of bias and no obvious reporting errors; complete reporting of data. Must be prospective. If study of intervention, must be RCT.
Fair quality Moderate risk of bias, but problems with study or paper are unlikely to cause major bias. If study of intervention, must be prospective.
Poor quality High risk of bias or cannot rule out possible signiﬁcant biases. Poor methods, incomplete data, reporting errors. Prospective or
retrospective.
RCT, randomized controlled trial.
Table 12 | GRADE system for grading quality of evidence
Step 1: starting grade for quality of
evidence based on study design Step 2: reduce grade Step 3: raise grade
Final grade for quality of evidence and
deﬁnition
Randomized trials ¼ high
Observational study ¼ low
Any other evidence ¼ very low
Study quality
1 level if serious limitations
2 levels if very serious limitations
Consistency
1 level if important inconsistency
Directness
1 level if some uncertainty
2 levels if major uncertainty
Other
1 level if sparse or imprecise datac
1 level if high probability of
reporting bias
Strength of association
+1 level if strong,a no plausible
confounders
+2 levels if very strong,b no major
threats to validity
Other
+1 level if evidence of a dose-
response gradient
+1 level if all residual plausible
confounders would have reduced
the observed effect
High ¼ further research is unlikely to
change conﬁdence in the estimate of
the effect
Moderate ¼ further research is likely to
have an important impact on
conﬁdence in the estimate of effect,
and may change the estimate
Low ¼ further research is very likely to
have an important impact on
conﬁdence in the estimate, and may
change the estimate
Very low ¼ any estimate of effect is
very uncertain
GRADE, Grading of Recommendations Assessment, Development and Evaluation.
aStrong evidence of association is deﬁned as “signiﬁcant relative risk of > 2 (< 0.5)” based on consistent evidence from 2 or more observational studies, with no plausible
confounders.
bVery strong evidence of association is deﬁned as “signiﬁcant relative risk of > 5 (< 0.2)” based on direct evidence with no major threats to validity.
cSparse if there is only 1 study or if total N < 500, and imprecise if there is a low event rate (0 or 1 event) in either arm or conﬁdence interval spanning a range > 1.
Adapted by permission from Uhlig K, Macleod A, Craig J, et al.353
Table 13 | Final grade for overall quality of evidence
Grade Quality of evidence Meaning
A High We are conﬁdent that the true effect lies close to that of the estimate of the effect.
B Moderate The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
C Low The true effect may be substantially different from the estimate of the effect.
D Very low The estimate of effect is very uncertain, and often will be far from the truth.
methods fo r gu ide l i ne deve lopment www.kisupplements.orgadjustment for different lengths of follow-up.352 Based on these
characteristics an overall assessment was made whether the study
was of good, fair, or poor quality (Table 11).
Each reported outcome was then evaluated and given an indi-
vidual grade depending on the quality of reporting and methodo-
logical issues speciﬁc to that outcome. However, the quality grade of
an individual outcome could not exceed the quality grade for the
overall study.
Grading the quality of evidence and the strength of a guideline
recommendation. A structured approach, based on GRADE353–355
and facilitated by the use of evidence proﬁles, was used to grade
the quality of the overall evidence and the strength of recommen-
dations. For each topic, the discussion on grading of the quality of
the evidence was led by the ERT, and the discussion regarding the
strength of the recommendations was led by the Work Group Co-
Chairs. The “strength of a recommendation” indicates the extent to
which one can be conﬁdent that adherence to the recommendation
will do more good than harm. The “quality of a body of evidence”
refers to the extent to which our conﬁdence in an estimate of effect is
sufﬁcient to support a particular recommendation.354146Grading the quality of evidence for each outcome across
studies. Following GRADE, the quality of a body of evidence pertaining
to a particular outcome of interest was initially categorized on the basis of
study design. For each outcome, the potential grade for the quality of
evidence for each intervention-outcome pair started at high but was then
lowered if there were serious limitations to the methodological quality of
the aggregate of studies, if there were important inconsistencies in the
results across studies, if there was uncertainty about the directness of ev-
idence including limited applicability of the ﬁndings to the population of
interest, if the datawere imprecise (a low event rate [0 or 1 event] in either
arm or a CI spanning a range > 1) or sparse (only 1 study or total N <
500), or if therewas thought to be a high likelihood of bias. Theﬁnal grade
for the quality of the evidence for an intervention-outcome pair could be
one of the following 4 grades: high,moderate, low, or very low (Table 12).
Grading the overall quality of evidence. The quality of the overall
body of evidence was then determined on the basis of the quality
grades for all outcomes of interest, taking into account explicit
judgments about the relative importance of each outcome. The
resulting 4 ﬁnal categories for the quality of overall evidence were A,
B, C, or D (Table 13).Kidney International Supplements (2018) 8, 91–165
Table 14 | Balance of beneﬁts and harms
When there was evidence to determine the balance of medical beneﬁts and harms of an intervention to a patient, conclusions were categorized as
follows:
 For statistically signiﬁcant beneﬁt or harm, report as “beneﬁt (or harm) of intervention.”
 For nonstatistically signiﬁcant beneﬁt or harm, report as “possible beneﬁt (or harm) of intervention.”
 In instances where studies are inconsistent, report as “possible beneﬁt (or harm) of intervention.”
 “No difference” can only be reported if a study is not imprecise.
 “Insufﬁcient evidence” is reported if imprecision is a factor.






Most people in your situation
would want the recommended
course of action and only a
small proportion would not.
Most patients should receive the
recommended course of action.
The recommendation can be evaluated
as a candidate for developing a policy
or a performance measure.
Level 2
“We suggest”
The majority of people in your
situation would want the
recommended course of action,
but many would not.
Different choices will be appropriate
for different patients. Each patient needs
help to arrive at a management decision
consistent with her or his values and
preferences.
The recommendation is likely to require
substantial debate and involvement of
stakeholders before policy can be
determined.
KDIGO, Kidney Disease: Improving Global Outcomes.
aThe additional category “not graded” was used, typically, to provide guidance based on common sense or where the topic does not allow adequate application of evidence.
The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations
are generally written as simple declarative statements. They should not be interpreted as being weaker recommendations than Level 1 or 2 recommendations.
Table 16 | Determinants of strength of recommendation
Factor Comment
Balance between desirable and
undesirable effects
The larger the difference between the desirable and undesirable effects, the more likely a strong
recommendation is warranted. The narrower the gradient, the more likely a weak recommendation is warranted.
Quality of the evidence The higher the quality of evidence, the more likely a strong recommendation is warranted.
Values and preferences The more variability in values and preferences, or the more uncertainty in values and preferences, the more likely
a weak recommendation is warranted. Values and preferences were obtained from the literature where possible
or were assessed in the judgment of the Work Group where robust evidence was not identiﬁed.
Costs (resource allocation) The higher the costs of an intervention—that is, the more resources consumed—the less likely a strong
recommendation is warranted.
www.kisupplements.org me thods fo r gu ide l i ne deve lopmentAssessment of the net health beneﬁt across all important clinical
outcomes. The net health beneﬁt was determined on the basis of
the anticipated balance of beneﬁts and harms across all clinically
important outcomes (Table 14). The assessment of net beneﬁt also
involved the judgment of the Work Group and the ERT.
Developing the recommendations. Draft recommendation state-
ments were developed by the Work Group Co-Chairs and Work
Group members with input from all Work Group members. The
health beneﬁts, side effects, and risks associated with each recom-
mendation were considered when formulating the guideline, as well
as information on patient preferences when available. Recommen-
dation statements were revised in a multistep process during face-to-
face meetings and by subsequent drafts by e-mail. Relevant recom-
mendations from the AASLD and EASL guidelines on management
of HCV were reviewed to maximize consistency between guidelines.
The ﬁnal draft was sent for external public review. Based onKidney International Supplements (2018) 8, 91–165feedback, it was further revised by the Work Group Co-Chairs and
members. All Work Group members provided feedback on initial
and ﬁnal drafts of the recommendation statements and guideline text
and approved the ﬁnal version of the guideline.
Grading the strength of the recommendations. The strength of a
recommendation is graded as level 1 or level 2. Table 15 shows the
KDIGO nomenclature for grading the strength of a recommendation
and the implications of each level for patients, clinicians, and policy
makers. Recommendations can be for or against doing something.
Each recommendation includes an explicit link between the quality
of the available evidence and the strength of that recommendation.
However, Table 16 shows that the strength of a recommendation is
determined not only by the quality of the evidence but also by other,
often complex judgments regarding the size of the net medical
beneﬁt (potential risks vs. beneﬁt), values, and preferences, and
costs. Formal decision analyses including cost analysis were not
conducted.147
Table 17 | The Conference on Guideline Standardization (COGS) checklist for reporting clinical practice guidelines
Topic Description Discussed in 2018 KDIGO HCV in CKD CPG
1. Overview material Provide a structured abstract that includes the
guideline’s release date, status (original, revised,
updated), and print and electronic sources.
See Abstract and Methods for Guideline Development.
2. Focus Describe the primary disease/condition and
intervention/service/technology that the guideline
addresses. Indicate any alternative preventative,
diagnostic, or therapeutic interventions that were
considered during development.
Management of HCV in terms of treatment,
monitoring, and prevention in adults with CKD,
including both dialysis and transplant populations.
3. Goal Describe the goal that following the guideline is
expected to achieve, including the rationale for
development of a guideline on this topic.
This CPG is intended to assist the practitioner caring
for patients with CKD and HCV and to prevent
transmission, resolve the infection, and prevent
adverse outcomes such as deaths, graft loss, and
progression to kidney failure while optimizing
patients’ quality of life.
4. User/setting Describe the intended users of the guideline (e.g.,
provider types, patients) and the settings in which the
guideline is intended to be used.
Target audience is practicing nephrologists and other
health care providers for adults with CKD and HCV
infection.
5. Target population Describe the patient population eligible for guideline
recommendations and list any exclusion criteria.
Adults with CKD and HCV infection; CKD patients on
dialysis therapy.
6. Developer Identify the organization(s) responsible for guideline
development and the names/credentials/potential
conﬂicts of interest of individuals involved in the
guideline’s development.
Organization: KDIGO.
Names/credentials/potential conﬂicts of interest of
individuals involved in the guideline’s development
are disclosed in the Biographic and Disclosure
Information.
7. Funding source/sponsor Identify the funding source/sponsor and describe its
role in developing and/or reporting the guideline.
Disclose potential conﬂict of interest.
This guideline is funded by KDIGO.
Financial disclosures of Work Group members are
published in Biographic and Disclosure Information
section of the guideline.
8. Evidence collection Describe the methods used to search the scientiﬁc
literature, including the range of dates and databases
searched, and criteria applied to ﬁlter the retrieved
evidence.
Topics were triaged either to (i) systematic review, (ii)
systematic search followed by narrative summary, or
(iii) narrative summary. For systematic reviews, we
searched PubMed, Embase, Cochrane Central Registry
for trials, and Cochrane database of systematic
reviews. Screening criteria for this and other topics are
outlined in the Methods for Guideline Development
chapter. The search was updated through May 2017
and supplemented by articles identiﬁed by Work
Group members through July 2018. We also searched




Describe the criteria used to rate the quality of
evidence that supports the recommendations and the
system for describing the strength of the
recommendations. Recommendation strength
communicates the importance of adherence to a
recommendation and is based on both the quality of
the evidence and the magnitude of anticipated
beneﬁts and harms.
Quality of individual studies was graded in a 3-tiered
grading system (see Table 11). Quality of evidence
and strength of recommendations were graded
following the GRADE approach (Tables 12, 13, and 15).
The Work Group could provide general guidance in
the form of ungraded statements.
10. Method for
synthesizing evidence
Describe how evidence was used to create
recommendations, e.g., evidence tables, meta-
analysis, decision analysis.
For systematic review topics, summary tables and
evidence proﬁles were generated. For
recommendations on interventions, the steps
outlined by GRADE were followed.
methods fo r gu ide l i ne deve lopment www.kisupplements.org
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Topic Description Discussed in 2018 KDIGO HCV in CKD CPG
11. Prerelease review Describe how the guideline developer reviewed and/
or tested the guidelines prior to release.
The guideline had undergone external public review
in February 2017. Public review comments were
compiled and fed back to the Work Group, which
considered comments in its revision of the guideline.
12. Update plan State whether or not there is a plan to update the
guideline and, if applicable, an expiration date for this
version of the guideline.
The requirement for an update will be assessed
periodically from the publication date or earlier if
important new evidence becomes available in the
interim. Such evidence might, for example, lead to
changes to the recommendations or may modify
information provided on the balance between
beneﬁts and harms of a particular therapeutic
intervention.
13. Deﬁnitions Deﬁne unfamiliar terms and those critical to correct
application of the guideline that might be subject to
misinterpretation.
See Abbreviations and Acronyms.
14. Recommendations and
rationale
State the recommended action precisely and the
speciﬁc circumstances under which to perform it.
Justify each recommendation by describing the
linkage between the recommendation and its
supporting evidence. Indicate the quality of evidence
and the recommendation strength, based on the
criteria described in Topic 9.
Each guideline chapter contains recommendations for
the management of HCV in CKD patients. Each
recommendation builds on a supporting rationale
with evidence tables if available. The strength of the
recommendation and the quality of evidence are
provided in parenthesis within each recommendation.
15. Potential beneﬁts and
harms
Describe anticipated beneﬁts and potential risks
associated with implementation of guideline
recommendations.
The beneﬁts and harm for each comparison of
interventions are provided in summary tables and
summarized in evidence proﬁles. The estimated
balance between potential beneﬁts and harm was
considered when formulating the recommendations.
16. Patient preferences Describe the role of patient preferences when a
recommendation involves a substantial element of
personal choice or values.
Recommendations that are level 2, or “discretionary,”
indicate a greater need to help each patient arrive at a
management decision consistent with her or his
values and preferences.
17. Algorithm Provide (when appropriate) a graphical description of
the stages and decisions in clinical care described by
the guideline.
Algorithms were developed where applicable (see
Chapters 2 and 4).
18. Implementation
considerations
Describe anticipated barriers to application of the
recommendations. Provide reference to any auxiliary
documents for providers or patients that are intended
to facilitate implementation. Suggest review criteria
for measuring changes in care when the guideline is
implemented.
These recommendations are global. Local versions of
the guideline are anticipated to facilitate
implementation and appropriate care. Review criteria
were not suggested because implementation with
prioritization and development of review criteria have
to proceed locally. Most recommendations are
discretionary, requiring substantial discussion among
stakeholders before they can be adopted as review
criteria. The decision whether to convert any
recommendations to review criteria will vary globally.
Research recommendations were also outlined to
address current gaps in the evidence base.
CKD, chronic kidney disease; CPG, clinical practice guideline; GRADE, Grading of Recommendations Assessment, Development and Evaluation; HCV, hepatitis C virus; KDIGO,
Kidney Disease: Improving Global Outcomes.
www.kisupplements.org me thods fo r gu ide l i ne deve lopmentUngraded statements. This category was designed to allow the Work
Group to issue general advice. Typically an ungraded statement
meets the following criteria: it provides guidance based on common
sense; it provides reminders of the obvious; and it is not sufﬁciently
speciﬁc to allow for application of evidence to the issue and therefore
it is not based on systematic evidence review. As such, ungradedKidney International Supplements (2018) 8, 91–165statements may be considered to be relatively strong recommenda-
tions; they should not be interpreted as weak recommendations
based on limited or poor evidence. Common examples include
recommendations about frequency of testing, referral to specialists,
and routine medical care. We strove to minimize the use of ungraded
recommendations.149
methods fo r gu ide l i ne deve lopment www.kisupplements.orgThis grading scheme, with 2 levels for the strength of a
recommendation together with four levels of grading the quality of
the evidence, as well as the option of an ungraded statement for
general guidance, was adopted by the KDIGO Board in December
2008. The Work Group took on the primary role of writing the
recommendations and rationale statements and retained ﬁnal re-
sponsibility for the content of the guideline statements and the
accompanying narrative. The ERT reviewed draft recommendations
and grades for consistency with the conclusions of the evidence
review.
Format for guideline recommendations. Each chapter contains 1 or
more speciﬁc recommendations. Within each recommendation, the
strength of recommendation is indicated as level 1 or level 2 and the
quality of the supporting evidence is shown as A, B, C, or D. The
recommendation statements and grades are followed by the rationale
text summarizing the key points of the evidence base and the
judgments supporting the recommendation. In relevant sections,
considerations of the guideline statements in international settings
and suggested audit criteria are also provided where applicable.
Important key points and research recommendations suggesting
future research to resolve current uncertainties are also outlined at
the conclusion of each chapter.150Limitations of approach
Although the literature searches were intended to be comprehensive,
they were not exhaustive. Medline, Embase, and Cochrane databases
were searched, but other specialty or regional databases were not.
Hand searches of journals were not performed, and review articles
and textbook chapters were not systematically searched. Recent
conference abstracts were screened from ASN and AASLD, but older
conference abstracts and other conference meetings were not spe-
ciﬁcally screened. We relied on Work Group members to provide the
ERTwith conference abstracts from recent EASL meetings. However,
any important studies known to domain experts that were missed by
the electronic literature searches were added to retrieved articles and
reviewed by the Work Group.
Review of guideline development process
The Conference on Guideline Standardization (COGS) checklist has
been developed to assess the quality of the methodological process
for systematic review and guideline development.356 Table 17 shows
the criteria that correspond to the COGS checklist and how each one
is addressed in this guideline. Similarly, Supplementary Appendix B
demonstrates the level of concurrence with which this guideline
corresponds to the Institute of Medicine’s standards for systematic
reviews and guidelines.348,349Kidney International Supplements (2018) 8, 91–165
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